(19) DANMARK

(10) **DK/EP 3459965 T3**

Patent- og
Varemærkestyrelsen

(12) Oversættelse af
europæisk patentskrift

(51) Int.Cl.: ***C 07 K 14/00 (2006.01)*** ***A 61 K 39/00 (2006.01)*** ***C 07 K 14/005 (2006.01)***
C 12 N 7/00 (2006.01) ***C 12 N 15/86 (2006.01)***

(45) Oversættelsen bekendtgjort den: **2021-02-22**

(80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2020-12-02**

(86) Europæisk ansøgning nr.: **18190809.6**

(86) Europæisk indleveringsdag: **2014-10-10**

(87) Den europæiske ansøgnings publiceringsdag: **2019-03-27**

(30) Prioritet: **2013-10-11 US 201361889827 P**

(62) Stamansøgningsnr: **14789476.0**

(84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(73) Patenthaver: **Massachusetts Eye & Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA**
Schepens Eye Research Institute, 20 Stanford Street, Boston, MA 02114, USA

(72) Opfinder: **VANDENBERGHE, Luk H., 20 Staniford Street, Boston, MA 02114, USA**
ZINN, Eric, 11 Manning Road, Lynn, MA 01902, USA

(74) Fuldmægtig i Danmark: **AWA Denmark A/S, Strandgade 56, 1401 København K, Danmark**

(54) Benævnelse: **FREMGANGSMÅDER TIL FORUDSIGELSE AF FORFÆDREVIRUSSEKVENSER OG ANVENDELSER DERAF**

(56) Fremdragne publikationer:
ROBERTO CALCEDO ET AL: "Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses", THE JOURNAL OF INFECTIOUS DISEASES, vol. 199, no. 3, 1 February 2009 (2009-02-01), pages 381-390, XP055172026, ISSN: 0022-1899, DOI: 10.1086/595830
DATABASE Geneseq [Online] 13 December 2007 (2007-12-13), "Adeno-associated viral capsid protein, AAV-8, SEQ ID 4.", XP002736456, retrieved from EBI accession no. GSP:ANJ81137 Database accession no. ANJ81137
"American Society of Gene & Cell Therapy17th Annual Meeting", Molecular Therapy Volume 22, Supplement 1, May 2014 Copyright The American Society of Gene & Cell Therapy, 1 May 2014 (2014-05-01), pages S1-S305, XP055161446, Retrieved from the Internet: URL:https://www.cell.com/molecular-therapy -family/molecular-therapy/issue?pii=S1525- 0016%2816%29X6120-5&page=0 [retrieved on 2015-01-12]
ERIC ZINN ET AL: "Adeno-associated virus: fit to serve", CURRENT OPINION IN VIROLOGY, vol. 8, 1 October 2014 (2014-10-01), pages 90-97, XP055172036, ISSN: 1879-6257, DOI: 10.1016/j.coviro.2014.07.008
MAHESHRI N ET AL: "Directed evolution of adeno-associated virus yields enhanced gene delivery vectors", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 24, no. 2, 22 January 2006 (2006-01-22), pages 198-204, XP002393459, ISSN: 1087-0156, DOI: 10.1038/NBT1182
M A BARTEL ET AL: "Directed evolution of novel adeno-associated viruses for therapeutic gene delivery", GENE THERAPY, vol. 19, no. 6, 8 March 2012 (2012-03-08), pages 694-700, XP055172045, ISSN: 0969-7128, DOI: 10.1038/gt.2012.20

Fortsættes ...

JAMES T KOERBER ET AL: "DNA Shuffling of Adeno-associated Virus Yields Functionally Diverse Viral Progeny", MOLECULAR THERAPY, vol. 16, no. 10, 26 August 2008 (2008-08-26), pages 1703-1709, XP055172086, ISSN: 1525-0016, DOI: 10.1038/mt.2008.167
SYLVIE BOUTIN ET AL: "Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors", HUMAN GENE THERAPY, vol. 21, no. 6, 1 June 2010 (2010-06-01), pages 704-712, XP055172076, ISSN: 1043-0342, DOI: 10.1089/hum.2009.182
GAO GUANGPING ET AL: "Clades of adeno-associated viruses are widely disseminated in human tissues", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 78, no. 12, 1 June 2004 (2004-06-01), pages 6381-6388, XP002321999, ISSN: 0022-538X, DOI: 10.1128/JVI.78.12.6381-6388.2004

DESCRIPTION

TECHNICAL FIELD

[0001] This disclosure generally relates to viruses.

BACKGROUND

[0002] Circumventing and avoiding a neutralizing or toxic immune response against a gene therapy vector is a major challenge with all gene transfer vector types. Gene transfer to date is most efficiently achieved using vectors based on viruses circulating in humans and animals, e.g., adenovirus and adeno-associated virus (AAV). However, if subjects have been naturally infected with a virus, a subsequent treatment with a vector based on that virus leads to increased safety risks and decreased efficiency of gene transfer due to cellular and humoral immune responses. Capsid antigens are primarily responsible for the innate and/or adaptive immunity toward virus particles, however, viral gene-encoded polypeptides also can be immunogenic.

[0003] Calcedo et al., 2009 discloses worldwide seroprevalence towards a number of different AAV types.

SUMMARY

[0004] The invention is defined by the claims.

[0005] This disclosure describes methods of predicting and synthesizing ancestral viral sequences or portions thereof, and also describes virus particles containing such ancestral viral sequences. The methods described herein were applied to adeno-associated virus (AAV); thus, this disclosure describes predicted ancestral AAV sequences and AAV virus particles containing such ancestral AAV sequences. This disclosure also describes the reduced seroprevalance exhibited by virus particles containing ancestral sequences relative to virus particles containing contemporary sequences.

[0006] In one aspect, this disclosure includes adeno-associated virus (AAV) capsid polypeptides, e.g., synthetic and/or artificial AAV capsid polypeptides, having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15 and 17. In some implementations, the AAV capsid polypeptides or virus particles comprising the AAV capsid polypeptides exhibit a lower seroprevalence than do an AAV2 capsid polypeptide or a virus particle comprising an AAV2 capsid polypeptide, and the AAV capsid polypeptides or virus particles comprising the AAV capsid polypeptides exhibit about the same or a lower

seroprevalence than do an AAV8 capsid polypeptide or a virus particle comprising an AAV8 capsid polypeptide. In some embodiments, the AAV capsid polypeptides or virus particles comprising the AAV capsid polypeptides are neutralized to a lesser extent by human serum than is an AAV2 capsid polypeptide or a virus particle comprising an AAV2 capsid polypeptide, and the AAV capsid polypeptides or virus particles comprising the AAV capsid polypeptides are neutralized to a similar or lesser extent by human serum as is an AAV8 capsid polypeptide or a virus particle comprising an AAV8 capsid polypeptide. In some embodiments, the AAV capsid polypeptides are purified. The AAV capsid polypeptides provided herein can be encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, and 18.

[0007] In one aspect, the disclosure provides nucleic acid molecules, e.g., synthetic and/or artificial nucleic acid molecules, encoding an adeno-associated virus (AAV) capsid polypeptide having a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, and 18. Also provided are vectors that includes such a nucleic acid, and a host cell that includes such a vector.

[0008] In another aspect, the disclosure provides purified virus particles that include an AAV capsid polypeptide described herein. In some embodiments, the virus particles include a transgene.

[0009] In other aspects, the disclosure provides adeno-associated virus (AAV) capsid polypeptides, e.g., synthetic and/or artificial AAV capsid polypeptides, having at least 95% (e.g., 97, 98, 99, or 100%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 20, 21, 22, 23, 24, 25 and 26. In some embodiments, the AAV capsid polypeptides or virus particles comprising the AAV capsid polypeptide exhibit a lower seroprevalence than does an AAV2 capsid polypeptide or a virus particle comprising an AAV2 capsid polypeptide, and the AAV capsid polypeptide or a virus particle comprising the AAV capsid polypeptide exhibit about the same or a lower seroprevalence than does an AAV8 capsid polypeptide or a virus particle comprising an AAV8 capsid polypeptide. In some embodiments, the AAV capsid polypeptides or virus particles comprising the AAV capsid polypeptide are neutralized to a lesser extent by human serum than is an AAV2 capsid polypeptide or a virus particle comprising an AAV2 capsid polypeptide, and the AAV capsid polypeptide or a virus particle comprising the AAV capsid polypeptide is neutralized to a similar or lesser extent by human serum as is an AAV8 capsid polypeptide or a virus particle comprising an AAV8 capsid polypeptide. In some embodiments, the AAV capsid polypeptides are purified.

[0010] In another aspect, the AAV capsid polypeptides described herein can be encoded by nucleic acid sequences as described herein. In one implementation, the disclosure provides nucleic acid molecules encoding an adeno-associated virus (AAV) capsid polypeptide, wherein the nucleic acid molecules have at least 95% (e.g., 97, 98, 99, or 100%) sequence identity to a nucleic acid sequence as shown herein. The disclosure also provides vectors including such nucleic acid molecules, as are host cells that include such a vector.

[0011] In one aspect, the disclosure provides virus particles that include at least one of the AAV capsid polypeptides described herein. In some embodiments, the virus particles include a transgene.

[0012] In certain aspects, the disclosure provides methods of administering a virus particle as described herein to a subject in need of gene transfer or vaccination. In some embodiments, the virus particles exhibit less seroprevalence than does an AAV2 virus particle. In some embodiments, the virus particles exhibit about the same or less seroprevalence than does an AAV8 virus particle. In some embodiments, the virus particles are neutralized to a lesser extent by human serum than is an AAV2 virus particle, and the AAV virus particles are neutralized to a similar or lesser extent by human serum than is an AAV8 virus particle.

[0013] In one aspect, the disclosure provides methods of administering a target antigen operably linked to an AAV capsid polypeptide as described herein to a subject in need of vaccination. In some embodiments, the AAV capsid polypeptides exhibit less seroprevalence than does an AAV2 capsid polypeptide. In some embodiments, the AAV capsid polypeptide exhibits about the same or less seroprevalence than does an AAV8 capsid polypeptide. In some embodiments, the AAV capsid polypeptides are neutralized to a lesser extent by human serum than is an AAV2 capsid polypeptide, and the AAV capsid polypeptide is neutralized to a similar or lesser extent by human serum than is an AAV8 capsid polypeptide.

[0014] In another aspect, the disclosure provides *in silico* methods of predicting a sequence of an ancestral virus or portion thereof. Such methods typically include providing nucleotide or amino acid sequences from a plurality of contemporary viruses or portions thereof; aligning the sequences using a multiple sequence alignment (MSA) algorithm; modeling evolution to obtain a predicted ancestral phylogeny of the plurality of contemporary viruses or portions thereof; estimating, at a phylogenic node of the predicted ancestral phylogeny, the evolutionary probability of a particular nucleotide or amino acid residue at each position of the sequence; and predicting, based on the estimated probability at each position, a sequence of an ancestral virus or portion thereof.

[0015] In some embodiments of the present disclosure, one or more, or all, of the steps are performed using a computer processor. In some embodiments of the present disclosure, the MSA algorithm uses phylogenetic information to predict if a gap in the alignment is a result of a deletion or an insertion. In some embodiments of the present disclosure, the MSA algorithm is a Probabilistic Alignment Kit (PRANK). In some embodiments of the present disclosure, the model used for modeling evolution is selected using Aikake Information Criterion (AIC). In some embodiments of the present disclosure, the predicted ancestral phylogeny is obtained using a JTT model with a Gamma distribution model ("+G") and a frequency calculation of πi ("+F"). In some embodiments of the present disclosure, the modeling the evolution step is performed using a JTT+G+F model. In some embodiments of the present disclosure, the methods include synthesizing, based on the predicted sequence, the ancestral virus or portion thereof. In some embodiments of the present disclosure, the methods include assembling the

ancestral virus or portion thereof into an ancestral virus particle.

[0016] In some embodiments, the methods also include screening the ancestral virus particle for at least one of the following: (a) replication; (b) gene transfer properties; (c) receptor binding; or (d) seroprevalence. In some embodiments, the ancestral virus particles exhibit less seroprevalence than does a virus particle assembled from at least one of the plurality of contemporary viruses or portions thereof. In some embodiments, the ancestral virus particle is neutralized to a lesser extent by human serum than is a virus particle assembled from at least one of the plurality of contemporary viruses or portions thereof. In some embodiments, the plurality of contemporary viruses or portions thereof belong to a family selected from the group consisting of adenovirus (AV), human immunodeficiency virus (HIV), retrovirus, lentivirus, herpes simplex virus (HSV), vaccinia virus, pox virus, influenza virus, respiratory syncytial virus, parainfluenza virus, and foamy virus.

[0017] Thus, the present disclosure provides ancestral viruses or portions thereof that exhibit reduced susceptibility to pre-existing immunity in current day human populations than do contemporary viruses or portions thereof. Generally, the reduced susceptibility to pre-existing immunity exhibited by the ancestral viruses or portions thereof in current day human populations is reflected as a reduced susceptibility to neutralizing antibodies.

[0018] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the methods and compositions of matter belong. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the methods and compositions of matter, suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

DESCRIPTION OF DRAWINGS

[0019] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.

Figure 1 is a schematic showing the relationships between ancestral/contemporary viral infections and ancestral/contemporary host immune response.

Figures 2A to 2D are a series of schematics showing an example of an ancestral reconstruction procedure. Data shown are excerpted from a full dataset and represent residues 564-584 (AAV2-VP1 numbering).

Figures 3A to 3C together illustrate a phylogenetic tree of AAV contemporary sequences generated using the methods described herein.

Figures 4A and 4B together illustrate an alignment of ancestral AAV VP 1 polypeptides.

Figures 5A and 5B together illustrate an alignment of functional ancestral AAV VP1 polypeptides and contemporary AAV VP1 polypeptides.

Figure 6 is an electrophoretic gel demonstrating that ancestral AAV VP1 sequences are transcribed and alternately spliced in a manner similar to that for contemporary AAV VP1 sequences.

Figure 7 is a graph showing the luciferase activity in HEK293 cells transduced with ancestral AAV vectors.

Figure 9 is a graph showing the sequence comparison (% up from diagonal, # of aa differences below) between the Anc80 library and Anc80L65.

Figures 10A-D are images of experimental results demonstrating that Anc80L65 is capable of assembling and yielding particles of high titer. Panel A shows that Anc80L65 is able to produce vector yields equivalent to AAV2; Panel B is a TEM image of virus particles that include Anc80L65; Panel C shows that virus particles that include Anc80L65 are able to produce AAV cap VP1, 2 and 3 proteins based on SDS-PAGE gel under denaturing conditions; and Panel D shows a Western blot of Anc80L65 using the AAV capsid antibody, B1.

Figures 11A-C are images of experimental results demonstrating that Anc80L65 is able to infect cells in vitro on HEK293 cells using GFP as readout (Panel A) or luciferase (Panel B) versus AAV2 and/or AAV8 controls and also is efficient at targeting liver following an IV injection of AAV encoding a nuclear LacZ transgene (top row, Panel C: liver), following direct IM injection of an AAV encoding GFP (middle row, Panel C: muscle), and following sub-retinal injection with AAV encoding GFP (bottom row, Panel C: retina).

Figures 13A and 13B are sequence identity matrices producing using MAFFT that show the amino acid sequences of the VP1 proteins of ancestral vectors aligned with those of representative extant AAVs (Figure 13A), and the amino acid sequences of the VP3 proteins of ancestral vectors aligned with those of representative extant AAVs (Figure 13B).

Figure 14 is a graph that demonstrates that AAV vectors were produced in triplicate in small scale (6-well dishes). Crude viruses were assessed via qPCR to determine the absolute production of each vector.

Figure 15 is a table showing the titers of each vector, averaged and compared, to those of AAV8.

Figure 16 are photographs that show the results of experiments in which 1.9E3 GC/cell of each vector was added to HEK293 cells (except for Anc126, in which case MOIs of 2.5E2 - 3.1E2 GC/cell were achieved). Sixty hours later, infectivity was assessed using fluorescence microscopy.

Figure 17 is a graph showing the results of experiments in which the same cells from Figure 16 were lysed and assayed for luciferase expression. As in Figure 16, Anc126 was not titer controlled with the other vectors, but rather ranged from an MOI of 2.5E2 - 3.1E2 GC/cell.

Figure 18 is a table showing the luminescence of cells transduced by each vector, which were averaged and compared to those of AAV8.

Figure 19 is a chart that provides a summary of *in vitro* experiments to determine the relative production and infectivity of the ancestral AAV vectors described herein.

DETAILED DESCRIPTION

[0020] Gene transfer, either for experimental or therapeutic purposes, relies upon a vector or vector system to shuttle genetic information into target cells. The vector or vector system is considered the major determinant of efficiency, specificity, host response, pharmacology, and longevity of the gene transfer reaction. Currently, the most efficient and effective way to accomplish gene transfer is through the use of vectors or vector systems based on viruses that have been made replication-defective.

[0021] Seroprevalence studies, however, indicate that significant proportions of worldwide human populations have been pre-exposed (e.g., by natural infection) to a large number of the viruses currently used in gene transfer and, therefore, harbor pre-existing immunity. Neutralizing antibodies toward the viral vector in these pre-exposed individuals are known to limit, sometimes significantly, the extent of gene transfer or even re-direct the virus away from the target. See, for example, Calcedo et al. (2009, J. Infect. Dis., 199:381-90) and Boutin et al. (2010, Human Gene Ther., 21:704-12). Thus, the present disclosure is based on the recognition that ancestral viruses or portions thereof exhibit reduced susceptibility to pre-existing immunity (e.g., reduced susceptibility to neutralizing antibodies) in current day human populations than do contemporary viruses or portions thereof.

[0022] Figure 1 is a schematic showing the relationships between ancestral and contemporary viral infections and ancestral and contemporary host immune response. Figure 1 shows how ancestral AAVs can be refractory to contemporary pre-existing immunity. A contemporary, extant virus (Vc) is presumed to have evolved from an ancestral species (Vanc), primarily under evolutionary pressures of host immunity through mechanisms of immune escape. Each of these species, Vanc and Vc, have the ability to induce adaptive immunity including B and T cell immunity (Ianc and Ic, respectively). It was hypothesized, and confirmed herein, that immunity induced by contemporary viruses does not necessarily cross-react with an ancestral viral species, which can be substantially different in terms of epitope composition than the extant virus.

[0023] This disclosure provides methods of predicting the sequence of an ancestral virus or a portion thereof. One or more of the ancestral virus sequences predicted using the methods described herein can be generated and assembled into a virus particle. As demonstrated herein, virus particles assembled from predicted ancestral viral sequences can exhibit less,

sometimes significantly less, seroprevalence than current-day, contemporary virus particles. Thus, the ancestral virus sequences disclosed herein are suitable for use in vectors or vector systems for gene transfer.

Methods of Predicting and Synthesizing an Ancestral Viral Sequence

[0024] To predict an ancestral viral sequence, nucleotide or amino acid sequences first are compiled from a plurality of contemporary viruses or portions thereof. While the methods described herein were exemplified using adeno-associated virus (AAV) capsid sequences, the same methods can be applied to other sequences from AAV (e.g., the entire genome, rep sequences, ITR sequences) or to any other virus or portion thereof. Viruses other than AAV include, without limitation, adenovirus (AV), human immunodeficiency virus (HIV), retrovirus, lentivirus, herpes simplex virus (HSV), measles, vaccinia virus, pox virus, influenza virus, respiratory syncytial virus, parainfluenza virus, foamy virus, or any other virus to which pre-existing immunity is considered a problem.

[0025] Sequences from as few as two contemporary viruses or portions thereof can be used, however, it is understood that a larger number of sequences of contemporary viruses or portions thereof is desirable so as to include as much of the landscape of modern day sequence diversity as possible, but also because a larger number of sequences can increase the predictive capabilities of the algorithms described and used. For example, sequences from 10 or more contemporary viruses or portions thereof can be used, sequences from 50 or more contemporary viruses or portions thereof can be used, or sequences from 100 or more contemporary viruses or portions thereof can be used.

[0026] Such sequences can be obtained, for example, from any number of public databases including, without limitation, GenBank, UniProt, EMBL, International Nucleotide Sequence Database Collaboration (INSDC), or European Nucleotide Archive. Additionally or alternatively, such sequences can be obtained from a database that is specific to a particular organism (e.g., HIV database). The contemporary sequences can correspond to the entire genome, or only a portion of the genome can be used such as, without limitation, sequences that encode one or more components of the viral capsid, the replication protein, or the ITR sequences.

[0027] Next, the contemporary sequences are aligned using a multiple sequence alignment (MSA) algorithm. Figure 2(a) is a schematic showing an alignment of multiple sequences. MSA algorithms are well known in the art and generally are designed to be applied to different size datasets and different inputs (e.g., nucleic acid or protein), and to align the sequences in a particular manner (e.g., dynamic programming, progressive, heuristic) and apply different scoring schemes in the alignment (e.g., matrix-based or consistency-based, e.g., minimum entropy, sum of pairs, similarity matrix, gap scores). Well known MSA algorithms include, for example, ClustalW (Thompson et al., 1994, Nuc. Acids Res., 22:4673-90), Kalign (Lassmann et al., 2006, Nuc. Acids Res., 34:W596-99), MAFFT (Katoh et al., 2005, Nuc. Acids Res., 33:511-8), MUSCLE (Edgar, 2004, BMC Bioinform., 5:113), and T-Coffee (Notredame et al.,

2000, J. Mol. Biol., 302:205-17).

[0028] As described herein, one of the main features when selecting a MSA algorithm for use in the methods described herein is the manner in which the algorithm treats a gap in the alignment. Gaps in a sequence alignment can be assigned a penalty value that is either dependent or independent on the size of the gap. In the present methods, it is preferred that the MSA algorithm used in the methods described herein apply phylogenetic information to predict whether a gap in the alignment is a result of a deletion or an insertion as opposed to a biased, non-phylogenetic treatment of gaps due to, e.g., insertions and/or deletions. A suitable method of treating gaps in alignments and evolutionary analysis is described in Loytynoja and Goldman, 2008, Science, 320:1632-5, and commercially available algorithms that apply gaps in alignments in a manner that is suitable for use in the methods described herein is a Probabilistic Alignment Kit (PRANK; Goldman Group Software; Loytynoja and Goldman, 2005, PNAS USA, 102:10557-62), and variations of the PRANK algorithm.

[0029] An evolutionary model is then applied to the resulting alignment to obtain a predicted ancestral phylogeny (see Figure 2(b)). There are a number of evolutionary models available in the art, each of which apply slightly different matrices of replacement rates for amino acids. Without limitation, algorithms for applying models of evolution include the Dayhoff models (e.g., PAM120, PAM160, PAM250; Dayhoff et al., 1978, In Atlas of Protein Sequence and Structure (ed. Dayhoff), pp. 345-52, National Biomedical Research Foundation, Washington D.C.), the JTT model (Jones et al., 1992, Comp. Appl. Biosci., 8:275-82), the WAG model (Whelan and Goldman, 2001, Mol. Biol. Evol., 18:691-9), and the Blosum models (e.g., Blosum45, Blosum62, Blosum80; Henikoff and Henikoff, 1992, PNAS USA, 89:10915-9).

[0030] In addition, the constraints that structure and function impose on an evolutionary model can themselves be modeled, for example, by considering that some positions are invariant ("+I"; Reeves, 1992, J. Mol. Evol., 35:17-31), that some positions undergo different rates of change ("+G"; Yang, 1993, Mol. Biol. Evol., 10:1396-1401), and/or that equilibrium frequencies of nucleotides or amino acids are the same as those in the alignment ("+F"; Cao et al., 1994, J. Mol. Evol., 39:519-27).

[0031] The fitness of one or more models of evolution can be evaluated using the Aikake Information Criterion (AIC; Akaike, 1973, In Second International Symposium on Information Theory, Petrov and Csaki, eds., pp 267-81, Budapest, Akademiai Kiado), the Bayesian Information Criterion (BIC; Schwarz, 1978, Ann. Statist. 6:461-4), or variations or combinations thereof. In addition, AIC, BIC, or variations or combinations thereof can be used to evaluate the relative importance of including one or more parameters (e.g., the constraints discussed above) in the evolutionary model.

[0032] As explained in the Example section below, ProTest3 (Darriba et al., 2011, Bioinformatics, 27(8):1164-5) can be used to determine, based on the lowest AIC, that a JTT+G+F algorithm was the most suitable model for AAV evolution. It would be understood by a skilled artisan that a JTT+G+F algorithm also may be used to predict ancestral viral

sequences other than AAV capsid polypeptides, however, it also would be understood by a skilled artisan that, depending on the dataset and the fitness score, a different model of evolution may be more suitable.

[0033] Once a model of evolution has been selected and its fitness determined, a phylogenetic tree of the virus sequences or portions thereof can be constructed. Constructing phylogenetic trees is known in the art and typically employs maximum likelihood methods such as those implemented by PhyML (Guindon and Gascuel, 2003, Systematic Biology, 52:696-704)), MOLPHY (Adachi and Hasegawa, 1996, ed. Tokyo Institute of Statistical Mathematics), BioNJ (Gascuel, 1997, Mol. Biol. Evol., 14:685-95), or PHYLIP (Felsenstein, 1973, Systematic Biology, 22:240-9). A skilled artisan would understand that a balance between computational complexity and the goodness of fit is desirable in a model of amino acid substitutions.

[0034] If desired, the phylogenetic tree can be assessed for significance. A number of statistical methods are available and routinely used to evaluate the significance of a model including, without limitation, bootstrap, jackknife, cross-validation, permutation tests, or combinations or variations thereof. Significance also can be evaluated using, for example, an approximate likelihood-ratio test (aLRT; Anisimova and Gascuel, 2006, Systematic Biology, 55:539-52)).

[0035] At any phylogenetic node of the phylogeny (e.g., an interior phylogenetic node), the sequence can be reconstructed by estimating the evolutionary probability of a particular nucleotide or amino acid residue at each position of the sequence (Figure 2(c)). A phylogenic node refers to an intermediate evolutionary branch point within the predicted ancestral phylogeny. As used herein, "evolutionary probability" refers to the probability of the presence of a particular nucleotide or amino acid at a particular position based on an evolutionary model as opposed to a model that does not take into account, for example, an evolutionary shift in the codon usage. Exemplary models that take into account the evolutionary probability of a particular nucleotide or amino acid residue at a particular position can be estimated using, for example, any number of maximum likelihood methods including, without limitation, Phylogenetic Analysis by Maximum Likelihood (PAML; Yang, 1997, Comp. Applic. BioSci., 13:555-6) or Phylogenetic Analysis Using Parsimony (PAUP; Sinauer Assoc., Inc., Sunderland, MA).

[0036] Based on the estimated evolutionary probability of a particular nucleotide or amino acid residue at each position, the predicted sequence of an ancestral virus or portion thereof can be assembled to form a complete or partial synthetic nucleic acid or polypeptide sequence. If desired, the likelihood that any residue was in a given state at a given node along the node can be calculated, and any position along the sequence having a calculated posterior probability beneath a particular threshold can be identified (Figure 2(d)). In this manner, an ancestral scaffold sequence can be generated, which can include variations at those positions having a probability below the particular threshold.

[0037] If the ancestral sequence that is predicted using the methods herein is a nucleic acid

sequence, the sequence then can be codon optimized so that it can be efficiently translated into an amino acid sequence. Codon usage tables for different organisms are known in the art. Optionally, however, a codon usage table can be designed based on one or more contemporary sequences that has homology (e.g., at least 90% sequence identity) to the ancestral scaffold sequence, and an ancestral sequence as described herein can be codon optimized toward mammalian (e.g., human) codon usage.

[0038] Any or all of the steps outlined herein for predicting an ancestral viral sequence can be performed or simulated on a computer (e.g., *in silico*) using a processor or a microprocessor.

Ancestral Adeno-Associated Virus (AAV) Scaffold Sequences

[0039] The methods described herein were applied to adeno-associated virus (AAV) using contemporary capsid sequences (described in detail in the Examples below). AAV is widely considered as a therapeutic gene transfer vector and a genetic vaccine vehicle, but exhibits a high seroprevalence in human populations. Using the methods described herein, a phylogenetic tree was assembled using contemporary AAV sequences (see Figures 3A-3C) and predicted ancestral scaffold sequences were obtained at the designated phylogenic node (Table 1). As used herein, an ancestral scaffold sequence refers to a sequence that is constructed using the methods described herein (e.g., using evolutionary probabilities and evolutionary modeling) and is not known to have existed in nature. As used herein, the ancestral scaffold sequences are different from consensus sequences, which are typically constructed using the frequency of nucleotides or amino acid residues at a particular position.

Table 1.

Node	Polypeptide (SEQ ID NO)	Nucleic Acid (SEQ ID NO)
Anc80	1	2
Anc81	3	4
Anc82	5	6
Anc83	7	8
Anc84	9	10
Anc94	11	12
Anc113	13	14
Anc126	15	16
Anc127	17	18

[0040] The scaffold sequence of the Anc80 polypeptide is shown in SEQ ID NO: 1, which is encoded by the scaffold sequence of the Anc80 nucleic acid shown in SEQ ID NO:2. The scaffold sequence of Anc80 contains 11 positions at which either of two residues were probable. Therefore, the Anc80 scaffold sequence represents 2048 (2^{11}) different sequences.

[0041] To demonstrate the effectiveness of the methods described herein for predicting the ancestral sequence of a virus or portion thereof, a library of the 2048 predicted ancestral sequences at the AAV Anc80 node was generated and, as described herein, demonstrated to form viable virus particles exhibiting less seroprevalence, in some instances, significantly less seroprevalance, than virus particles assembled with contemporary capsid polypeptides.

Methods of Making Ancestral Virus Particles

[0042] After the predicted ancestral sequence of a virus or portion thereof has been obtained, the actual nucleic acid molecule and/or polypeptide(s) can be generated, e.g., synthesized. Methods of generating an artificial nucleic acid molecule or polypeptide based on a sequence obtained, for example, *in silico,* are known in the art and include, for example, chemical synthesis or recombinant cloning. Additional methods for generating nucleic acid molecules or polypeptides are known in the art and are discussed in more detail below.

[0043] Once an ancestral polypeptide has been produced, or once an ancestral nucleic acid molecule has been generated and expressed to produce an ancestral polypeptide, the ancestral polypeptide can be assembled into an ancestral virus particle using, for example, a packaging host cell. The components of a virus particle (e.g., rep sequences, cap sequences, inverted terminal repeat (ITR) sequences) can be introduced, transiently or stably, into a packaging host cell using one or more vectors as described herein. One or more of the components of a virus particle can be based on a predicted ancestral sequence as described herein, while the remaining components can be based on contemporary sequences. In some instances, the entire virus particle can be based on predicted ancestral sequences.

[0044] Such ancestral virus particles can be purified using routine methods. As used herein, "purified" virus particles refer to virus particles that are removed from components in the mixture in which they were made such as, but not limited to, viral components (e.g., rep sequences, cap sequences), packaging host cells, and partially- or incompletely-assembled virus particles.

[0045] Once assembled, the ancestral virus particles can be screened for, e.g., the ability to replicate; gene transfer properties; receptor binding ability; and/or seroprevalence in a population (e.g., a human population). Determining whether a virus particle can replicate is routine in the art and typically includes infecting a host cell with an amount of virus particles and determining if the virus particles increase in number over time. Determining whether a virus particle is capable of performing gene transfer also is routine in the art and typically includes infecting host cells with virus particles containing a transgene (e.g., a detectable transgene such as a reporter gene, discussed in more detail below). Following infection and clearance of the virus, the host cells can be evaluated for the presence or absence of the transgene. Determining whether a virus particle binds to its receptor is routine in the art, and such methods can be performed *in vitro* or *in vivo.*

[0046] Determining the seroprevalence of a virus particle is routinely performed in the art and typically includes using an immunoassay to determine the prevalence of one or more antibodies in samples (e.g., blood samples) from a particular population of individuals. Seroprevalence is understood in the art to refer to the proportion of subjects in a population that is seropositive (i.e., has been exposed to a particular pathogen or immunogen), and is calculated as the number of subjects in a population who produce an antibody against a particular pathogen or immunogen divided by the total number of individuals in the population examined. Immunoassays are well known in the art and include, without limitation, an immunodot, Western blot, enzyme immunoassays (EIA), enzyme-linked immunosorbent assay (ELISA), or radioimmunoassay (RIA). As indicated herein, ancestral virus particles exhibit less seroprevalence than do contemporary virus particles (i.e., virus particles assembled using contemporary virus sequences or portions thereof). Simply by way of example, see Xu et al. (2007, Am. J. Obstet. Gynecol., 196:43.e1-6); Paul et al. (1994, J. Infect. Dis., 169:801-6); Sauerbrei et al. (2011, Eurosurv., 16(44):3); and Sakhria et al. (2013, PLoS Negl. Trop. Dis., 7:e2429), each of which determined seroprevalence for a particular antibody in a given population.

[0047] As described herein, ancestral virus particles are neutralized by a person's, e.g., patient's, immune system to a lesser extent than are contemporary virus particles. Several methods to determine the extent of neutralizing antibodies in a serum sample are available. For example, a neutralizing antibody assay measures the titer at which an experimental sample contains an antibody concentration that neutralizes infection by 50% or more as compared to a control sample without antibody. See, also, Fisher et al. (1997, Nature Med., 3:306-12) and Manning et al. (1998, Human Gene Ther., 9:477-85).

[0048] With respect to the ancestral AAV capsid polypeptides exemplified herein, the seroprevalence and/or extent of neutralization can be compared, for example, to an AAV8 capsid polypeptide or virus particle that includes an AAV8 capsid polypeptide, or an AAV2 capsid polypeptide or virus particle that includes an AAV2 capsid polypeptide. It is generally understood in the art that AAV8 capsid polypeptides or virus particles exhibit a seroprevalance, and a resulting neutralization, in the human population that is considered low, while AAV2 capsid polypeptide or virus particles exhibit a seroprevalance, and a resulting neutralization, in the human population that is considered high. Obviously, the particular seroprevalence will depend upon the population examined as well as the immunological methods used, but there are reports that AAV8 exhibits a seroprevalence of about 22% up to about 38%, while AAV2 exhibits a seroprevalence of about 43.5% up to about 72%. See, for example, Boutin et al., 2010, "Prevalence of serum IgG and neutralizing factors against AAV types 1, 2, 5, 6, 8 and 9 in the healthy population: implications for gene therapy using AAV vectors," Hum. Gene Ther., 21:704-12. See, also, Calcedo et al., 2009, J. Infect. Dis., 199:381-90.

Predicted Adeno-Associated Virus (AAV) Ancestral Nucleic Acid and Polypeptide Sequences

[0049] A number of different clones from the library encoding predicted ancestral capsid polypeptides from the Anc80 node were sequenced, and the amino acid sequences of representative AAV predicted ancestral capsid polypeptides are shown in SEQ ID NO: 19 (Anc80L27); SEQ ID NO: 20 (Anc80L59); SEQ ID NO: 21 (Anc80L60); SEQ ID NO: 22 (Anc80L62); SEQ ID NO: 23 (Anc80L65); SEQ ID NO: 24 (Anc80L33); SEQ ID NO: 25 (Anc80L36); and SEQ ID NO:26 (Anc80L44). Those skilled in the art would appreciate that the nucleic acid sequence encoding each amino acid sequence can readily be determined.

[0050] In addition to the predicted ancestral capsid polypeptides having the sequences shown in SEQ ID NOs: 19, 20, 21, 22, 23, 24, 25 or 26, polypeptides are provided that have at least 95% sequence identity (e.g., at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity) to the predicted ancestral capsid polypeptides having the sequences shown in SEQ ID NOs: 19, 20, 21, 22, 23, 24, 25, or 26. Similarly, nucleic acid molecules are provided that have at least 95% sequence identity (e.g., at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity) to the nucleic acid molecules encoding the ancestral capsid polypeptides (i.e., having at least 95% sequence identity).

[0051] In calculating percent sequence identity, two sequences are aligned and the number of identical matches of nucleotides or amino acid residues between the two sequences is determined. The number of identical matches is divided by the length of the aligned region (i.e., the number of aligned nucleotides or amino acid residues) and multiplied by 100 to arrive at a percent sequence identity value. It will be appreciated that the length of the aligned region can be a portion of one or both sequences up to the full-length size of the shortest sequence. It also will be appreciated that a single sequence can align with more than one other sequence and hence, can have different percent sequence identity values over each aligned region.

[0052] The alignment of two or more sequences to determine percent sequence identity can be performed using the algorithm described by Altschul et al. (1997, Nucleic Acids Res., 25:3389 3402) as incorporated into BLAST (basic local alignment search tool) programs, available at ncbi.nlm.nih.gov on the World Wide Web. BLAST searches can be performed to determine percent sequence identity between a sequence (nucleic acid or amino acid) and any other sequence or portion thereof aligned using the Altschul et al. algorithm. BLASTN is the program used to align and compare the identity between nucleic acid sequences, while BLASTP is the program used to align and compare the identity between amino acid sequences. When utilizing BLAST programs to calculate the percent identity between a sequence and another sequence, the default parameters of the respective programs generally are used.

[0053] Representative alignments are shown in Figures 4A and 4B and Figures 5A and 5B. Figures 4A and 4B show an alignment of ancestral AAV VP1 capsid polypeptides, designated Anc80L65 (SEQ ID NO: 23), Anc80L27 (SEQ ID NO: 19), Anc80L33 (SEQ ID NO: 24), Anc80L36 (SEQ ID NO: 25), Anc80L44 (SEQ ID NO: 26), Anc80L59 (SEQ ID NO: 20), Anc80L60 (SEQ ID NO: 21), and Anc80L62 (SEQ ID NO: 22). The alignment shown in Figures

4A and 4B confirms the predicted variation at each of the 11 sites, and a single non-synonymous mutation at position 609E of Anc80L60 (SEQ ID NO: 21), which may be a cloning artifact. Figures 5A and 5B shows an alignment between ancestral AAV VP1 capsid polypeptides (Anc80L65 (SEQ ID NO: 23), Anc80L27 (SEQ ID NO: 19), Anc80L33 (SEQ ID NO: 24), Anc80L36 (SEQ ID NO: 25), Anc80L60 (SEQ ID NO: 21), Anc80L62 (SEQ ID NO: 22), Anc80L44 (SEQ ID NO: 26), and Anc80L59 (SEQ ID NO: 20)) and contemporary AAV VP1 capsid polypeptides (AAV8 (SEQ ID NO: 27), AAV9 (SEQ ID NO: 28), AAV6 (SEQ ID NO: 29), AAV1 (SEQ ID NO: 30), AAV2 (SEQ ID NO: 31), AAV3 (SEQ ID NO: 32), AAV3B (SEQ ID NO: 33), and AAV7 (SEQ ID NO: 34)). The alignment in Figures 5A and 5B shows that the ancestral AAV sequences have between about 85% and 91% sequence identity to contemporary AAV sequences.

[0054] Vectors containing nucleic acid molecules that encode polypeptides also are provided. Vectors, including expression vectors, are commercially available or can be produced by recombinant technology. A vector containing a nucleic acid molecule can have one or more elements for expression operably linked to such a nucleic acid molecule, and further can include sequences such as those encoding a selectable marker (e.g., an antibiotic resistance gene), and/or those that can be used in purification of a polypeptide (e.g., 6xHis tag). Elements for expression include nucleic acid sequences that direct and regulate expression of nucleic acid coding sequences. One example of an expression element is a promoter sequence. Expression elements also can include one or more of introns, enhancer sequences, response elements, or inducible elements that modulate expression of a nucleic acid molecule. Expression elements can be of bacterial, yeast, insect, mammalian, or viral origin and vectors can contain a combination of expression elements from different origins. As used herein, operably linked means that elements for expression are positioned in a vector relative to a coding sequence in such a way as to direct or regulate expression of the coding sequence.

[0055] A nucleic acid molecule, e.g., a nucleic acid molecule in a vector (e.g., an expression vector, a viral vector) can be introduced into a host cell. The term "host cell" refers not only to the particular cell(s) into which the nucleic acid molecule has been introduced, but also to the progeny or potential progeny of such a cell. Many suitable host cells are known to those skilled in the art; host cells can be prokaryotic cells (e.g., E. coli) or eukaryotic cells (e.g., yeast cells, insect cells, plant cells, mammalian cells). Representative host cells can include, without limitation, A549, WEHI, 3T3, 10T1/2, BHK, MDCK, COS 1, COS 7, BSC 1, BSC 40, BMT 10, VERO, WI38, HeLa, 293 cells, Saos, C2C12, L cells, HT1080, HepG2 and primary fibroblast, hepatocyte and myoblast cells derived from mammals including human, monkey, mouse, rat, rabbit, and hamster. Methods for introducing nucleic acid molecules into host cells are well known in the art and include, without limitation, calcium phosphate precipitation, electroporation, heat shock, lipofection, microinjection, and viral-mediated nucleic acid transfer (e.g., transduction).

[0056] With respect to polypeptides, "purified" refers to a polypeptide (i.e., a peptide or a polypeptide) that has been separated or purified from cellular components that naturally accompany it. Typically, the polypeptide is considered "purified" when it is at least 70% (e.g., at

least 75%, 80%, 85%, 90%, 95%, or 99%) by dry weight, free from the polypeptides and naturally occurring molecules with which it is naturally associated. Since a polypeptide that is chemically synthesized is, by nature, separated from the components that naturally accompany it, a synthetic polypeptide is considered "purified," but further can be removed from the components used to synthesize the polypeptide (e.g., amino acid residues). With respect to nucleic acid molecules, "isolated" refers to a nucleic acid molecule that is separated from other nucleic acid molecules that are usually associated with it in the genome. In addition, an isolated nucleic acid molecule can include an engineered nucleic acid molecule such as a recombinant or a synthetic nucleic acid molecule.

[0057] Polypeptides can be obtained (e.g., purified) from natural sources (e.g., a biological sample) by known methods such as DEAE ion exchange, gel filtration, and/or hydroxyapatite chromatography. A purified polypeptide also can be obtained, for example, by expressing a nucleic acid molecule in an expression vector or by chemical synthesis. The extent of purity of a polypeptide can be measured using any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. Similarly, nucleic acid molecules can be obtained (e.g., isolated) using routine methods such as, without limitation, recombinant nucleic acid technology (e.g., restriction enzyme digestion and ligation) or the polymerase chain reaction (PCR; see, for example, PCR Primer: A Laboratory Manual, Dieffenbach & Dveksler, Eds., Cold Spring Harbor Laboratory Press, 1995). In addition, isolated nucleic acid molecules can be chemically synthesized.

Methods of Using Ancestral Viruses or Portions Thereof

[0058] An ancestral virus or portion thereof as described herein, particularly those that exhibit reduced seroprevalence relative to contemporary viruses or portions thereof, can be used in a number of research and/or therapeutic applications. For example, an ancestral virus or portion thereof as described herein can be used in human or animal medicine for gene therapy (e.g., in a vector or vector system for gene transfer) or for vaccination (e.g., for antigen presentation). More specifically, an ancestral virus or portion thereof as described herein can be used for gene addition, gene augmentation, genetic delivery of a polypeptide therapeutic, genetic vaccination, gene silencing, genome editing, gene therapy, RNAi delivery, cDNA delivery, mRNA delivery, miRNA delivery, miRNA sponging, genetic immunization, optogenetic gene therapy, transgenesis, DNA vaccination, or DNA immunization.

[0059] A host cell can be transduced or infected with an ancestral virus or portion thereof *in vitro* (e.g., growing in culture) or *in vivo* (e.g., in a subject). Host cells that can be transduced or infected with an ancestral virus or portion thereof *in vitro* are described herein; host cells that can be transduced or infected with an ancestral virus or portion thereof *in vivo* include, without limitation, brain, liver, muscle, lung, eye (e.g., retina, retinal pigment epithelium), kidney, heart, gonads (e.g., testes, uterus, ovaries), skin, nasal passages, digestive system, pancreas, islet cells, neurons, lymphocytes, ear (e.g., inner ear), hair follicles, and/or glands (e.g., thyroid).

[0060] An ancestral virus or portion thereof as described herein can be modified to include a transgene (in *cis* or *trans* with other viral sequences). A transgene can be, for example, a reporter gene (e.g., beta-lactamase, beta-galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent polypeptide (GFP), chloramphenicol acetyltransferase (CAT), or luciferase, or fusion polypeptides that include an antigen tag domain such as hemagglutinin or Myc) or a therapeutic gene (e.g., genes encoding hormones or receptors thereof, growth factors or receptors thereof, differentiation factors or receptors thereof, immune system regulators (e.g., cytokines and interleukins) or receptors thereof, enzymes, RNAs (e.g., inhibitory RNAs or catalytic RNAs), or target antigens (e.g., oncogenic antigens, autoimmune antigens)).

[0061] The particular transgene will depend, at least in part, on the particular disease or deficiency being treated. Simply by way of example, gene transfer or gene therapy can be applied to the treatment of hemophilia, retinitis pigmentosa, cystic fibrosis, leber congenital amaurosis, lysosomal storage disorders, inborn errors of metabolism (e.g., inborn errors of amino acid metabolism including phenylketonuria, inborn errors of organic acid metabolism including propionic academia, inborn errors of fatty acid metabolism including medium-chain acyl-CoA dehydrogenase deficiency (MCAD)), cancer, achromatopsia, cone-rod dystrophies, macular degenerations (e.g., age-related macular degeneration), lipopolypeptide lipase deficiency, familial hypercholesterolemia, spinal muscular atrophy, Duchenne's muscular dystrophy, Alzheimer's disease, Parkinson's disease, obesity, inflammatory bowel disorder, diabetes, congestive heart failure, hypercholesterolemia, hearing loss, coronary heart disease, familial renal amyloidosis, Marfan's syndrome, fatal familial insomnia, Creutzfeldt-Jakob disease, sickle-cell disease, Huntington's disease, fronto-temporal lobar degeneration, Usher syndrome, lactose intolerance, lipid storage disorders (e.g., Niemann-Pick disease, type C), Batten disease, choroideremia, glycogen storage disease type II (Pompe disease), ataxia telangiectasia (Louis-Bar syndrome), congenital hypothyroidism, severe combined immunodeficiency (SCID), and/or amyotrophic lateral sclerosis (ALS).

[0062] A transgene also can be, for example, an immunogen that is useful for immunizing a subject (e.g., a human, an animal (e.g., a companion animal, a farm animal, an endangered animal). For example, immunogens can be obtained from an organism (e.g., a pathogenic organism) or an immunogenic portion or component thereof (e.g., a toxin polypeptide or a by-product thereof). By way of example, pathogenic organisms from which immunogenic polypeptides can be obtained include viruses (e.g., picornavirus, enteroviruses, orthomyxovirus, reovirus, retrovirus), prokaryotes (e.g., Pneumococci, Staphylococci, Listeria, Pseudomonas), and eukaryotes (e.g., amebiasis, malaria, leishmaniasis, nematodes). It would be understood that the methods described herein and compositions produced by such methods are not to be limited by any particular transgene.

[0063] An ancestral virus or portion thereof, usually suspended in a physiologically compatible carrier, can be administered to a subject (e.g., a human or non-human mammal). Suitable carriers include saline, which may be formulated with a variety of buffering solutions (e.g., phosphate buffered saline), lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin,

and water. The ancestral virus or portion thereof is administered in sufficient amounts to transduce or infect the cells and to provide sufficient levels of gene transfer and expression to provide a therapeutic benefit without undue adverse effects. Conventional and pharmaceutically acceptable routes of administration include, but are not limited to, direct delivery to an organ such as, for example, the liver or lung, orally, intranasally, intratracheally, by inhalation, intravenously, intramuscularly, intraocularly, subcutaneously, intradermally, transmucosally, or by other routes of administration. Routes of administration can be combined, if desired.

[0064] The dose of the ancestral virus or portion thereof administered to a subject will depend primarily on factors such as the condition being treated, and the age, weight, and health of the subject. For example, a therapeutically effective dosage of an ancestral virus or portion thereof to be administered to a human subject generally is in the range of from about 0.1 ml to about 10 ml of a solution containing concentrations of from about 1×10^1 to 1×10^{12} genome copies (GCs) of ancestral viruses (e.g., about 1×10^3 to 1×10^9 GCs). Transduction and/or expression of a transgene can be monitored at various time points following administration by DNA, RNA, or protein assays. In some instances, the levels of expression of the transgene can be monitored to determine the frequency and/or amount of dosage. Dosage regimens similar to those described for therapeutic purposes also may be utilized for immunization.

[0065] The methods described herein also can be used to model forward evolution, so as to modify or ablate one or more immunogenic domains of a virus or portion thereof.

[0066] In accordance with the present invention, there may be employed conventional molecular biology, microbiology, biochemical, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. The invention will be further described in the following examples, which do not limit the scope of the methods and compositions of matter described in the claims.

EXAMPLES

Example 1 - Computational Prediction of Ancestral Sequences

[0067] A set of 75 different amino acid sequences of AAV capsids was obtained from a number of public databases including GenBank, and the sequences were aligned using the PRANK-MSA algorithm, version 121002, with the option "-F".

[0068] ProtTest3 (see, for example, Darriba et al., 2011, Bioinformatics, 27(8):1164-5; available at darwin.uvigo.es/software/prottest3 on the World Wide Web) was used to evaluate different models of polypeptide evolution (e.g., those included in ProTest3, namely, JTT, LG, WAG, VT, CpRev, RtRev, Dayhoff, DCMut, FLU, Blosum62, VT, HIVb, MtArt, MtMam) under

different conditions (e.g., those included in ProTest3, namely, "+I", "+F", "+ G", and combinations thereof). The JTT model (Jones et al., 1992, Comp. Appl. Biosci., 8:275-82) with +G and +F (Yang, 1993, Mol. Biol. Evol., 10:1396-1401; and Cao et al., 1994, J. Mol. Evol., 39:519-27) was selected based on its Aikake Information Criterion (AIC; Hirotugu, 1974, IEEE Transactions on Automatic Control, 19:716-23) score as implemented in ProTest3.

[0069] A phylogeny of AAV evolution was constructed using PhyML (Guindon and Gascuel, 2003, Systematic Biology, 52:696-704)). See Figure 3. The tree was generated using the JTT + F substitution model with 4 discrete substitution categories and an estimated Gamma shape parameter. The resultant trees were improved via Nearest Neighbor Interchange (NNI) and Subtree Pruning and Re-Grafting (SPR), and assessed for significance via bootstrap and approximate likelihood-ratio test (aLRT; Anisimova and Gascuel, 2006, Systematic Biology, 55:539-52)) using the "SH-Like" variant.

[0070] The phylogenic tree constructed above was then used to estimate the ancestral states of the AAV capsid at every node interior to the phylogeny. The ancestral capsid sequences were reconstructed using maximum likelihood principles through the Phylogenetic Analysis by Maximum Likelihood (PAML) software (Yang, 1997, Comp. Applic. BioSci., 13:555-6; available at abacus.gene.ucl.ac.uk/software/paml.html on the World Wide Web) wrapped in Lazarus (Sourceforge at sf.net). More specifically, the Lazarus/PAML reconstruction was set to generate an amino acid reconstruction using the JTT+F substitution model using 4 gamma-distributed categories. AAV5 was used as an outgroup. Finally, the "I" option was added to place indels (i.e., coded binarily and placed via Maximum Parsimony using Fitch's algorithm) after the PAML reconstruction was done.

[0071] Because the reconstruction was done in a maximum-likelihood fashion, the likelihood that any residue was in a given position at a given node can be calculated. To do this, an additional script was written to identify all positions along the sequence with a calculated posterior probability beneath a certain threshold. A threshold of 0.3 was selected, meaning that any amino acid with a calculated posterior probability of greater than 0.3 was included in the synthesis of the library. These residues were selected to be variants of interest in the library.

[0072] To finalize the sequence, an additional utility had to be coded to select codons. A script was written to derive codons similar to those of another AAV sequence (AVVRh10, which has about 92% sequence identity to the Anc80 scaffold sequence) and apply a novel algorithm to substitute codons where there were sequence mismatches based on a codon-substitution matrix. The novel algorithm is shown below:

Given: amino acid sequence, Pt, with corresponding nucleotide sequence, Nt, where Nt codes for Pt; and protein sequence, Pi, where Pi exhibits strong homology to Pt.

Align Pi with Pt using Needleman-Wunsch using the Blosum62 table for scoring. Generate a new nucleotide sequence, Ni, by stepping through the protein alignment, using the corresponding codon from Nt,

where the amino acid in Pt exactly matches that in Pi,

the "best scoring" codon from the Codon-PAM matrix (Schneider et al., 2005, BMC Bioinform., 6:134) where there is a substitution,

a gap where there exists a gap in Pi aligned against an amino-acid in Pt, and

the most frequently occurring nucleotide in the Nt (coding for a given amino acid) where there exists an amino-acid in Pi aligned against a gap in Pt.

[0073] In addition, two single nucleotide changes were made to ablate transcription of assembly-activating protein (AAP), which is encoded out of frame within the AAV capsid gene in the wild type AAV. Since the coding of AAP (contemporary or ancestral) was not a part of this reconstruction, the expression of AAP was ablated by making a synonymous mutation in the cap sequence, and the AAP sequence was provided in trans during viral production.

Example 2 - Expression of Ancestral AAV VP1 Sequences

[0074] Experiments were performed to determine whether predicted ancestral AAV capsid sequences can be used to make viral vectors.

[0075] A number of the predicted ancestral AAV capsid sequences were cloned. The library of ancestral capsids was transferred to a rep-cap expression plasmid to enable viral particle formation in transient transfection. To maintain appropriate expression levels and splicing of VP1, VP2, and VP3, library cap genes were cloned by cutting *Hind*III, located 5' of cap in the rep coding sequence, and *Spe*I, which was engineered between the *cap* stop codon and the polyadenylation signal. Consequently, to clone the ancestral capsids into a more conventional "REP/CAP" construct, the passaging-plasmid was digested with *Hind*III and *Spe*I, gel purified, and ligated into a similarly digested rep/cap plasmid.

[0076] The expressed polypeptides were resolved on a 10% SDS gel. As shown in Figure 6, the capsid polypeptides were appropriately expressed and spliced into VP1, VP2, and VP3 from a number of ancestral AAV sequences (Anc80L44, Anc80L27, and Anc80L65) as well as from a contemporary AAV sequence, AAV2/8.

Example 3 - Viral Titration

[0077] AAV was produced in HEK293 cells via transient co-transfection of plasmids encoding all elements required for viral particle assembly. Briefly, HEK293 cells were grown to 90% confluency and transfected with (a) the viral genome plasmid encoding the luciferase transgene (expressed by the CMV promoter) flanked by AAV2 ITRs, (b) the AAV packaging

plasmid encoding AAV2 rep and the synthesized capsid proteins disclosed herein, (c) AAV2-AAP expressing capsid, and (d) adenoviral helper genes needed for AAV packaging and assembly. Cells were incubated at 37°C for 2 days, and cells and media were harvested and collected.

[0078] The cell-media suspension was lysed by 3 consecutive freeze-thaw cycles. Next, the lysate was cleared by centrifugation and treated with an enzyme under conditions to perform exhaustive DNA digestion, here Benzonase™, to digest any DNA present outside of the virus particle. The AAV preparation was diluted to fall within the linear measurement range of a control DNA template, in this case linearized plasmid with identical TaqMan™ primer and probe binding sequence as compared to the vector genome. TaqMan™ PCR was performed with primers and probe annealing to the viral vector genome of choice. Titer was calculated based on the TaqMan™ measurement in genome copies (GC) per milliliter (ml) as shown in Table 2 below.

Table 2

Titers (GC/ml)	Small scale #1	Small scale #2
AAV2/2	1.12×10^9	1.99×10^9
AAV2/8	4.17×10^{10}	5.91×10^{10}
Anc80L27	8.01×10^8	1.74×10^9
Anc80L44	1.52×10^9	1.43×10^9
Anc80L65	1.42×10^9	2.05×10^9
No capsid control	5.23×10^5	7.25×10^5

[0079] Small scale vector production results on ancestrally reconstructed AAV capsid particles demonstrated yields that were similar to AAV2, but reduced relative to AAV8, both of which are vector preparations based on contemporary AAVs.

Example 4 - *In Vitro* Viral Transduction

[0080] *In vitro* viral transductions were performed to evaluate the ability of viruses containing the predicted ancestral AAV sequences to infect cells.

[0081] Following high throughput vector production using the Anc80 library of sequences, HEK293 cells were transduced with each viral vector. In addition to an Anc80 sequence, each viral vector contained a luciferase transgene. Luciferase was measured by quantification of bioluminescence in a 96 well plate reader following addition of luciferin substrate to the transduced cells or cell lysate. Following quantification, a heat map of luciferase expression in four concatenated 96-well plates was produced (excluding a column of controls in each plate). Due to the large number of insertions, deletions, and transitions associated with the process of

high throughput vector production, many of the vectors were non-functional. For purposes herein, only viruses that were functional in this assay (i.e., able to transduce HEK293 cells and express the transgene) were evaluated further.

[0082] HEK293 cells were transduced, at equal multiplicity of infection (MOI) of 1 x 10^4 genome copies (GC) per cell, with two contemporary AAV vectors (AAV2/2 and AAV2/8) and three predicted ancestral AAV vectors (Anc80L27, Anc80L44, and Anc80L65). Each vector contained either a luciferase-encoding transgene or an eGFP-encoding transgene. Cells were imaged 60 hours later using the GFP channel of an AMG EvosFl Optical Microscope. Figure 7 shows the luciferase expression following the *in vitro* transduction. Each of the ancestral AAV viruses demonstrated efficient transduction of HEK293 cells.

Example 5 - *In Vivo* Retinal Transduction

[0083] Retinal transductions were performed to determine whether or not the ancestral AAV vectors are able to target murine retinal cells *in vivo.*

[0084] Murine eyes were transduced with 2 x 10^8 genome copies (GC) of three different ancestral AAVs (Anc80L27, Anc80L44, and Anc80L65) and a contemporary AAV (AAV2/8), all of which included an eGFP-encoding transgene. For transductions, each AAV vector was surgically delivered below the retina by generating a space between the photoreceptor and retinal pigment epithelium layer through delivery of a vector bolus with an injection device. The vector bolus was left in the sub-retinal space and the sub-retinal detachment resolved over time. GFP expression was monitored non-invasively by fundus photography of the retina of the animal following pupil dilation with Tropicamide™. All of the presented retinas demonstrated varying degrees of successful targeting of ancestral AAVs to the retina.

[0085] Retinal histology also was performed and visualized under fluorescent microscopy to identify the transduced cell type(s). Histology was performed on a murine retina transduced with the Anc80L65 ancestral AAV vector as described above. Anc80L65-mediated eGFP expression was evident in the outer nuclear layer (ONL), the inner segments (IS), and the retinal pigment epithelium (RPE), indicating that the ancestral Anc80L65 vector targets murine photoreceptors and retinal pigment epithelial cells.

Example 6 - Neutralizing Antibody Assay

[0086] Neutralizing antibody assays were performed to evaluate whether or not an ancestral AAV virus is more resistant to antibody-neutralization than a contemporary AAV virus. Neutralizing antibody assays measure the antibody concentration (or the titer at which an experimental sample contains an antibody concentration) that neutralizes an infection by 50% or more as compared to a control in the absence of the antibody.

[0087] Serum samples or IVIG stock solution (200 mg/ml) were serially diluted by 2-fold, and undiluted and diluted samples were co-incubated with an ancestral AAV virus, Anc80L65, and a contemporary AAV virus, AAV2/8, at a MOI of 10^4 for about 30 minutes at 37°C. Each virus included a luciferase transgene. The admixed vector and an antibody sample then were transduced into HEK293 cells. For these experiments, the antibody sample used was intravenous immunoglobulin (IVIG), pooled IgGs extracted from the plasma of over one thousand blood donors (sold commercially, for example, as Gammagard™ (Baxter Healthcare; Deerfield, IL) or Gamunex™ (Grifols; Los Angeles, CA)). 48 hours following initiation of transduction, cells were assayed by bioluminescence to detect luciferase. Neutralizing antibody titer was determined by identifying the dilution of sample for which 50% or more neutralization (transduction of sample/ transduction of control virus in absence of sample) was reached.

Example 7 - Characterization of Anc80

[0088] Based on the methods described herein, the most probable Anc80 sequence (as determined through posterior probability) was obtained and designated Anc80L1 (SEQ ID NO:35 shows the nucleic acid sequence of the Anc80L1 capsid and SEQ ID NO:36 shows the amino acid sequence of the Anc80L1 VP1 polypeptide). The Anc80 probabilistic library also was synthesized using the sequences described herein by a commercial company and sub-cloned into expression vectors.

[0089] The Anc80 library was clonally evaluated for vector yield and infectivity in combined assays. Out of this screening, Anc80L65 (SEQ ID NO:23), as well as several other variants, were further characterized.

[0090] The Anc80 library and Anc80L65 were compared in terms of sequence difference (Figure 9; % up from diagonal, # of amino acid differences below). Using NCBI-BLAST, the closest publically available sequence to Anc80L65 is rh10 (GenBank Accession No. AAO88201.1).

[0091] Figure 10 shows that Anc80L65 produced vector yields equivalent to AAV2 (Panel A), generated virus particles under Transmission Electroscopy (TEM) (Panel B), and biochemically produced the AAV cap and the VP1, 2 and 3 proteins based on SDS page under denaturing conditions (Panel C) and Western Blotting using the AAV capsid antibody, B1 (Panel D). These experiments are described in more detail in the following paragraphs.

[0092] Briefly, AAV2/8, AAV2/2, AAV2/Anc80L27, AAV2/Anc80L44, and AAV2/Anc80L65 vectors were produced in small scale containing a reporter construct comprised of eGFP and firefly luciferase under a CMV promoter were produced in small scale. Titers of these small scale preparations of viruses were then obtained via qPCR. Based on these experiments, Anc80L27, Anc80L44, and Anc80L65 vectors were found to produce viral levels comparable to that of AAV2 (Figure 10A).

[0093] To confirm that the Anc80L65 capsid proteins assembled into intact virus-like-particles of the proper size and conformation, micrographs were obtained using transmission electron microscopy (TEM). A large scale, purified preparation of Anc80-L065 was loaded onto polyvinyl formal (Formvar®) coated copper grids and was then stained with uranyl acetate. Micrographs revealed intact, hexagonal particles with diameters between 20 and 25 nm (Figure 10B).

[0094] In order to determine whether the synthetic ancestral capsid genes were properly processed (i.e. spliced and expressed), large-scale purified preparations of AAV2/8, AAV2/2, and AAV2/Anc80L65 vectors were loaded onto an SDS-PAGE gel (1E10 GC/well) under denaturing conditions. Bands representing viral capsid proteins VP1, VP2, and VP3 were clearly present for each vector preparation (Figure 10C). Western blotting with the AAV capsid antibody B1 further confirmed that these bands represented the predicted proteins (Figure 10D).

[0095] In addition, Figure 11 shows that Anc80L65 infected mammalian tissue and cells *in vitro* on HEK293 cells at MOI 10E4 GC/cell using GFP as readout (Panel A) or luciferase (Panel B) versus AAV2 and/or AAV8 controls. Anc80L65 also was efficient at targeting liver following an IV injection of the indicated AAV encoding a nuclear LacZ transgene (top row, Panel C), following direct intramuscular (IM) injection of the indicated AAV encoding GFP (middle row, Panel C), and following subretinal injection with the indicated AAV encoding GFP (bottom row, Panel C). These experiments are described in more detail in the following paragraphs.

[0096] To obtain a relative measure of the infectivity of ancestral virions, crude preparations of AAV2/2, AAV2/8, AAV2/Anc80L65, AAV2/Anc80L44, AAV2/Anc80L27, AAV2/Anc80L121, AAV2/Anc80L122, AAV2/Anc80L123, AAV2/Anc80L124, and AAV2/Anc80L125 containing a bi-cistronic reporter construct that includes an eGFP and firefly luciferase sequences under control of a CMV promoter were produced. 96-well plates confluent with HEK293 cells were then subjected to transduction with each vector at an MOI of 1E4 GC/cell (titers obtained via qPCR as above). 48 hours later, fluorescent microscopy confirmed the presence of GFP in transduced cells (Figure 11A). Cells were then assayed for the presence of luciferase (Figure 11B), which determined that expression of luciferase in cells transduced with Anc80-derived vectors was in-between that of cells transduced with AAV8 (lower level of transduction) and AAV2 (higher level of transduction).

[0097] To assess the relative efficiency of gene transfer in an in vivo context, purified high-titer preparations of AAV2/2, AAV2/8, and AAV2/Anc80L65 were obtained. 3.9E10 GC of each vector, encapsidating a transgene encoding nuclear LacZ under control of a TBG promoter, were injected into C57BL/6 mice (3 mice per condition) via IP injection following general anesthetization. 28 days post-injection, mice were sacrificed and tissues were collected. Livers were sectioned via standard histological techniques and stained for beta-galactosidase. Sections were then imaged under a microscope and representative images are shown in Figure 11C, top row.

[0098] Vectors of the same serotypes were then obtained containing a bicistronic transgene encoding eGFP and hA1AT under control of a pCASI promoter. To assess the ability of Anc80L65 to transduce murine skeletal muscle, 1E10 GC of each vector was injected into skeletal muscle of C57BL/6 mice (5 mice per condition) following general anesthetization. 28 days post-injection, mice were sacrificed, tissues were cryosectioned, and the presence of eGFP was assessed using fluorescent confocal microscopy (blue is DAPI, green is eGFP). Representative images are shown in Figure 11C, middle row. These experiments demonstrated that Anc80L65 vectors were capable of transducing murine skeletal muscle via intramuscular injection.

[0099] Vectors of the same serotypes were obtained, this time encapsidating constructs encoding only an eGFP transgene under control of a CMV promoter. 2E9 particles were injected sub-retinally into C57BL/6 mice following general anesthetization. 28 days post-injection, mice were sacrificed and the eyes were collected, cryosectioned, and the presence of eGFP was assessed using fluorescent confocal microscopy (blue is DAPI, green is eGFP). Representative images are shown in Figure 11C, bottom row. These experiments demonstrate that Anc80L65 vectors are able to transduce murine retina at a level that is comparable to AAV8 vectors.

[0100] Briefly, purified, high titer preparations of AAV2/8, AAV2/2, AAV2/rh32.33, and AAV2/Anc80L65 viral vectors encapsidating a bicistronic transgene that includes eGFP and firefly luciferase under control of a CMV promoter were obtained. These vectors were then either incubated with two-fold serial dilutions of IVIG (10mg, 5mg, 2.5mg, etc.) or incubated without IVIG (1E9 GC per condition). Following incubation, vectors were used to transduce HEK293 cells at an MOI of 1E4 per well (one dilution per well).

Example 8 - Generation of Additional Ancestral AAV Capsids

[0101] The most probable ancestral AAV capsid sequences (as determined through posterior probability) were then synthesized through a commercial lab (Gen9) and provided as linear dsDNA. These amino acid sequences were then compared to those of extant AAVs in order to ascertain the degree to which they differ (Figure 13). Each ancestral VP1 protein differs from those of selected representative extant AAVs by between 3.6% and 9.3% (Figure 13A), while the ancestral VP3 proteins differ by between 4.2 and 9.4% (Figure 13B). These capsids were each subcloned into AAV production plasmids (pAAVector2/Empty) via restriction enzyme digestion (HindIII & SpeI) and T4 ligation. These clones were confirmed via restriction digestion and Sanger sequencing, and medium scale preparations of plasmid DNA were then produced.

[0102] Each of these plasmids were then used to produce AAV vectors containing a reporter gene encoding both eGFP and firefly luciferase. These vectors were produced in triplicate in small scale as previously described. Crude preparations of the virus were then titered via qPCR and were found to produce between 2.71% and 183.1% viral particles relative to AAV8 (Figures 14 and 15). These titers were then used to set up a titer controlled experiment to

assess relative infectivity. Anc126 was not titer controlled due to its significantly depressed production, and consequently, the data regarding the infectivity of Anc126 cannot be accurately compared to the infectivity of the other viruses in the experiment. The other vectors were used to transduce HEK293 cells at a multiplicity of infection (MOI) of 1.9E3 GC/cell.

[0103] 60 hours post transduction, cells were assessed for GFP expression via fluorescence microscopy. eGFP positive cells were detected under each of the conditions except for the negative control (Figure 16). This indicates that each of the ancestral sequences that were predicted, synthesized, and cloned is capable of producing viable, infectious virus particles. To get an idea of the relative levels of infectivity, luciferase assays also were performed on the same cells. The results indicate that each of the ancestral vectors is capable of transducing HEK293 cells between 28.3% and 850.8% relative to AAV8 (Figures 17 and 18). It is noted that Anc126 was excluded from the analysis of relative transduction since it was not titer-controlled.

[0104] In summary, eight novel ancestral AAV capsid genes were synthesized and used in the production of functional viral vectors along with AAV8, AAV2, and the previously described Anc80L65 vectors. Production and infectivity were assessed in vitro and a summary of those findings is shown in Figure 19.

Example 9 - Vectored Immunoprophylaxis

[0105] In vectored immunoprophylaxis, gene therapy vehicles (such as AAV) are used to deliver transgenes encoding broadly neutralizing antibodies against infectious agents. See, for example, Balazs et al. (2013, Nat. Biotechnol., 31:647-52); Limberis et al. (2013, Sci. Transl. Med., 5:187ra72); Balazs et al. (2012, Nature, 481:81-4); and Deal et al. (2014, PNAS USA, 111:12528-32). One advantage of this treatment is that the host produces the antibodies in their own cells, meaning that a single administration has the potential to confer a lifetime of protection against etiologic agents.

Example 10 - Drug Delivery Vehicles

[0106] LUCENTIS® (ranibizumab) and AVASTIN® (bevacizumab) are both anti-angiogenesis agents based on the same humanized mouse monoclonal antibodies against vascular endothelial growth factor A (VEGF-A). Although bevacizumab is a full antibody and ranibizumab is a fragment (Fab), they both act to treat wet age-related macular degeneration through the same mechanism - by antagonizing VEGF. See, for example, Mao et al. (2011, Hum. Gene Ther., 22:1525-35); Xie et al. (2014, Gynecol. Oncol., doi: 10.1016/j.ygyno.2014.07.105); and Watanabe et al. (2010, Gene Ther., 17:1042-51). Because both of these molecules are proteins, they can be encoded by DNA and produced in cells transduced with vectors containing a transgene, and are small enough to be packaged into AAV vectors.

OTHER EMBODIMENTS

[0107] It is to be understood that, while the methods and compositions of matter have been described herein in conjunction with a number of different aspects, the foregoing description of the various aspects is intended to illustrate and not limit the scope of the methods and compositions of matter. Other aspects, advantages, and modifications are within the scope of the following claims.

[0108] Disclosed are methods and compositions that can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed methods and compositions. These and other materials are disclosed herein, and it is understood that combinations, subsets, interactions, groups, etc. of these methods and compositions are disclosed. That is, while specific reference to each various individual and collective combinations and permutations of these compositions and methods may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular composition of matter or a particular method is disclosed and discussed and a number of compositions or methods are discussed, each and every combination and permutation of the compositions and the methods are specifically contemplated unless specifically indicated to the contrary. Likewise, any subset or combination of these is also specifically contemplated and disclosed.

APPENDIX A

[0109]

SEQ ID NO:1: Anc80 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEQSPQEPDSSSGIGKKGQQPAX1KRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSNTM
X2AGGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSQSGX3STN
DNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKX4LNFKLFNIQVKEVTTNDGTTTIANN
LTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQML
RTGNNFX5FSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTSGTAGNRX6LQFSQAGPSS
MANQAKNWLPGPCYRQQRVSKTX7NQNNNSNFAWTGATKYHLNGRDSLVNPGPAMATHKDDEDKFFPM
SGVLIFGKQGAGNSNVDLDNVMITX8EEEIKTTNPVATEX9YGTVATNLQSX10NTAPATGTVNSQGA
LPGMVWQX11RDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPTTFSPAKF
ASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYNKSTNVDFAVDTNGVYSEPRPIGTRYLTRN
L

X1 = K/R; X2 = A/S; X3 = A/G; X4 = R/K; X5 = E/Q; X6 = T/E; X7 = A/T; X8 = S/N; X9 = Q/E; X10 = S/A; X11 = N/D

SEQ ID NO:2: Anc80 DNA

ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTG
GGACTTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGCAAAAGCAGGACGACGGCCGGGGTCTGG
TGCTTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGCGGCG
GACGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACCT
GCGGTATAACCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGTCTTTTGGGGGCAACC
TCGGGCGAGCAGTCTTCCAGGCCAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCT
AAGACGGCTCCTGGAAAGAAGAGACCGGTAGAGCAATCACCCCAGGAACCAGACTCCTCTTCGGGCAT
CGGCAAGAAAGGCCAGCAGCCCGCGXXX1AAGAGACTCAACTTTGGGCAGACAGGCGACTCAGAGTCA
GTGCCCGACCCTCAACCACTCGGAGAACCCCCCGCAGCCCCCTCTGGTGTGGGATCTAATACAATGXX

X2GCAGGCGGTGGCGCTCCAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAACGCCTCAGGA
AATTGGCATTGCGATTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCT
CCCCACCTACAACAACCACCTCTACAAGCAAATCTCCAGCCAATCGGGAXXX3AGCACCAACGACAAC
ACCTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTTAACAGATTCCACTGCCACTTCTCACC
ACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCCAAGXXX4CTCAACTTCAAGCTC
TTCAACATCCAGGTCAAGGAGGTCACGACGAATGATGGCACCACGACCATCGCCAATAACCTTACCAG
CACGGTTCAGGTCTTTACGGACTCGGAATACCAGCTCCCGTACGTCCTCGGCTCTGCGCACCAGGGCT
GCCTGCCTCCGTTCCCGGCGGACGTCTTCATGATTCCTCAGTACGGGTACCTGACTCTGAACAATGGC
AGTCAGGCCGTGGGCCGTTCCTCCTTCTACTGCCTGGAGTACTTTCCTTCTCAAATGCTGAGAACGGG
CAACAACTTTXXX5TTCAGCTACACGTTTGAGGACGTGCCTTTTCACAGCAGCTACGCGCACAGCCAA
AGCCTGGACCGGCTGATGAACCCCCTCATCGACCAGTACCTGTACTACCTGTCTCGGACTCAGACCAC
GAGTGGTACCGCAGGAAATCGGXXX6TTGCAATTTTCTCAGGCCGGGCCTAGTAGCATGGCGAATCAG
GCCAAAAACTGGCTACCCGGGCCCTGCTACCGGCAGCAACGCGTCTCCAAGACAXXX7AATCAAAATA
ACAACAGCAACTTTGCCTGGACCGGTGCCACCAAGTATCATCTGAATGGCAGAGACTCTCTGGTAAAT
CCCGGTCCCGCTATGGCAACCCACAAGGACGACGAAGACAAATTTTTTCCGATGAGCGGAGTCTTAAT
ATTTGGGAAACAGGGAGCTGGAAATAGCAACGTGGACCTTGACAACGTTATGATAACCXXX8GAGGAA
GAAATTAAAACCACCAACCCAGTGGCCACAGAAXXX9TACGGCACGGTGGCCACTAACCTGCAATCGX
XX10AACACCGCTCCTGCTACAGGGACCGTCAACAGTCAAGGAGCCTTACCTGGCATGGTCTGGCAGX
XX11CGGGACGTGTACCTGCAGGGTCCTATCTGGGCCAAGATTCCTCACACGGACGGACACTTTCATC

CCTCGCCGCTGATGGGAGGCTTTGGACTGAAACACCCGCCTCCTCAGATCCTGATTAAGAATACACCT
GTTCCCGCGAATCCTCCAACTACCTTCAGTCCAGCTAAGTTTGCGTCGTTCATCACGCAGTACAGCAC
CGGACAGGTCAGCGTGGAAATTGAATGGGAGCTGCAGAAAGAAAACAGCAAACGCTGGAACCCAGAGA
TTCAATACACTTCCAACTACAACAAATCTACAAATGTGGACTTTGCTGTTGACACAAATGGCGTTTAT
TCTGAGCCTCGCCCCATCGGCACCCGTTACCTCACCCGTAATCTG

XXX1 = AAG/AAA; XXX2 = GCA/AGC; XXX3 = GCA/GGC; XXX4 = AGA/AAG; XXX5 = GAG/CAG; XXX6 = ACG/GAG; XXX7 = GCG/ACC; XXX8 = AGT/AAC; XXX9 = CAG/GAG; XXX10 = TCA/GCC; XXX11 = AAC/GAC

SEQ ID NO:3: Anc81 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEQSPQEPDSSX1GIGKKGQQPAX2KRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSNT
MAAGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISX3X4QSGGS
TNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKX5LNFKLFNIQVKEVTTNDGTTTIA
NNLTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQ
MLRTGNNFX6FSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTGGTAGNX7X8LQFSQAG
PSSMANQAKNWLPGPCYRQQRVSKTTNQNNNSNFAWTGATKYHLNGRDSLVNPGVAMATHKDDEDRFF
PSSGVLIFGKQGAGNX9NVDX10X11NVMITX12EEEIKTTNPVATEEYGX13VATNLQSX14NTAPQ
TGTVNSQGALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPANPPT
TFX15PAKFASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYNKSTNVDFAVDTEGVYSEPRP
IGTRYLTRNL

X1=T/S; X2=K/R; X3=N/S; X4=S/H; X5=R/K; X6=E/Q; X7=R/Q; X8=T/E; X9=D/S; X10=L/Y; X11=D/S; X12=S/N; X13=V/I; X14=A/S; X15=S/T

SEQ ID NO:4: Anc81 DNA

ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTG
GGACTTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGCAAAAGCAGGACGACGGCCGGGGTCTGG
TGCTTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGCGGCG
GACGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACCT
GCGGTATAACCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGTCTTTTGGGGGCAACC
TCGGGCGAGCAGTCTTCCAGGCCAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCT
AAGACGGCTCCTGGAAAGAAGAGACCGGTAGAGCAATCACCCCAGGAACCAGACTCCTCTXXX1GGCA
TCGGCAAGAAAGGCCAGCAGCCCGCGXXX2AAGAGACTCAACTTTGGGCAGACTGGCGACTCAGAGTC
AGTGCCCGACCCTCAACCACTCGGAGAACCCCCCGCAGCCCCCTCTGGTGTGGGATCTAATACAATGG
CTGCAGGCGGTGGCGCTCCAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAATGCCTCAGGA
AATTGGCATTGCGATTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCT
CCCCACCTACAACAACCACCTCTACAAGCAAATCTCCXXX3XXX4CAATCGGGAGGAAGCACCAACGA
CAACACCTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTTAACAGATTCCACTGCCACTTCT
CACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCCAAGXXX5CTCAACTTCAA
GCTCTTCAACATCCAGGTCAAGGAGGTCACGACGAATGATGGCACCACGACCATCGCCAATAACCTTA
CCAGCACGGTTCAGGTCTTTACGGACTCGGAATACCAGCTCCCGTACGTCCTCGGCTCTGCGCACCAG
GGCTGCCTGCCTCCGTTCCCGGCGGACGTCTTCATGATTCCTCAGTACGGGTACCTGACTCTGAACAA
TGGCAGTCAGGCCGTGGGCCGTTCCTCCTTCTACTGCCTGGAGTACTTTCCTTCTCAAATGCTGAGAA
CGGGCAACAACTTTXXX6TTCAGCTACACGTTTGAGGACGTGCCTTTTCACAGCAGCTACGCGCACAG
CCAAAGCCTGGACCGGCTGATGAACCCCCTCATCGACCAGTACCTGTACTACCTGTCTCGGACTCAGA

CCACGGGAGGTACCGCAGGAAATXXX7XXX8TTGCAATTTTCTCAGGCCGGGCCTAGTAGCATGGCGA
ATCAGGCCAAAAACTGGCTACCCGGGCCCTGCTACCGGCAGCAACGCGTCTCCAAGACAACGAATCAA
AATAACAACAGCAACTTTGCCTGGACCGGTGCCACCAAGTATCATCTGAATGGCAGAGACTCTCTGGT

AAATCCCGGTGTCGCTATGGCAACCCACAAGGACGACGAAGACCGATTTTTTCCGTCCAGCGGAGTCT
TAATATTTGGGAAACAGGGAGCTGGAAATXXX9AACGTGGACXXX10XXX11AACGTTATGATAACCX
XX12GAGGAAGAAATTAAAACCACCAACCCAGTGGCCACAGAAGAGTACGGCXXX13GTGGCCACTAA
CCTGCAATCGXXX14AACACCGCTCCTCAAACAGGGACCGTCAACAGTCAAGGAGCCTTACCTGGCAT
GGTCTGGCAGAACCGGGACGTGTACCTGCAGGGTCCTATCTGGGCCAAGATTCCTCACACGGACGGAA
ACTTTCATCCCTCGCCGCTGATGGGAGGCTTTGGACTGAAACACCCGCCTCCTCAGATCCTGATTAAG
AATACACCTGTTCCCGCGAATCCTCCAACTACCTTCXXX15CCAGCTAAGTTTGCGTCGTTCATCACG
CAGTACAGCACCGGACAGGTCAGCGTCGAAATTGAATGGGAGCTGCAGAAAGAAAACAGCAAACGCTG
GAACCCAGAGATTCAATACACTTCCAACTACAACAAATCTACAAATGTGGACTTTGCTGTTGACACAG
AAGGCGTTTATTCTGAGCCTCGCCCCATCGGCACCCGTTACCTCACCCGTAATCTG

XXX1 = ACG/AGC; XXX2 = AAA/AAG; XXX3 = AAC/AGT; XXX4 = AGC/CAC; XXX5 = AGA/AAG; XXX6 = GAG/CAG; XXX7 = CGG/CAG; XXX8 = ACG/GAG; XXX9 = GAC/AGC; XXX10 = CTT/TAC; XXX11 = GAC/AGC; XXX12 = AGT/AAC; XXX13 = GTG/ATC; XXX14 = GCA/AGC; XXX15 = AGT/ACC

SEQ ID NO:5: Anc82 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEQSPQREPDSSX1GIGKKGQQPAX2KRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSN
TMAAGGAPMADNNEGADGVGNSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGST
NDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTTNEGTKTIANN
LTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQML
RTGNNFQFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTGGTAGTQTLQFSQAGPSSMA
NQAKNWLPGPCYRQQRVSTTTNQNNNSNFAWTGATKYHLNGRDSLVNPGVAMATHKDDEDRFFPSSGV
LIFGKQGAGNDNVDYSNVMITX3EEEIKTTNPVATEEYGVVATNLQSANTAPQTGTVNSQGALPGMVW
QNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFNQAKLNSFITQYS
TGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGVYSEPRPIGTRYLTRNL

X1=T/S; X2=K/R; X3=S/N

SEQ ID NO:6: Anc82 DNA

ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTG
GGACCTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGCAAAAGCAGGACGACGGCCGGGGTCTGG
TGCTTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGCGGCG
GACGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACCT
GCGGTATAATCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGTCTTTTGGGGGCAACC
TCGGGCGAGCAGTCTTCCAGGCCAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCT
AAGACGGCTCCTGGAAAGAAGAGACCGGTAGAGCAGTCACCACAGCGTGAGCCCGACTCCTCCXXX1G
GCATCGGCAAGAAAGGCCAGCAGCCCGCCXXX2AAGAGACTCAATTTCGGTCAGACTGGCGACTCAGA
GTCAGTCCCCGACCCTCAACCTCTCGGAGAACCTCCAGCAGCGCCCTCTGGTGTGGGATCTAATACAA
TGGCTGCAGGCGGTGGCGCACCAATGGCAGACAATAACGAAGGTGCCGACGGAGTGGGTAATTCCTCG
GGAAATTGGCATTGCGATTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGC
CCTGCCCACCTACAACAACCACCTCTACAAGCAAATCTCCAACGGGACCTCGGGAGGCAGCACCAACG
ACAACACCTACTTTGGCTACAGCACCCCCTGGGGGTATTTTGACTTTAACAGATTCCACTGCCACTTC
TCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCCAAGAGACTCAACTTCAA
GCTCTTCAACATCCAGGTCAAAGAGGTCACGACGAATGAAGGCACCAAGACCATCGCCAATAACCTCA
CCAGCACCGTCCAGGTGTTTACGGACTCGGAATACCAGCTGCCGTACGTCCTCGGCTCTGCCCACCAG
GGCTGCCTGCCTCCGTTCCCGGCGGACGTCTTCATGATTCCTCAGTACGGCTACCTGACTCTCAACAA
CGGTAGTCAGGCCGTGGGACGTTCCTCCTTCTACTGCCTGGAGTACTTCCCCTCTCAGATGCTGAGAA
CGGGCAACAACTTTCAATTCAGCTACACTTTCGAGGACGTGCCTTTCCACAGCAGCTACGCGCACAGC

CAGAGTTTGGACAGGCTGATGAATCCTCTCATCGACCAGTACCTGTACTACCTGTCAAGAACCCAGAC
TACGGGAGGCACAGCGGGAACCCAGACGTTGCAGTTTTCTCAGGCCGGGCCTAGCAGCATGGCGAATC
AGGCCAAAAACTGGCTGCCTGGACCCTGCTACAGACAGCAGCGCGTCTCCACGACAACGAATCAAAAC
AACAACAGCAACTTTGCCTGGACTGGTGCCACCAAGTATCATCTGAACGGCAGAGACTCTCTGGTGAA
TCCGGGCGTCGCCATGGCAACCCACAAGGACGACGAGGACCGCTTCTTCCCATCCAGCGGCGTCCTCA
TATTTGGCAAGCAGGGAGCTGGAAATGACAACGTGGACTATAGCAACGTGATGATAACCXXX3GAGGA
AGAAATCAAGACCACCAACCCCGTGGCCACAGAAGAGTATGGCGTGGTGGCTACTAACCTACAGTCGG
CAAACACCGCTCCTCAAACGGGGACCGTCAACAGCCAGGGAGCCTTACCTGGCATGGTCTGGCAGAAC
CGGGACGTGTACCTGCAGGGTCCTATTTGGGCCAAGATTCCTCACACAGATGGCAACTTTCACCCGTC
TCCTTTAATGGGCGGCTTTGGACTTAAACATCCGCCTCCTCAGATCCTCATCAAAAACACTCCTGTTC
CTGCGGATCCTCCAACAACGTTCAACCAGGCCAAGCTGAATTCTTTCATCACGCAGTACAGCACCGGA

CAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAGAACAGCAAGCGCTGGAACCCAGAGATCA
GTATACTTCCAACTACTACAAATCTACAAATGTGGACTTTGCTGTTAATACTGAGGGTGTTTACTCTG
AGCCTCGCCCCATTGGCACTCGTTACCTCACCCGTAATCTG

XXX1 = ACG/AGC; XXX2 = AAA/AGA; XXX¬3 = AGC/AAC

SEQ ID NO:7: Anc83 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEQSPQREPDSSX1GIGKKGQQPAX2KRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSN
TMAAGGAPMADNNEGADGVGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGST
NDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLX3FKLFNIQVKEVTQNEGTKTIAN
NLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQM
LRTGNNFX4FSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTGGTAGTQTLQFSQAGPSX
5MANQAKNWLPGPCYRQQRVSTTTSQNNNSNFAWTGATKYHLNGRDSLVNPGVAMATHKDDEX7RFFP
SSGX7LIFGKQGAGKDNVDYSNVMLTSEEEIKTTNPVATEEYGVVADNLQQQNTAPQX8GTVNSQGAL
PGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFNQAKLNSF
ITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGVYSEPRPIGTRYLTRNL

X1=T/S; X2=R/K; X3=N/S; X4=Q/E; X5=N/T/S; X6=D/E; X7=I/V; X8=I/V

SEQ ID NO:8: Anc83 DNA

ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTG
GGACCTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGCAAAAGCAGGACGACGGCCGGGGTCTGG
TGCTTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGCGGCG
GACGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACCT
GCGGTATAATCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGTCTTTTGGGGGCAACC
TCGGGCGAGCAGTCTTCCAGGCCAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCT
AAGACGGCTCCTGGAAAGAAGAGACCGGTAGAGCAGTCACCACAGCGTGAGCCCGACTCCTCCXXX1G
GCATCGGCAAGAAAGGCCAGCAGCCCCGCCXXX2AAGAGACTCAATTTCGGTCAGACTGGCGACTCAGA
GTCAGTCCCCGACCCTCAACCTCTCGGAGAACCTCCAGCAGCGCCCTCTGGTGTGGGATCTAATACAA
TGGCTGCAGGCGGTGGCGCACCAATGGCAGACAATAACGAAGGTGCCGACGGAGTGGGTAGTTCCTCG
GGAAATTGGCATTGCGATTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGC
CCTGCCCACCTACAACAACCACCTCTACAAGCAAATCTCCAACGGGACCTCGGGAGGCAGCACCAACG
ACAACACCTACTTTGGCTACAGCACCCCCTGGGGGTATTTTGACTTTAACAGATTCCACTGCCACTTC
TCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCCAAGAGACTCXXX3TTCA
AGCTCTTCAACATCCAGGTCAAAGAGGTCACGCAGAATGAAGGCACCAAGACCATCGCCAATAACCTC
ACCAGCACCATCCAGGTGTTTACGGACTCGGAATACCAGCTGCCGTACGTCCTCGGCTCTGCCCACCA
GGGCTGCCTGCCTCCGTTCCCGGCGGACGTCTTCATGATTCCTCAGTACGGCTACCTGACTCTCAACA
ACGGTAGTCAGGCCGTGGGACGTTCCTCCTTCTACTGCCTGGAGTACTTCCCCTCTCAGATGCTGAGA

ACGGGCAACAACTTTXXX4TTCAGCTACACTTTCGAGGACGTGCCTTTCCACAGCAGCTACGCGCACA
GCCAGAGTTTGGACAGGCTGATGAATCCTCTCATCGACCAGTACCTGTACTACCTGTCAAGAACCCAG
ACTACGGGAGGCACAGCGGGAACCCAGACGTTGCAGTTTTCTCAGGCCGGGCCTAGCXXX5ATGGCGA
ATCAGGCCAAAAACTGGCTGCCTGGACCCTGCTACAGACAGCAGCGCGTCTCCACGACAACGTCGCAA
AACAACAACAGCAACTTTGCCTGGACTGGTGCCACCAAGTATCATCTGAACGGCAGAGACTCTCTGGT
GAATCCGGGCGTCGCCATGGCAACCCACAAGGACGACGAGXXX6CGCTTCTTCCCATCCAGCGGCXXX
7CTCATATTTGGCAAGCAGGGAGCTGGAAAAGACAACGTGGACTATAGCAACGTGATGCTAACCAGCG
AGGAAGAAATCAAGACCACCAACCCCGTGGCCACAGAAGAGTATGGCGTGGTGGCTGATAACCTACAG
CAGCAAAACACCGCTCCTCAAXXX8GGGACCGTCAACAGCCAGGGAGCCTTACCTGGCATGGTCTGGC
AGAACCGGGACGTGTACCTGCAGGGTCCTATTTGGGCCAAGATTCCTCACACAGATGGCAACTTTCAC
CCGTCTCCTTTAATGGGCGGCTTTGGACTTAAACATCCGCCTCCTCAGATCCTCATCAAAAACACTCC
TGTTCCTGCGGATCCTCCAACAACGTTCAACCAGGCCAAGCTGAATTCTTTCATCACGCAGTACAGCA
CCGGACAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAGAACAGCAAGCGCTGGAACCCAGAG
ATTCAGTATACTTCCAACTACTACAAATCTACAAATGTGGACTTTGCTGTTAATACTGAGGGTGTTTA
CTCTGAGCCTCGCCCCATTGGCACTCGTTACCTCACCCGTAATCTG

XXX1 = ACG/AGC; XXX2 = AGA/AAG; XXX3 = AAC/AGC; XXX4 = CAA/GAA; XXX¬5 = AAC/ACC/AGC; XXX¬6 = GAC/GAG; XXX7 = ATC/GTC; XXX8 = ATA/GTA

SEQ ID NO:9: Anc84 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEPSPQRSPDSSTGIGKKGQQPAX1KRLNFGQTGDSESVPDPQPIGEPPAAPSGVGSGT
MAAGGAPMADNNEGADGVGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTN
DNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLX2FKLFNIQVKEVTQNEGTKTIANN
LTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQML
RTGNNFEFSYTFEDVPFHSSYAHSQSIDRLMNPLIDQYLYYLSRTQSTGGTAGTQQLLFSQAGPSNMS
AQAKNWLPGPCYRQQRVSTTLSQNNNSNFAWTGATKYHLNGRDSLVNPGVAMATHKDDEX3RFFPSSG
X4LMFGKQGAGKDNVDYSNVMLTSEEEIKTTNPVATEQYGVVADNLQQQNTAPIVGAVNSQGALPGMV
WQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFNQAKLNSFITQY

STGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGVYSEPRPIGTRYLTRNL

X1=R/K; X2=N/S; X3=D/E; X4=I/V

SEQ ID NO:10: Anc84 DNA

ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTG
GGACCTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGCAAAAGCAGGACGACGGCCGGGGTCTGG
TGCTTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGCGGCG
GACGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACCT
GCGGTATAATCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGTCTTTTGGGGGCAACC
TCGGGCGAGCAGTCTTCCAGGCCAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCT
AAGACGGCTCCTGGAAAGAAGAGACCGGTAGAGCCGTCACCACAGCGTTCCCCCGACTCCTCCACGGG
CATCGGCAAGAAAGGCCAGCAGCCCGCCXXX1AAGAGACTCAATTTCGGTCAGACTGGCGACTCAGAG
TCAGTCCCCGACCCTCAACCTATCGGAGAACCTCCAGCAGCGCCCTCTGGTGTGGGATCTGGTACAAT
GGCTGCAGGCGGTGGCGCACCAATGGCAGACAATAACGAAGGTGCCGACGGAGTGGGTAGTTCCTCGG
GAAATTGGCATTGCGATTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCC
CTGCCCACCTACAACAACCACCTCTACAAGCAAATCTCCAACGGGACCTCGGGAGGCAGCACCAACGA
CAACACCTACTTTGGCTACAGCACCCCCTGGGGGTATTTTGACTTTAACAGATTCCACTGCCACTTCT
CACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCCAAGAGACTCXXX2TTCAA
GCTCTTCAACATCCAGGTCAAAGAGGTCACGCAGAATGAAGGCACCAAGACCATCGCCAATAACCTCA
CCAGCACCATCCAGGTGTTTACGGACTCGGAATACCAGCTGCCGTACGTCCTCGGCTCTGCCCACCAG

GGCTGCCTGCCTCCGTTCCCGGCGGACGTCTTCATGATTCCTCAGTACGGCTACCTGACTCTCAACAA
CGGTAGTCAGGCCGTGGGACGTTCCTCCTTCTACTGCCTGGAGTACTTCCCCTCTCAGATGCTGAGAA
CGGGCAACAACTTTGAGTTCAGCTACACTTTCGAGGACGTGCCTTTCCACAGCAGCTACGCGCACAGC
CAGAGTTTGGACAGGCTGATGAATCCTCTCATCGACCAGTACCTGTACTACCTGTCAAGAACCCAGTC
TACGGGAGGCACAGCGGGAACCCAGCAGTTGCTGTTTTCTCAGGCCGGGCCTAGCAACATGTCGGCTC
AGGCCAAAAACTGGCTGCCTGGACCCTGCTACAGACAGCAGCGCGTCTCCACGACACTGTCGCAAAAC
AACAACAGCAACTTTGCCTGGACTGGTGCCACCAAGTATCATCTGAACGGCAGAGACTCTCTGGTGAA
TCCGGGCGTCGCCATGGCAACCCACAAGGACGACGAGXXX3CGCTTCTTCCCATCCAGCGGCXXX4CT
CATGTTTGGCAAGCAGGGAGCTGGAAAAGACAACGTGGACTATAGCAACGTGATGCTAACCAGCGAGG
AAGAAATCAAGACCACCAACCCCGTGGCCACAGAACAGTATGGCGTGGTGGCTGATAACCTACAGCAG
CAAAACACCGCTCCTATTGTGGGGGCCGTCAACAGCCAGGGAGCCTTACCTGGCATGGTCTGGCAGAA
CCGGGACGTGTACCTGCAGGGTCCTATTTGGGCCAAGATTCCTCACACAGATGGCAACTTTCACCCGT
CTCCTTTAATGGGCGGCTTTGGACTTAAACATCCGCCTCCTCAGATCCTCATCAAAAACACTCCTGTT
CCTGCGGATCCTCCAACAACGTTCAACCAGGCCAAGCTGAATTCTTTCATCACGCAGTACAGCACCGG
ACAAGTCAGCGTGGAGATCGAGTGGGAGCTGCAGAAGGAGAACAGCAAGCGCTGGAACCCAGAGATTC
AGTATACTTCCAACTACTACAAATCTACAAATGTGGACTTTGCTGTTAATACTGAGGGTGTTTACTCT
GAGCCTCGCCCCATTGGCACTCGTTACCTCACCCGTAATCTG

XXX¬1 = AGA/AAA; XXX2 = AAC/AGC; XXX3 = GAC/GAG; XXX4 = ATC/GTC

SEQ ID NO:11: Anc94 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEPSPQRSPDSSTGIGKKGQQPAKKRLNFGQTGDSESVPDPQPIGEPPAGPSGLGSGTM
AAGGAPMADNNEGADGVGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTND
NTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNEGTKTIANNLT
STIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRT
GNNFEFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQSTGGTAGTQQLLFSQAGPX1NMSA
QAKNWLPGPCYRQQRVSTTLSQNNNSNFAWTGATKYHLNGRDSLVNPGVAMATHKDDEERFFPSSGVL
MFGKQGAGKDNVDYSSVMLTSEEEIKTTNPVATEQYGVVADNLQQQNTAPIVGAVNSQGALPGMVWQN
RDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFSQAKLASFITQYSTG
QVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGTYSEPRPIGTRYLTRNL

X1=S/N

SEQ ID NO:12: Anc94 DNA

ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTG
GGACTTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGCAAAAGCAGGACGACGGCCGGGGTCTGG
TGCTTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGCGGCG
GACGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACCT
GCGGTATAACCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGTCTTTTGGGGGCAACC
TCGGGCGAGCAGTCTTCCAGGCCAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCT
AAGACGGCTCCTGGAAAGAAGAGACCGGTAGAGCCATCACCCCAGCGTTCTCCAGACTCCTCTACGGG
CATCGGCAAGAAAGGCCAGCAGCCCGCGAAAAAGAGACTCAACTTTGGGCAGACTGGCGACTCAGAGT
CAGTGCCCGACCCTCAACCAATCGGAGAACCCCCCGCAGGCCCCTCTGGTCTGGGATCTGGTACAATG
GCTGCAGGCGGTGGCGCTCCAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAGTTCCTCAGG
AAATTGGCATTGCGATTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCC
TCCCCACCTACAACAACCACCTCTACAAGCAAATCTCCAACGGGACTTCGGGAGGAAGCACCAACGAC
AACACCTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTTAACAGATTCCACTGCCACTTCTC

ACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCCAAGAGACTCAACTTCAAGC
TCTTCAACATCCAGGTCAAGGAGGTCACGCAGAATGAAGGCACCAAGACCATCGCCAATAACCTTACC

AGCACGATTCAGGTCTTTACGGACTCGGAATACCAGCTCCCGTACGTCCTCGGCTCTGCGCACCAGGG
CTGCCTGCCTCCGTTCCCGGCGGACGTCTTCATGATTCCTCAGTACGGGTACCTGACTCTGAACAATG
GCAGTCAGGCCGTGGGCCGTTCCTCCTTCTACTGCCTGGAGTACTTTCCTTCTCAAATGCTGAGAACG
GGCAACAACTTTGAGTTCAGCTACACGTTTGAGGACGTGCCTTTTCACAGCAGCTACGCGCACAGCCA
AAGCCTGGACCGGCTGATGAACCCCCTCATCGACCAGTACCTGTACTACCTGTCTCGGACTCAGTCCA
CGGGAGGTACCGCAGGAACTCAGCAGTTGCTATTTTCTCAGGCCGGGCCTXXXAACATGTCGGCTCAG
GCCAAAAACTGGCTACCCGGGCCCTGCTACCGGCAGCAACGCGTCTCCACGACACTGTCGCAAAATAA
CAACAGCAACTTTGCCTGGACCGGTGCCACCAAGTATCATCTGAATGGCAGAGACTCTCTGGTAAATC
CCGGTGTCGCTATGGCAACCCACAAGGACGACGAAGAGCGATTTTTTCCGTCCAGCGGAGTCTTAATG
TTTGGGAAACAGGGAGCTGGAAAAGACAACGTGGACTATAGCAGCGTTATGCTAACCAGTGAGGAAGA
AATTAAAACCACCAACCCAGTGGCCACAGAACAGTACGGCGTGGTGGCCGATAACCTGCAACAGCAAA
ACACCGCTCCTATTGTAGGGGCCGTCAACAGTCAAGGAGCCTTACCTGGCATGGTCTGGCAGAACCGG
GACGTGTACCTGCAGGGTCCTATCTGGGCCAAGATTCCTCACACGGACGGAAACTTTCATCCCTCGCC
GCTGATGGGAGGCTTTGGACTGAAACACCCGCCTCCTCAGATCCTGATTAAGAATACACCTGTTCCCG
CGGATCCTCCAACTACCTTCAGTCAAGCTAAGCTGGCGTCGTTCATCACGCAGTACAGCACCGGACAG
GTCAGCGTGGAAATTGAATGGGAGCTGCAGAAAGAAAACAGCAAACGCTGGAACCCAGAGATTCAATA
CACTTCCAACTACTACAAATCTACAAATGTGGACTTTGCTGTTAACACAGAAGGCACTTATTCTGAGC
CTCGCCCCATCGGCACCCGTTACCTCACCCGTAATCTG

XXX1 = AGT/AAT

SEQ ID NO:13: Anc113 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEX1SPQRSPDSSTGIGKKGQQPAX2KRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSG
TMAAGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSQSAGSTN
DNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKKLX3FKLFNIQVKEVTTNDGVTTIANN
LTSTVQVFSDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQSVGRSSFYCLEYFPSQML
RTGNNFEFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLARTQSTTGGTAGNRELQFX4QAGPST
MAEQAKNWLPGPCYRQQRVSKTLDQNNNSNFAWTGATKYHLNGRNSLVNPGVAMATHKDDEDRFFPSS
GVLIFGKTGAANKTTLENVLMTX5EEEIKTTNPVATEEYGX6VSSNLQSX7NTAPQTQTVNSQGALPG
MVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPANPPEVFTPAKFASFIT
QYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYDKSTNVDFAVDSEGVYSEPRPIGTRYLTRNL

X¬1=P/Q; X¬2=K/R; X¬3=R/N; X4=Y/H; X¬5=N/S; X¬6=V/I; X¬7=A/S

SEQ ID NO:14: Anc113 DNA

ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTG
GGACCTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGCAAAAGCAGGACGACGGCCGGGGTCTGG
TGCTTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGCGGCG
GACGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACCT
GCGGTATAACCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGTCATTTGGGGGCAACC
TCGGGCGAGCAGTCTTCCAGGCCAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCT
AAGACGGCTCCTGGAAAGAAGAGACCGGTAGAGXXX1TCACCTCAGCGTTCCCCCGACTCCTCCACGG
GCATCGGCAAGAAAGGCCAGCAGCCCGCCXXX2AAGAGACTCAATTTCGGTCAGACTGGCGACTCAGA
GTCAGTCCCCGACCCTCAACCTCTCGGAGAACCTCCAGCAGCGCCCTCTGGTGTGGGATCTGGTACAA
TGGCTGCAGGCGGTGGCGCACCAATGGCAGACAATAACGAAGGTGCCGACGGAGTGGGTAATGCCTCA
GGAAATTGGCATTGCGATTCCACATGGCTGGGCGACAGAGTCATTACCACCAGCACCCGAACCTGGGC
CCTGCCCACCTACAACAACCACCTCTACAAGCAAATCTCCAGTCAAAGTGCAGGTAGTACCAACGACA
ACACCTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTTAACAGATTCCACTGCCACTTCTCA
CCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCCAAGAAGCTGXXX3TTCAAGC

TCTTCAACATCCAGGTCAAGGAGGTCACGACGAATGACGGCGTTACGACCATCGCTAATAACCTTACC
AGCACGGTTCAGGTATTCTCGGACTCGGAATACCAGCTGCCGTACGTCCTCGGCTCTGCGCACCAGGG
CTGCCTGCCTCCGTTCCCGGCGGACGTCTTCATGATTCCTCAGTACGGCTACCTGACTCTCAACAATG
GCAGTCAGTCTGTGGGACGTTCCTCCTTCTACTGCCTGGAGTACTTCCCCTCTCAGATGCTGAGAACG
GGCAACAACTTTGAGTTCAGCTACACCTTCGAGGACGTGCCTTTCCACAGCAGCTACGCACACAGCCA
GAGCCTGGACCGGCTGATGAATCCCCTCATCGACCAGTACTTGTACTACCTGGCCAGAACACAGAGTA
CCACAGGAGGCACAGCTGGCAATCGGGAACTGCAGTTTXXX4CAGGCCGGGCCTTCAACTATGGCCGA
ACAAGCCAAGAATTGGTTACCTGGACCTTGCTACCGGCAACAAAGAGTCTCCAAAACGCTGGATCAAA
ACAACAACAGCAACTTTGCTTGGACTGGTGCCACCAAATATCACCTGAACGGCAGAAACTCGTTGGTT
AATCCCGGCGTCGCCATGGCAACTCACAAGGACGACGAGGACCGCTTTTTCCCATCCAGCGGAGTCCT
GATTTTTGGAAAAACTGGAGCAGCTAACAAAACTACATTGGAAAATGTGTTAATGACAXXX5GAAGAA
GAAATTAAAACTACTAATCCTGTAGCCACGGAAGAATACGGGXXX6GTCAGCAGCAACTTACAATCGX
XX7AATACTGCACCCCAGACACAAACTGTCAACAGCCAGGGAGCCTTACCTGGCATGGTCTGGCAGAA
CCGGGACGTGTACCTGCAGGGTCCCATCTGGGCCAAGATTCCTCACACGGATGGCAACTTTCACCCGT

CTCCTTTGATGGGCGGCTTTGGACTTAAACATCCGCCTCCTCAGATCCTGATCAAGAACACTCCCGTT
CCCGCTAATCCTCCGGAGGTGTTTACTCCTGCCAAGTTTGCTTCGTTCATCACACAGTACAGCACCGG
ACAAGTCAGCGTGGAAATCGAGTGGGAGCTGCAGAAGGAAAACAGCAAGCGCTGGAACCCGGAGATTC
AGTACACCTCCAACTATGATAAGTCGACTAATGTGGACTTTGCCGTTGACAGCGAGGGTGTTTACTCT
GAGCCTCGCCCTATTGGCACTCGTTACCTCACCCGTAATCTG

XXX1 = CCG/CAG; XXX2 = AAA/AGA; XXX3 = CGG/AAC; XXX4 = TAC/CAC; XXX5 = AAT/AGT; XXX6 = GTA/ATA; XXX7 = GCT/TCT

SEQ ID NO:15: Anc126 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEQSPQEPDSSSGIGKX1GQQPAX2KRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSNT
MASGGGAPMADNNEGADGVGNX3SGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSQSGASND
NHYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKX4LNFKLFNIQVKEVTTNDGTTTIANNL
TSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLR
TGNNFX5FSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLX6RTQTTSGTAQNRELX7FSQAGPSS
MX8NQAKNWLPGPCYRQQRVSKTANDNNNSNFAWTGATKYHLNGRDSLVNPGPAMASHKDDEDKFFPM
SGVLIFGKQGAGASNVDLDNVMITDEEEIKTTNPVATEQYGTVATNLQSSNTAPATGTVNSQGALPGM
VWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPTTFSPAKFASFITQ
YSTGQVSVEIEWELQKENSKRWNPEIQYTSNYNKSX9NVDFTVDTNGVYSEPRPIGTRYLTRNL

X1=S/T; X2=K/R; X3=A/S; X4=R/K; X5=T/Q; X6=S/N; X7=Q/L; X8=A/S; X9=A/T

SEQ ID NO:16: Anc126 DNA

ATGGCTGCCGATGGTTATCTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTG
GGACTTGAAACCTGGAGCCCCGAAACCCAAAGCCAACCAGCAAAAGCAGGACGACGGCCGGGGTCTGG
TGCTTCCTGGCTACAAGTACCTCGGACCCTTCAACGGACTCGACAAGGGGGAGCCCGTCAACGCGGCG
GATGCAGCGGCCCTCGAGCACGACAAGGCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACCT
GCGGTATAACCACGCCGACGCCGAGTTTCAGGAGCGTCTGCAAGAAGATACGTCTTTTGGGGGCAACC
TCGGGCGAGCAGTCTTCCAGGCCAAGAAGAGGGTTCTCGAACCTCTTGGTCTGGTTGAGGAAGGTGCT
AAGACGGCTCCTGGAAAGAAACGTCCGGTAGAGCAGTCGCCACAAGAGCCAGACTCCTCCTCGGGCAT
TGGCAAGXXX1GGCCAGCAGCCCGCTXXX2AAGAGACTCAATTTTGGTCAGACTGGCGACTCAGAGTC
AGTCCCCGACCCACAACCTCTCGGAGAACCTCCAGCAGCCCCCTCTGGTGTGGGATCTAATACAATGG
CTTCAGGCGGTGGCGCACCAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAATXXX3TCAGG
AAATTGGCATTGCGATTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGAACATGGGCCT
TGCCCACCTATAACAACCACCTCTACAAGCAAATCTCCAGTCAATCAGGGGCCAGCAACGACAACCAC
TACTTCGGCTACAGCACCCCCTGGGGGTATTTTGATTTCAACAGATTCCACTGCCATTTCTCACCACG
TGACTGGCAGCGACTCATCAACAACAATTGGGGATTCCGGCCCAAGXXX4CTCAACTTCAAGCTCTTC
AACATCCAAGTCAAGGAGGTCACGACGAATGATGGCACCACGACCATCGCTAATAACCTTACCAGCAC
GGTTCAAGTCTTCACGGACTCGGAGTACCAGTTGCCGTACGTCCTCGGCTCTGCGCACCAGGGCTGCC
TCCCTCCGTTCCCGGCGGACGTGTTCATGATTCCGCAGTACGGCTACCTAACGCTCAACAATGGCAGC
CAGGCAGTGGGACGGTCATCCTTTTACTGCCTGGAATATTTCCCATCGCAGATGCTGAGAACGGGCAA
TAACTTTXXX5TTCAGCTACACCTTCGAGGACGTGCCTTTCCACAGCAGCTACGCGCACAGCCAGAGC
CTGGACCGGCTGATGAATCCTCTCATCGACCAGTACCTGTATTACCTGXXX6AGAACTCAGACTACGT
CCGGAACTGCCCAAAACAGGGAGTTGXXX7TTTAGCCAGGCGGGTCCATCTAGCATGXXX8AATCAGG
CCAAAAACTGGCTACCTGGACCCTGTTACCGGCAGCAGCGCGTTTCTAAAACAGCAAATGACAACAAC
AACAGCAACTTTGCCTGGACTGGTGCTACAAAATATCACCTTAATGGGCGTGATTCTTTAGTCAACCC
TGGCCCTGCTATGGCCTCACACAAAGACGACGAAGACAAGTTCTTTCCCATGAGCGGTGTCTTGATTT
TTGGAAAGCAGGGCGCCGGAGCTTCAAACGTTGATTTGGACAATGTCATGATCACAGACGAAGAGGAA
ATCAAAACCACTAACCCCGTGGCCACCGAACAATATGGGACTGTGGCAACCAATCTCCAGAGCAGCAA
CACAGCCCCTGCGACCGGAACTGTGAATTCTCAGGGAGCCTTACCTGGAATGGTGTGGCAAGACAGAG
ACGTATACCTGCAGGGTCCTATTTGGGCCAAAATTCCTCACACGGATGGACACTTTCACCCGTCTCCT
CTCATGGGCGGCTTTGGACTTAAGCACCCGCCTCCTCAGATCCTCATCAAAAACACGCCTGTTCCTGC
GAATCCTCCGACAACGTTTTCGCCTGCAAAGTTTGCTTCATTCATCACCCAGTATTCCACAGGACAAG
TGAGCGTGGAGATTGAATGGGAGCTGCAGAAAGAAAACAGCAAACGCTGGAATCCCGAAATACAGTAT
ACATCTAACTATAATAAATCTXXX9AACGTTGATTTCACTGTGGACACCAATGGAGTTTATAGTGAGC
CTCGCCCCATTGGCACCCGTTACCTCACCCGTAACCTG

XXX1 = TCA/ACA; XXX2 = AAA/AGA; XXX3 = GCC/TCC; XXX4 = AGA/AAA; XXX5 = ACC/CAG; XXX6 = AGC/AAC; XXX7 = CAG/CTG; XXX8 = GCT/TCT; XXX9 = GCC/ACC

SEQ ID NO:17: Anc127 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPQPKANQQHQDDX1RGLVLPGYKYLGPFNGLDKGEPVNE
ADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEA
AKTAPGKKRPVEQSPQEPDSSSGIGKSGQQPAX2KRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSNT
MASGGGAPMADNNEGADGVGNSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSQSGASNDN
HYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKX3LNFKLFNIQVKEVTQNDGTTTIANNLT
STVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRT

GNNFX4FSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLX5RTQTTSGTTQQSRLX6FSQAGPSSM
X7QQAX8NWLPGPCYRQQRVSKTANDNNNSNFAWTX9ATKYHLNGRDSLVNPGPAMASHKDDEEKFFP
MHGX10LIFGKQGTGASNVDLDNVMITDEEEIRTTNPVATEQYGTVATNLQSSNTAPATGTVNSQGAL
PGMVWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPTTFSPAKFASF
ITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYNKSVNVDFTVDTNGVYSEPRPIGTRYLTRNL

X1=G/S; X2=R/K; X3=K/R; X4=T/Q; X5=S/R; X6=Q/L; X7=A/S; X8=K/R; X9=G/A; X10=V/N

SEQ ID NO:18: Anc127 DNA

ATGGCTGCTGACGGTTATCTTCCAGATTGGCTCGAGGACAACCTTTCTGAAGGCATTCGTGAGTGGTG
GGATCTGAAACCTGGAGCCCCTCAACCCAAAGCGAACCAACAACACCAGGACGACXXX1CGGGGTCTT
GTGCTTCCGGGTTACAAATACCTCGGACCCTTTAACGGACTCGACAAAGGAGAGCCGGTCAACGAGGC
GGACGCGGCAGCCCTCGAACACGACAAAGCTTACGACCAGCAGCTCAAGGCCGGTGACAACCCGTACC
TCAAGTACAACCACGCCGACGCCGAGTTTCAGGAGCGTCTTCAAGAAGATACGTCTTTTGGGGGCAAC
CTTGGCAGAGCAGTCTTCCAGGCCAAAAAGAGGGTCCTTGAGCCTCTTGGTCTGGTTGAGGAAGCAGC
TAAAACGGCTCCTGGAAAGAAGAGGCCTGTAGAACAGTCTCCTCAGGAACCGGACTCATCATCTGGTA

TTGGCAAATCGGGCCAACAGCCTGCCXXX2AAAAGACTAAATTTCGGTCAGACTGGAGACTCAGAGTC
AGTCCCAGACCCTCAACCTCTCGGAGAACCACCAGCAGCCCCCTCAGGTGTGGGATCTAATACAATGG
CTTCAGGCGGTGGCGCACCAATGGCAGACAATAACGAGGGTGCCGATGGAGTGGGTAATTCCTCAGGA
AATTGGCATTGCGATTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCAGAACCTGGGCCCT
GCCCACTTACAACAACCATCTCTACAAGCAAATCTCCAGCCAATCAGGAGCTTCAAACGACAACCACT
ACTTTGGCTACAGCACCCCTTGGGGGTATTTTGACTTTAACAGATTCCACTGCCACTTCTCACCACGT
GACTGGCAGCGACTCATTAACAACAACTGGGGATTCCGGCCCAAGXXX3CTCAACTTCAAGCTCTTCA
ACATCCAAGTTAAAGAGGTCACGCAGAACGATGGCACGACGACTATTGCCAATAACCTTACCAGCACG
GTTCAAGTGTTTACGGACTCGGAGTATCAGCTCCCGTACGTGCTCGGGTCGGCGCACCAAGGCTGTCT
CCCGCCGTTTCCAGCGGACGTCTTCATGATCCCTCAGTATGGATACCTCACCCTGAACAACGGAAGTC
AAGCGGTGGGACGCTCATCCTTTTACTGCCTGGAGTACTTCCCTTCGCAGATGCTAAGGACTGGAAAT
AACTTCXXX4TTCAGCTATACCTTCGAGGATGTACCTTTTCACAGCAGCTACGCTCACAGCCAGAGTT
TGGATCGCTTGATGAATCCTCTTATTGATCAGTATCTGTACTACCTGXXX5AGAACGCAAACAACCTC
TGGAACAACCCAACAATCACGGCTGXXX6TTTAGCCAGGCTGGGCCTTCGTCTATGXXX7CAGCAGGC
CXXX8AATTGGCTACCTGGGCCCTGCTACCGGCAACAGAGAGTTTCAAAGACTGCTAACGACAACAAC
AACAGTAACTTTGCTTGGACAXXX9GCCACCAAATATCATCTCAATGGCCGCGACTCGCTGGTGAATC
CAGGACCAGCTATGGCCAGTCACAAGGACGATGAAGAAAAATTTTTCCCTATGCACGGCXXX10CTAA
TATTTGGCAAACAAGGGACAGGGGCAAGTAACGTAGATTTAGATAATGTAATGATTACGGATGAAGAA
GAGATTCGTACCACCAATCCTGTGGCAACAGAGCAGTATGGAACTGTGGCAACTAACTTGCAGAGCTC
AAATACAGCTCCCGCGACTGGAACTGTCAATAGTCAGGGGGCCTTACCTGGCATGGTGTGGCAAGATC
GTGACGTGTACCTTCAAGGACCTATCTGGGCAAAGATTCCTCACACGGATGGACACTTTCATCCTTCT
CCTCTGATGGGAGGCTTTGGACTGAAACATCCGCCTCCTCAAATCTTGATCAAAAATACTCCGGTACC
GGCAAATCCTCCGACGACTTTCAGCCCGGCCAAGTTTGCTTCATTTATCACTCAGTACTCCACTGGAC
AGGTCAGCGTGGAAATTGAGTGGGAGCTACAGAAAGAAAACAGCAAACGTTGGAATCCAGAGATTCAG
TACACTTCCAACTACAACAAGTCTGTTAATGTGGACTTTACTGTAGACACTAATGGTGTTTATAGTGA
ACCTCGCCCTATTGGAACCCGGTATCTCACACGAAACTTG

XXX¬1 = GGT/AGT; XXX2 = AGA/AAA; XXX3 = AAA/AGA; XXX4 = ACA/CAG; XXX5 = AGC/AGA; XXX6 = CAA/CTC; XXX7 = GCT/TCT; XXX8 = AAA/AGA; XXX9 = GGG/GCG; XXX10 = GTT/GAC

SEQ ID NO:19: Anc80L27 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEQSPQEPDSSSGIGKKGQQPARKRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSNTMA
AGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSQSGGSTNDNT
YFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTTNDGTTTIANNLTST
VQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGN
NFEFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTSGTAGNRTLQFSQAGPSSMANQAK
NWLPGPCYRQQRVSKTANQNNNSNFAWTGATKYHLNGRDSLVNPGPAMATHKDDEDKFFPMSGVLIFG
KQGAGNSNVDLDNVMITNEEEIKTTNPVATEQYGTVATNLQSANTAPATGTVNSQGALPGMVWQDRDV
YLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPTTFSPAKFASFITQYSTGQVS
VEIEWELQKENSKRWNPEIQYTSNYNKSTNVDFAVDTNGVYSEPRPIGTRYLTRNL

SEQ ID NO:20: Anc80L59 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEQSPQEPDSSSGIGKKGQQPAKKRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSNTMA
SGGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSQSGASTNDNT
YFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTTNDGTTTIANNLTST

VQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGN
NFQFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTSGTAGNRELQFSQAGPSSMANQAK
NWLPGPCYRQQRVSKTTNQNNNSNFAWTGATKYHLNGRDSLVNPGPAMATHKDDEDKFFPMSGVLIFG
KQGAGNSNVDLDNVMITNEEEIKTTNPVATEEYGTVATNLQSANTAPATGTVNSQGALPGMVWQNRDV
YLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPTTFSPAKFASFITQYSTGQVS
VEIEWELQKENSKRWNPEIQYTSNYNKSTNVDFAVDTNGVYSEPRPIGTRYLTRNL

SEQ ID NO:21: Anc80L60 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEQSPQEPDSSSGIGKKGQQPARKRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSNTMA
AGGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSQSGGSTNDNT
YFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTTNDGTTTIANNLTST
VQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGN
NFEFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTSGTAGNRELQFSQAGPSSMANQAK
NWLPGPCYRQQRVSKTTNQNNNSNFAWTGATKYHLNGRDSLVNPGPAMATHKDDEDKFFPMSGVLIFG
KQGAGNSNVDLDNVMITSEEEIKTTNPVATEEYGTVATNLQSSNTAPATGTVNSQGALPGMVWQERDV
YLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPTTFSPAKFASFITQYSTGQVS
VEIEWELQKENSKRWNPEIQYTSNYNKSTNVDFAVDTNGVYSEPRPIGTRYLTRNL

SEQ ID NO:22: Anc80L62 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEQSPQEPDSSSGIGKKGQQPARKRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSNTMA
SGGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSQSGGSTNDNT
YFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKKLNFKLFNIQVKEVTTNDGTTTIANNLTST
VQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGN
NFEFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTSGTAGNRELQFSQAGPSSMANQAK
NWLPGPCYRQQRVSKTTNQNNNSNFAWTGATKYHLNGRDSLVNPGPAMATHKDDEDKFFPMSGVLIFG
KQGAGNSNVDLDNVMITSEEEIKTTNPVATEEYGTVATNLQSANTAPATGTVNSQGALPGMVWQDRDV
YLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPTTFSPAKFASFITQYSTGQVS
VEIEWELQKENSKRWNPEIQYTSNYNKSTNVDFAVDTNGVYSEPRPIGTRYLTRNL

SEQ ID NO:23: Anc80L65 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEQSPQEPDSSSGIGKKGQQPARKRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSNTMA
AGGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSQSGGSTNDNT
YFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKKLNFKLFNIQVKEVTTNDGTTTIANNLTST
VQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGN
NFQFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTSGTAGNRTLQFSQAGPSSMANQAK
NWLPGPCYRQQRVSKTTNQNNNSNFAWTGATKYHLNGRDSLVNPGPAMATHKDDEDKFFPMSGVLIFG
KQGAGNSNVDLDNVMITNEEEIKTTNPVATEEYGTVATNLQSANTAPATGTVNSQGALPGMVWQDRDV
YLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPTTFSPAKFASFITQYSTGQVS
VEIEWELQKENSKRWNPEIQYTSNYNKSTNVDFAVDTNGVYSEPRPIGTRYLTRNL

SEQ ID NO:24: Anc80L33 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEQSPQEPDSSSGIGKKGQQPAKKRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSNTMA
AGGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSQSGGSTNDNT

YFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKKLNFKLFNIQVKEVTTNDGTTTIANNLTST
VQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGN
NFEFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTSGTAGNRTLQFSQAGPSSMANQAK
NWLPGPCYRQQRVSKTANQNNNSNFAWTGATKYHLNGRDSLVNPGPAMATHKDDEDKFFPMSGVLIFG
KQGAGNSNVDLDNVMITSEEEIKTTNPVATEQYGTVATNLQSSNTAPATGTVNSQGALPGMVWQNRDV
YLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPTTFSPAKFASFITQYSTGQVS
VEIEWELQKENSKRWNPEIQYTSNYNKSTNVDFAVDTNGVYSEPRPIGTRYLTRNL

SEQ ID NO:25: Anc80L36 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA

KTAPGKKRPVEQSPQEPDSSSGIGKKGQQPAKKRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSNTMA
SGGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSQSGGSTNDNT
YFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKKLNFKLFNIQVKEVTTNDGTTTIANNLTST
VQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGN
NFEFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTSGTAGNRTLQFSQAGPSSMANQAK
NWLPGPCYRQQRVSKTANQNNNSNFAWTGATKYHLNGRDSLVNPGPAMATHKDDEDKFFPMSGVLIFG
KQGAGNSNVDLDNVMITSEEEIKTTNPVATEEYGTVATNLQSSNTAPATGTVNSQGALPGMVWQNRDV
YLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPTTFSPAKFASFITQYSTGQVS
VEIEWELQKENSKRWNPEIQYTSNYNKSTNVDFAVDTNGVYSEPRPIGTRYLTRNL

SEQ ID NO:26: Anc80L44 polypeptide

MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAA
DAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGA
KTAPGKKRPVEQSPQEPDSSSGIGKKGQQPAKKRLNFGQTGDSESVPDPQPLGEPPAAPSGVGSNTMA
SGGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSQSGGSTNDNT
YFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKKLNFKLFNIQVKEVTTNDGTTTIANNLTST
VQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGN
NFQFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTSGTAGNRELQFSQAGPSSMANQAK
NWLPGPCYRQQRVSKTTNQNNNSNFAWTGATKYHLNGRDSLVNPGPAMATHKDDEDKFFPMSGVLIFG
KQGAGNSNVDLDNVMITNEEEIKTTNPVATEQYGTVATNLQSANTAPATGTVNSQGALPGMVWQDRDV
YLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPTTFSPAKFASFITQYSTGQVS
VEIEWELQKENSKRWNPEIQYTSNYNKSTNVDFAVDTNGVYSEPRPIGTRYLTRNL

SEQUENCE LISTING

[0110]

<110> MASSACHUSETTS EYE & EAR INFIRMARY

<120> METHODS OF PREDICTING ANCESTRAL VIRUS SEQUENCES AND USES THEREOF

<130> 00633-0155WO1

<140> PCT/US2014/060163
<141> 2014-10-10

<150> 61/889,827
<151> 2013-10-11

<160> 44

<170> PatentIn version 3.5

<210> 1
<211> 736
<212> PRT
<213> Adeno-associated virus

<220>
<221> VARIANT
<222> (168)..(168)
<223> /replace="Arg"

<220>
<221> VARIANT
<222> (204)..(204)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (266)..(266)
<223> /replace="Gly"

<220>
<221> VARIANT
<222> (311)..(311)
<223> /replace="Lys"

<220>
<221> VARIANT
<222> (411)..(411)
<223> /replace="Gln"

<220>
<221> VARIANT
<222> (460)..(460)
<223> /replace="Glu"

<220>
<221> VARIANT
<222> (493)..(493)
<223> /replace="Thr"

<220>
<221> VARIANT
<222> (562)..(562)
<223> /replace="Asn"

<220>
<221> VARIANT
<222> (576)..(576)
<223> /replace="Glu"

<220>
<221> VARIANT
<222> (587)..(587)
<223> /replace="Ala"

<220>
<221> VARIANT

<222> (609)..(609)
<223> /replace="Asp"

<220>
<221> misc_feature
<222> (1)..(736)
<223> /note="Variant residues given in the sequence have no preference with respect to those in the annotations for variant positions"

<400> 1

```
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1               5                  10                  15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
            20                  25                  30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
        35                  40                  45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
    50                  55                  60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65                  70                  75                  80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
                85                  90                  95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
            100                 105                 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
        115                 120                 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
    130                 135                 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145                 150                 155                 160

Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
                165                 170                 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
            180                 185                 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ala Gly Gly Gly
        195                 200                 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
    210                 215                 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
```

225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Ala Ser Thr Asn Asp Asn Thr
260 265 270

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285

His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300

Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320

Val Lys Glu Val Thr Thr Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn
325 330 335

Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro
340 345 350

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
370 375 380

Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe

405 410 415

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg
435 440 445

Thr Gln Thr Thr Ser Gly Thr Ala Gly Asn Arg Thr Leu Gln Phe Ser
450 455 460

Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Lys Asn Trp Leu Pro
465 470 475 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Ala Asn Gln Asn
485 490 495

Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn
500 505 510

Gly Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Thr His Lys
515 520 525

```
Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Leu Ile Phe Gly
    530                 535                 540

Lys Gln Gly Ala Gly Asn Ser Asn Val Asp Leu Asp Asn Val Met Ile
545                 550                 555                 560

Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Gln
                565                 570                 575

Tyr Gly Thr Val Ala Thr Asn Leu Gln Ser Ser Asn Thr Ala Pro Ala
            580                 585                 590

Thr Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln
        595                 600                 605

Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
    610                 615                 620

Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
625                 630                 635                 640

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
                645                 650                 655

Asn Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser Phe Ile Thr
            660                 665                 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
        675                 680                 685

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
    690                 695                 700

Tyr Asn Lys Ser Thr Asn Val Asp Phe Ala Val Asp Thr Asn Gly Val
705                 710                 715                 720

Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
                725                 730                 735
```

<210> 2

<211> 2208

<212> DNA

<213> Adeno-associated virus

<220>

<221> variation

<222> (502)..(504)

<223> /replace="aaa"

<220>

<221> variation

<222> (610)..(612)

<223> /replace="agc"

<220>
<221> variation
<222> (796)..(798)
<223> /replace="ggc"

<220>
<221> variation
<222> (931)..(933)
<223> /replace="aag"

<220>
<221> variation
<222> (1231)..(1233)
<223> /replace="cag"

<220>
<221> variation
<222> (1378)..(1380)
<223> /replace="gag"

<220>
<221> variation
<222> (1477)..(1479)
<223> /replace="acc"

<220>
<221> variation
<222> (1684)..(1686)
<223> /replace="aac"

<220>
<221> variation
<222> (1726)..(1728)
<223> /replace="gag"

<220>
<221> variation
<222> (1759)..(1761)
<223> /replace="gcc"

<220>
<221> variation
<222> (1825)..(1827)
<223> /replace="gac"

<220>
<221> misc_feature

<222> (1)..(2208)
<223> /note="Variation nucleotides given in the sequence have no preference with respect to those in the annotations for variation positions"

<400> 2

atggctgccg atggttatct tccagattgg ctcgaggaca acctctctga gggcattcgc 60

gagtggtggg acttgaaacc tggagccccg aaacccaaag ccaaccagca aaagcaggac 120

gacggccggg gtctggtgct tcctggctac aagtacctcg gacccttcaa cggactcgac 180

aaggggagc ccgtcaacgc ggcggacgca gcggccctcg agcacgacaa ggcctacgac 240

cagcagctca aagcgggtga caatccgtac ctgcggtata accacgccga cgccgagttt 300

caggagcgtc tgcaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttccag 360

gccaagaagc gggttctcga acctctcggt ctggttgagg aaggcgctaa gacggctcct 420

ggaaagaaga gaccggtaga gcaatcaccc caggaaccag actcctcttc gggcatcggc 480

aagaaaggcc agcagcccgc gaagaagaga ctcaactttg ggcagacagg cgactcagag 540

tcagtgcccg accctcaacc actcggagaa ccccccgcag ccccctctgg tgtgggatct 600

aatacaatgg cagcaggcgg tggcgctcca atggcagaca ataacgaagg cgccgacgga 660

gtgggtaacg cctcaggaaa ttggcattgc gattccacat ggctgggcga cagagtcatc 720

accaccagca cccgaacctg ggccctcccc acctacaaca accacctcta caagcaaatc 780

tccagccaat cgggagcaag caccaacgac aacacctact tcggctacag caccccctgg 840

gggtattttg actttaacag attccactgc cacttctcac cacgtgactg gcagcgactc 900

atcaacaaca actggggatt ccggcccaag agactcaact tcaagctctt caacatccag 960

gtcaaggagg tcacgacgaa tgatggcacc acgaccatcg ccaataacct taccagcacg 1020

gttcaggtct ttacggactc ggaataccag ctcccgtacg tcctcggctc tgcgcaccag 1080

ggctgcctgc ctccgttccc ggcggacgtc ttcatgattc ctcagtacgg gtacctgact 1140

-

ctgaacaatg gcagtcaggc cgtgggccgt tcctccttct actgcctgga gtactttcct 1200

tctcaaatgc tgagaacggg caacaacttt gagttcagct acacgtttga ggacgtgcct 1260

tttcacagca gctacgcgca cagccaaagc ctggaccggc tgatgaaccc cctcatcgac 1320

cagtacctgt actacctgtc tcggactcag accacgagtg gtaccgcagg aaatcggacg 1380

ttgcaatttt ctcaggccgg gcctagtagc atggcgaatc aggccaaaaa ctggctaccc 1440

gggccctgct accggcagca acgcgtctcc aagacagcga atcaaaataa caacagcaac 1500

tttgcctgga ccggtgccac caagtatcat ctgaatggca gagactctct ggtaaatccc 1560

ggtcccgcta tggcaaccca caaggacgac gaagacaaat tttttccgat gagcggagtc 1620

ttaatatttg ggaaacaggg agctggaaat agcaacgtgg accttgacaa cgttatgata 1680

accagtgagg aagaaattaa aaccaccaac ccagtggcca cagaacagta cggcacggtg 1740

gccactaacc tgcaatcgtc aaacaccgct cctgctacag ggaccgtcaa cagtcaagga 1800

gccttacctg gcatggtctg gcagaaccgg gacgtgtacc tgcagggtcc tatctgggcc 1860

aagattcctc acacggacgg acactttcat ccctcgccgc tgatgggagg ctttggactg 1920

```
aaacacccgc ctcctcagat cctgattaag aatacacctg ttcccgcgaa tcctccaact     1980
accttcagtc cagctaagtt tgcgtcgttc atcacgcagt acagcaccgg acaggtcagc     2040
gtggaaattg aatgggagct gcagaaagaa aacagcaaac gctggaaccc agagattcaa     2100
tacacttcca actacaacaa atctacaaat gtggactttg ctgttgacac aaatggcgtt     2160
tattctgagc ctcgccccat cggcacccgt tacctcaccc gtaatctg                 2208
```

<210> 3
<211> 737
<212> PRT
<213> Adeno-associated virus

<220>
<221> VARIANT
<222> (157)..(157)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (168)..(168)
<223> /replace="Arg"

<220>
<221> VARIANT
<222> (262)..(262)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (263)..(263)
<223> /replace="His"

<220>
<221> VARIANT
<222> (312)..(312)
<223> /replace="Lys"

<220>
<221> VARIANT
<222> (412)..(412)
<223> /replace="Gln"

<220>
<221> VARIANT
<222> (460)..(460)
<223> /replace="Gln"

<220>
<221> VARIANT
<222> (461)..(461)
<223> /replace="Glu"

<220>
<221> VARIANT
<222> (552)..(552)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (556)..(556)
<223> /replace="Tyr"

<220>
<221> VARIANT
<222> (557)..(557)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (563)..(563)
<223> /replace="Asn"

<220>
<221> VARIANT
<222> (580)..(580)
<223> /replace="Ile"

<220>
<221> VARIANT
<222> (588)..(588)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (664)..(664)
<223> /replace="Thr"

<220>
<221> misc_feature
<222> (1)..(737)
<223> /note="Variant residues given in the sequence have no preference with respect to those in the annotations for variant positions"

<400> 3
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser

[illegible]
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Thr Gly Ile Gly
145 150 155 160

Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
180 185 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ala Gly Gly Gly
195 200 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255

-

Tyr Lys Gln Ile Ser Asn Ser Gln Ser Gly Gly Ser Thr Asn Asp Asn
260 265 270

Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
275 280 285

Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
290 295 300

Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile
305 310 315 320

Gln Val Lys Glu Val Thr Thr Asn Asp Gly Thr Thr Thr Ile Ala Asn
325 330 335

Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu
340 345 350

Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro
355 360 365

Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn
370 375 380

Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400

Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr
405 410 415

Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430

Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser
435 440 445

Arg Thr Gln Thr Thr Gly Gly Thr Ala Gly Asn Arg Thr Leu Gln Phe
450 455 460

Ser Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Lys Asn Trp Leu
465 470 475 480

Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Thr Asn Gln
485 490 495

Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu

500 505 510

Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His
515 520 525

Lys Asp Asp Glu Asp Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe
530 535 540

Gly Lys Gln Gly Ala Gly Asn Asp Asn Val Asp Leu Asp Asn Val Met
545 550 555 560

Ile Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu
565 570 575

Glu Tyr Gly Val Val Ala Thr Asn Leu Gln Ser Ala Asn Thr Ala Pro
580 585 590

Gln Thr Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp

595 600 605

Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro
610 615 620

His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly
625 630 635 640

Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro
645 650 655

Ala Asn Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser Phe Ile
660 665 670

Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu
675 680 685

Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser
690 695 700

Asn Tyr Asn Lys Ser Thr Asn Val Asp Phe Ala Val Asp Thr Glu Gly
705 710 715 720

Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn
725 730 735

Leu

<210> 4
<211> 2211
<212> DNA
<213> Adeno-associated virus

<220>
<221> variation
<222> (469)..(471)
<223> /replace="agc"

<220>
<221> variation
<222> (502)..(504)
<223> /replace="aag"

<220>
<221> variation
<222> (784)..(786)
<223> /replace="agt"

<220>
<221> variation
<222> (787)..(789)

<223> /replace="cac"

<220>
<221> variation
<222> (934)..(936)
<223> /replace="aag"

<220>
<221> variation
<222> (1234)..(1236)
<223> /replace="cag"

<220>
<221> variation
<222> (1378)..(1380)
<223> /replace="cag"

<220>
<221> variation
<222> (1381)..(1383)
<223> /replace="gag"

<220>
<221> variation
<222> (1654)..(1656)
<223> /replace="agc"

<220>
<221> variation
<222> (1666)..(1668)
<223> /replace="tac"

<220>
<221> variation
<222> (1669)..(1671)
<223> /replace="agc"

<220>
<221> variation
<222> (1687)..(1689)
<223> /replace="aac"

<220>
<221> variation
<222> (1738)..(1740)
<223> /replace="atc"

<220>
<221> variation
<222> (1762)..(1764)
<223> /replace="agc"

<220>
<221> variation
<222> (1990)..(1992)
<223> /replace="acc"

<220>
<221> misc_feature
<222> (1)..(2211)
<223> /note="Variation nucleotides given in the sequence have no preference with respect to those in the annotations for variation positions"

<400> 4

```
atggctgccg atggttatct tccagattgg ctcgaggaca acctctctga gggcattcgc       60

gagtggtggg acttgaaacc tggagccccg aaacccaaag ccaaccagca aaagcaggac      120

gacggccggg gtctggtgct tcctggctac aagtacctcg gacccttcaa cggactcgac      180

aaggggggagc ccgtcaacgc ggcggacgca gcggccctcg agcacgacaa ggcctacgac      240

cagcagctca aagcgggtga caatccgtac ctgcggtata accacgccga cgccgagttt      300

caggagcgtc tgcaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttccag      360

gccaagaagc gggttctcga acctctcggt ctggttgagg aaggcgctaa gacggctcct      420

ggaaagaaga gaccggtaga gcaatcaccc caggaaccag actcctctac gggcatcggc      480

aagaaaggcc agcagcccgc gaaaaagaga ctcaactttg ggcagactgg cgactcagag      540

tcagtgcccg accctcaacc actcggagaa ccccccgcag ccccctctgg tgtgggatct      600

aatacaatgg ctgcaggcgg tggcgctcca atggcagaca ataacgaagg cgccgacgga      660

gtgggtaatg cctcaggaaa ttggcattgc gattccacat ggctgggcga cagagtcatc      720

accaccagca cccgaacctg ggccctcccc acctacaaca accacctcta caagcaaatc      780

tccaacagcc aatcgggagg aagcaccaac gacaacacct acttcggcta cagcaccccc      840

tgggggtatt ttgactttaa cagattccac tgccacttct caccacgtga ctggcagcga      900

ctcatcaaca acaactgggg attccggccc aagagactca acttcaagct cttcaacatc      960

caggtcaagg aggtcacgac gaatgatggc accacgacca tcgccaataa ccttaccagc     1020

acggttcagg tctttacgga ctcggaatac cagctcccgt acgtcctcgg ctctgcgcac     1080

cagggctgcc tgcctccgtt cccggcggac gtcttcatga ttcctcagta cgggtacctg     1140

                                    -

actctgaaca atggcagtca ggccgtgggc cgttcctcct tctactgcct ggagtacttt     1200

ccttctcaaa tgctgagaac gggcaacaac tttgagttca gctacacgtt tgaggacgtg     1260

ccttttcaca gcagctacgc gcacagccaa agcctggacc ggctgatgaa ccccctcatc     1320

gaccagtacc tgtactacct gtctcggact caqaccacqq qaqqtaccqc aqqaaatcqq     1380
```

acgttgcaat tttctcaggc cgggcctagt agcatggcga atcaggccaa aaactggcta 1440

cccgggccct gctaccggca gcaacgcgtc tccaagacaa cgaatcaaaa taacaacagc 1500

aactttgcct ggaccggtgc caccaagtat catctgaatg gcagagactc tctggtaaat 1560

cccggtgtcg ctatggcaac ccacaaggac gacgaagacc gatttttcc gtccagcgga 1620

gtcttaatat ttgggaaaca gggagctgga aatgacaacg tggaccttga caacgttatg 1680

ataaccagtg aggaagaaat taaaaccacc aacccagtgg ccacagaaga gtacggcgtg 1740

gtggccacta acctgcaatc ggcaaacacc gctcctcaaa cagggaccgt caacagtcaa 1800

ggagccttac ctggcatggt ctggcagaac cgggacgtgt acctgcaggg tcctatctgg 1860

gccaagattc ctcacacgga cggaaacttt catccctcgc cgctgatggg aggctttgga 1920

ctgaaacacc cgcctcctca gatcctgatt aagaatacac ctgttcccgc gaatcctcca 1980

actaccttca gtccagctaa gtttgcgtcg ttcatcacgc agtacagcac cggacaggtc 2040

agcgtggaaa ttgaatggga gctgcagaaa gaaaacagca aacgctggaa cccagagatt 2100

caatacactt ccaactacaa caaatctaca aatgtggact ttgctgttga cacagaaggc 2160

gtttattctg agcctcgccc catcggcacc cgttacctca cccgtaatct g 2211

<210> 5

<211> 738

<212> PRT

<213> Adeno-associated virus

<220>

<221> VARIANT

<222> (158) .. (158)

<223> /replace="Ser"

<220>

<221> VARIANT

<222> (169)..(169)

<223> /replace="Arg"

<220>

<221> VARIANT

<222> (564) .. (564)

<223> /replace="Asn"

<220>

<221> misc_feature

<222> (1)..(738)

<223> /note="Variant residues given in the sequence have no preference with respect to those in the annotations for variant positions"

<400> 5

```
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1               5                  10                  15
```

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

Pro Val Glu Gln Ser Pro Gln Arg Glu Pro Asp Ser Ser Thr Gly Ile
145 150 155 160

Gly Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln
165 170 175

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro
180 185 190

Pro Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ala Gly Gly
195 200 205

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn
210 215 220

Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val
225 230 235 240

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His
245 250 255

Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp
260 265 270

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn
275 280 285

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn
290 295 300

```
Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn
305                 310                 315                 320

Ile Gln Val Lys Glu Val Thr Thr Asn Glu Gly Thr Lys Thr Ile Ala
                325                 330                 335

Asn Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln
            340                 345                 350

Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe
        355                 360                 365

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn
    370                 375                 380

Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr
385                 390                 395                 400

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr
                405                 410                 415

Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser
            420                 425                 430

Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu
        435                 440                 445

Ser Arg Thr Gln Thr Thr Gly Gly Thr Ala Gly Thr Gln Thr Leu Gln
    450                 455                 460

Phe Ser Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Lys Asn Trp
465                 470                 475                 480

Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Thr Asn
                485                 490                 495

Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His
            500                 505                 510

Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr
        515                 520                 525

His Lys Asp Asp Glu Asp Arg Phe Phe Pro Ser Ser Gly Val Leu Ile
    530                 535                 540

Phe Gly Lys Gln Gly Ala Gly Asn Asp Asn Val Asp Tyr Ser Asn Val
545                 550                 555                 560

Met Ile Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr
                565                 570                 575

Glu Glu Tyr Gly Val Val Ala Thr Asn Leu Gln Ser Ala Asn Thr Ala
            580                 585                 590

Pro Gln Thr Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val
        595                 600                 605
```

```
Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile
    610                 615                 620

Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe
625                 630                 635                 640

Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val
                645                 650                 655

Pro Ala Asp Pro Pro Thr Thr Phe Asn Gln Ala Lys Leu Asn Ser Phe
            660                 665                 670

Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu
        675                 680                 685

Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr
    690                 695                 700

Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu
705                 710                 715                 720

Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg
                725                 730                 735

Asn Leu
```

<210> 6

<211> 2214

<212> DNA

<213> Adeno-associated virus

<220>

<221> variation

<222> (472)..(474)

<223> /replace="agc"

<220>

<221> variation

<222> (505) .. (507)

<223> /replace="aga"

<220>

<221> variation

<222> (1690) .. (1692)

<223> /replace="aac"

<220>

<221> misc_feature

<222> (1) .. (2214)

<223> /note="Variation nucleotides given in the sequence have no preference with respect to those in the annotations for variation positions"

<400> 6

atggctgccg atggttatct tccagattgg ctcgaggaca acctctctga gggcattcgc 60

gagtggtggg acctgaaacc tggagccccg aaacccaaag ccaaccagca aaagcaggac 120

gacggccggg gtctggtgct tcctggctac aagtacctcg gacccttcaa cggactcgac 180

aaggggggagc ccgtcaacgc ggcggacgca gcggccctcg agcacgacaa ggcctacgac 240

cagcagctca aagcgggtga caatccgtac ctgcggtata atcacgccga cgccgagttt 300

caggagcgtc tgcaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttccag 360

gccaagaagc gggttctcga acctctcggt ctggttgagg aaggcgctaa gacggctcct 420

ggaaagaaga gaccggtaga gcagtcacca cagcgtgagc ccgactcctc cacgggcatc 480

ggcaagaaag gccagcagcc cgccaaaaag agactcaatt tcggtcagac tggcgactca 540

gagtcagtcc ccgaccctca acctctcgga gaacctccag cagcgccctc tggtgtggga 600

tctaatacaa tggctgcagg cggtggcgca ccaatggcag acaataacga aggtgccgac 660

ggagtgggta attcctcggg aaattggcat tgcgattcca catggctggg cgacagagtc 720

atcaccacca gcacccgaac ctgggccctg cccacctaca acaaccacct ctacaagcaa 780

atctccaacg ggacctcggg aggcagcacc aacgacaaca cctactttgg ctacagcacc 840

ccctgggggt attttgactt taacagattc cactgccact tctcaccacg tgactggcag 900

cgactcatca acaacaactg gggattccgg cccaagagac tcaacttcaa gctcttcaac 960

-

atccaggtca aagaggtcac gacgaatgaa ggcaccaaga ccatcgccaa taacctcacc 1020

agcaccgtcc aggtgtttac ggactcggaa taccagctgc cgtacgtcct cggctctgcc 1080

caccagggct gcctgcctcc gttcccggcg gacgtcttca tgattcctca gtacggctac 1140

ctgactctca acaacggtag tcaggccgtg ggacgttcct ccttctactg cctggagtac 1200

ttcccctctc agatgctgag aacgggcaac aactttcaat tcagctacac tttcgaggac 1260

gtgcctttcc acagcagcta cgcgcacagc cagagtttgg acaggctgat gaatcctctc 1320

atcgaccagt acctgtacta cctgtcaaga acccagacta cgggaggcac agcgggaacc 1380

cagacgttgc agttttctca ggccgggcct agcagcatgg cgaatcaggc caaaaactgg 1440

ctgcctggac cctgctacag acagcagcgc gtctccacga caacgaatca aaacaacaac 1500

agcaactttg cctggactgg tgccaccaag tatcatctga acggcagaga ctctctggtg 1560

aatccgggcg tcgccatggc aacccacaag gacgacgagg accgcttctt cccatccagc 1620

ggcgtcctca tatttggcaa gcagggagct ggaaatgaca acgtggacta tagcaacgtg 1680

atgataacca gcgaggaaga aatcaagacc accaaccccg tggccacaga agagtatggc 1740

gtggtggcta ctaacctaca gtcggcaaac accgctcctc aaacggggac cgtcaacagc 1800

cagggagcct tacctggcat ggtctggcag aaccgggacg tgtacctgca gggtcctatt 1860

tgggccaaga ttcctcacac agatggcaac tttcacccgt ctcctttaat gggcggcttt 1920

ggacttaaac atccgcctcc tcagatcctc atcaaaaaca ctcctgttcc tgcggatcct 1980

ccaacaacgt tcaaccaggc caagctgaat tctttcatca cgcagtacag caccggacaa 2040

gtcagcgtgg agatcgagtg ggagctgcag aaggagaaca gcaagcgctg gaacccagag 2100

attcagtata cttccaacta ctacaaatct acaaatgtgg actttgctgt taatactgag 2160

ggtgtttact ctgagcctcg ccccattggc actcgttacc tcacccgtaa tctg 2214

<210> 7
<211> 738
<212> PRT
<213> Adeno-associated virus

<220>
<221> VARIANT
<222> (158) .. (158)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (169)..(169)
<223> /replace="Lys"

<220>
<221> VARIANT
<222> (315) .. (315)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (413)..(413)
<223> /replace="Glu"

<220>
<221> VARIANT
<222> (472)..(472)
<223> /replace="Thr" or "Ser"

<220>
<221> VARIANT
<222> (534) .. (534)
<223> /replace="Glu"

<220>
<221> VARIANT
<222> (542)..(542)
<223> /replace="Val"

<220>
<221> VARIANT
<222> (595)..(595)
<223> /replace="Val"

<220>
<221> misc_feature
<222> (1)..(738)
<223> /note="Variant residues given in the sequence have no preference with respect to those in the annotations for variant positions"

<400> 7

```
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1               5                  10                  15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
            20                  25                  30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
        35                  40                  45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
    50                  55                  60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65                  70                  75                  80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
                85                  90                  95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
            100                 105                 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
        115                 120                 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
    130                 135                 140

Pro Val Glu Gln Ser Pro Gln Arg Glu Pro Asp Ser Ser Thr Gly Ile
145                 150                 155                 160

Gly Lys Lys Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln
                165                 170                 175

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro
            180                 185                 190

Pro Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ala Gly Gly
        195                 200                 205

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser
    210                 215                 220

Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val
225                 230                 235                 240

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His
                245                 250                 255
```

```
Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp
            260                 265                 270

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn
        275                 280                 285

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn
    290                 295                 300

Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn
305                 310                 315                 320

Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala
                325                 330                 335

Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln
            340                 345                 350

Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe
        355                 360                 365

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn
    370                 375                 380

Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr
385                 390                 395                 400

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr
                405                 410                 415

Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser
            420                 425                 430

Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu
        435                 440                 445

Ser Arg Thr Gln Thr Thr Gly Gly Thr Ala Gly Thr Gln Thr Leu Gln
    450                 455                 460

Phe Ser Gln Ala Gly Pro Ser Asn Met Ala Asn Gln Ala Lys Asn Trp
465                 470                 475                 480

Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Thr Ser
                485                 490                 495

Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His
            500                 505                 510

Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr
        515                 520                 525

His Lys Asp Asp Glu Asp Arg Phe Phe Pro Ser Ser Gly Ile Leu Ile
    530                 535                 540

Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Asn Val
545                 550                 555                 560
```

Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr
565 570 575

Glu Glu Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Thr Ala
580 585 590

Pro Gln Ile Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val
595 600 605

Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile
610 615 620

Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe
625 630 635 640

Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val
645 650 655

Pro Ala Asp Pro Pro Thr Thr Phe Asn Gln Ala Lys Leu Asn Ser Phe
660 665 670

Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu
675 680 685

Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr
690 695 700

Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu
705 710 715 720

Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg
725 730 735

Asn Leu

<210> 8

<211> 2214

<212> DNA

<213> Adeno-associated virus

<220>

<221> variation

<222> (472)..(474)

<223> /replace="agc"

<220>

<221> variation

<222> (505) .. (507)

<223> /replace="aag"

<220>

<221> variation
<222> (943)..(945)
<223> /replace="agc"

<220>
<221> variation
<222> (1237)..(1239)
<223> /replace="gaa"

<220>
<221> variation
<222> (1414)..(1416)
<223> /replace="aac" or "agc"

<220>
<221> variation
<222> (1600) .. (1602)
<223> /replace="gag"

<220>
<221> variation
<222> (1624) .. (1626)
<223> /replace="gtc"

<220>
<221> variation
<222> (1783) .. (1785)
<223> /replace="gta"

<220>
<221> misc_feature
<222> (1) .. (2214)
<223> /note="Variation nucleotides given in the sequence have no preference with respect to those in the annotations for variation positions"

<400> 8
atggctgccg atggttatct tccagattgg ctcgaggaca acctctctga gggcattcgc 60

gagtggtggg acctgaaacc tggagccccg aaacccaaag ccaaccagca aaagcaggac 120

gacggccggg gtctggtgct tcctggctac aagtacctcg gacccttcaa cggactcgac 180

aaggggggagc ccgtcaacgc ggcggacgca gcggccctcg agcacgacaa ggcctacgac 240

cagcagctca aagcgggtga caatccgtac ctgcggtata atcacgccga cgccgagttt 300

caggagcgtc tgcaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttccag 360

gccaagaagc gggttctcga acctctcggt ctggttgagg aaggcgctaa gacggctcct 420

ggaaagaaga gaccggtaga gcagtcacca cagcgtgagc ccgactcctc cacgggcatc 480

ggcaagaaag gccagcagcc cgccagaaag agactcaatt tcggtcagac tggcgactca 540

gagtcagtcc ccgaccctca acctctcgga gaacctccag cagcgccctc tggtgtggga 600

tctaatacaa tggctgcagg cggtggcgca ccaatggcag acaataacga aggtgccgac 660

ggagtgggta gttcctcggg aaattggcat tgcgattcca catggctggg cgacagagtc 720

atcaccacca gcacccgaac ctgggccctg cccacctaca acaaccacct ctacaagcaa 780

atctccaacg ggacctcggg aggcagcacc aacgacaaca cctactttgg ctacagcacc 840

ccctgggggt attttgactt taacagattc cactgccact tctcaccacg tgactggcag 900

cgactcatca acaacaactg gggattccgg cccaagagac tcaacttcaa gctcttcaac 960

atccaggtca aagaggtcac gcagaatgaa ggcaccaaga ccatcgccaa taacctcacc 1020

agcaccatcc aggtgtttac ggactcggaa taccagctgc cgtacgtcct cggctctgcc 1080

caccagggct gcctgcctcc gttcccggcg gacgtcttca tgattcctca gtacggctac 1140

ctgactctca acaacggtag tcaggccgtg ggacgttcct ccttctactg cctggagtac 1200

ttcccctctc agatgctgag aacgggcaac aactttcaat tcagctacac tttcgaggac 1260

gtgcctttcc acagcagcta cgcgcacagc cagagtttgg acaggctgat gaatcctctc 1320

atcgaccagt acctgtacta cctgtcaaga acccagacta cgggaggcac agcgggaacc 1380

cagacgttgc agttttctca ggccgggcct agcaacatgg cgaatcaggc caaaaactgg 1440

ctgcctggac cctgctacag acagcagcgc gtctccacga caacgtcgca aaacaacaac 1500

agcaactttg cctggactgg tgccaccaag tatcatctga acggcagaga ctctctggtg 1560

aatccgggcg tcgccatggc aacccacaag gacgacgagg accgcttctt cccatccagc 1620

ggcatcctca tatttggcaa gcagggagct ggaaaagaca acgtggacta tagcaacgtg 1680

atgctaacca gcgaggaaga aatcaagacc accaaccccg tggccacaga agagtatggc 1740

gtggtggctg ataacctaca gcagcaaaac accgctcctc aaatagggac cgtcaacagc 1800

cagggagcct tacctggcat ggtctggcag aaccgggacg tgtacctgca gggtcctatt 1860

tgggccaaga ttcctcacac agatggcaac tttcacccgt ctcctttaat gggcggcttt 1920

ggacttaaac atccgcctcc tcagatcctc atcaaaaaca ctcctgttcc tgcggatcct 1980

ccaacaacgt tcaaccaggc caagctgaat tctttcatca cgcagtacag caccggacaa 2040

gtcagcgtgg agatcgagtg ggagctgcag aaggagaaca gcaagcgctg gaacccagag 2100

attcagtata cttccaacta ctacaaatct acaaatgtgg actttgctgt taatactgag 2160

ggtgtttact ctgagcctcg ccccattggc actcgttacc tcacccgtaa tctg 2214

<210> 9

<211> 738

<212> PRT

<213> Adeno-associated virus

<220>

<221> VARIANT

<222> (169)..(169)

<223> /replace="Lys"

<220>
<221> VARIANT
<222> (315) .. (315)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (534) .. (534)
<223> /replace="Glu"

<220>
<221> VARIANT
<222> (542)..(542)
<223> /replace="Val"

<220>
<221> misc_feature
<222> (1)..(738)
<223> /note="Variant residues given in the sequence have no preference with respect to those in the annotations for variant positions"

<400> 9

```
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1               5                   10                  15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
            20                  25                  30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
        35                  40                  45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
    50                  55                  60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65                  70                  75                  80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
                85                  90                  95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
            100                 105                 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
        115                 120                 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
    130                 135                 140

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile
145                 150                 155                 160
```

Gly Lys Lys Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln
165 170 175

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro
180 185 190

Pro Ala Ala Pro Ser Gly Val Gly Ser Gly Thr Met Ala Ala Gly Gly
195 200 205

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser
210 215 220

Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val
225 230 235 240

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His
245 250 255

Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp
260 265 270

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn
275 280 285

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn
290 295 300

Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn
305 310 315 320

Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala
325 330 335

Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln
340 345 350

Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe
355 360 365

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn
370 375 380

Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr
385 390 395 400

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr
405 410 415

Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser
420 425 430

Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu
435 440 445

Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu
450 455 460

Phe Ser Gln Ala Gly Pro Ser Asn Met Ser Ala Gln Ala Lys Asn Trp
465 470 475 480

Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser
485 490 495

Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His
500 505 510

Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr
515 520 525

His Lys Asp Asp Glu Asp Arg Phe Phe Pro Ser Ser Gly Ile Leu Met
530 535 540

Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Asn Val
545 550 555 560

Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr
565 570 575

Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Thr Ala
580 585 590

Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val
595 600 605

Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile
610 615 620

Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe
625 630 635 640

Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val
645 650 655

Pro Ala Asp Pro Pro Thr Thr Phe Asn Gln Ala Lys Leu Asn Ser Phe
660 665 670

Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu
675 680 685

Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr
690 695 700

Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu
705 710 715 720

Gly Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg

725 730 735

Asn Leu

<210> 10

<211> 2214
<212> DNA
<213> Adeno-associated virus

<220>
<221> variation
<222> (505) .. (507)
<223> /replace="aaa"

<220>
<221> variation
<222> (943)..(945)
<223> /replace="agc"

<220>
<221> variation
<222> (1600) .. (1602)
<223> /replace="gag"

<220>
<221> variation
<222> (1624) .. (1626)
<223> /replace="gtc"

<220>
<221> misc_feature
<222> (1) .. (2214)
<223> /note="Variation nucleotides given in the sequence have no preference with respect to those in the annotations for variation positions"

<400> 10

```
atggctgccg atggttatct tccagattgg ctcgaggaca acctctctga gggcattcgc       60

gagtggtggg acctgaaacc tggagccccg aaacccaaag ccaaccagca aaagcaggac      120

gacggccggg gtctggtgct tcctggctac aagtacctcg gacccttcaa cggactcgac      180

aagggggagc ccgtcaacgc ggcggacgca gcggccctcg agcacgacaa ggcctacgac      240

cagcagctca aagcgggtga caatccgtac ctgcggtata atcacgccga cgccgagttt      300

caggagcgtc tgcaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttccag      360

gccaagaagc gggttctcga acctctcggt ctggttgagg aaggcgctaa gacggctcct      420

ggaaagaaga gaccggtaga gccgtcacca cagcgttccc ccgactcctc cacgggcatc      480

ggcaagaaag gccagcagcc cgccagaaag agactcaatt tcggtcagac tggcgactca      540

gagtcagtcc ccgaccctca acctatcgga gaacctccag cagcgccctc tggtgtggga      600

tctggtacaa tggctgcagg cggtggcgca ccaatggcag acaataacga aggtgccgac      660

ggagtgggta gttcctcggg aaattggcat tgcgattcca catggctggg cgacagagtc      720
```

atcaccacca gcacccgaac ctgggccctg cccacctaca acaaccacct ctacaagcaa 780

atctccaacg ggacctcggg aggcagcacc aacgacaaca cctactttgg ctacagcacc 840

ccctgggggt attttgactt taacagattc cactgccact tctcaccacg tgactggcag 900

cgactcatca acaacaactg gggattccgg cccaagagac tcaacttcaa gctcttcaac 960

atccaggtca aagaggtcac gcagaatgaa ggcaccaaga ccatcgccaa taacctcacc 1020

agcaccatcc aggtgtttac ggactcggaa taccagctgc cgtacgtcct cggctctgcc 1080

caccagggct gcctgcctcc gttcccggcg gacgtcttca tgattcctca gtacggctac 1140

ctgactctca acaacggtag tcaggccgtg ggacgttcct ccttctactg cctggagtac 1200

ttcccctctc agatgctgag aacgggcaac aactttgagt tcagctacac tttcgaggac 1260

gtgcctttcc acagcagcta cgcgcacagc cagagtttgg acaggctgat gaatcctctc 1320

atcgaccagt acctgtacta cctgtcaaga acccagtcta cgggaggcac agcgggaacc 1380

cagcagttgc tgttttctca ggccgggcct agcaacatgt cggctcaggc caaaaactgg 1440

ctgcctggac cctgctacag acagcagcgc gtctccacga cactgtcgca aaacaacaac 1500

agcaactttg cctggactgg tgccaccaag tatcatctga acggcagaga ctctctggtg 1560

aatccgggcg tcgccatggc aacccacaag gacgacgagg accgcttctt cccatccagc 1620

ggcatcctca tgtttggcaa gcagggagct ggaaaagaca acgtggacta tagcaacgtg 1680

atgctaacca gcgaggaaga aatcaagacc accaaccccg tggccacaga acagtatggc 1740

gtggtggctg ataacctaca gcagcaaaac accgctccta ttgtgggggc cgtcaacagc 1800

cagggagcct tacctggcat ggtctggcag aaccgggacg tgtacctgca gggtcctatt 1860

tgggccaaga ttcctcacac agatggcaac tttcacccgt ctcctttaat gggcggcttt 1920

ggacttaaac atccgcctcc tcagatcctc atcaaaaaca ctcctgttcc tgcggatcct 1980

ccaacaacgt tcaaccaggc caagctgaat tctttcatca cgcagtacag caccggacaa 2040

gtcagcgtgg agatcgagtg ggagctgcag aaggagaaca gcaagcgctg gaacccagag 2100

attcagtata cttccaacta ctacaaatct acaaatgtgg actttgctgt taatactgag 2160

ggtgtttact ctgagcctcg ccccattggc actcgttacc tcacccgtaa tctg 2214

<210> 11
<211> 738
<212> PRT
<213> Adeno-associated virus

<220>
<221> VARIANT
<222> (471)..(471)
<223> /replace="Asn"

<220>
<221> misc_feature
<222> (1)..(738)
<223> /note="Variant residues given in the sequence have no preference with respect to those in the annotations for variant positions"

<400> 11

```
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1               5                  10                  15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
            20                  25                  30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
        35                  40                  45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
    50                  55                  60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65                  70                  75                  80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
                85                  90                  95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
            100                 105                 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
        115                 120                 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
    130                 135                 140

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile
145                 150                 155                 160

Gly Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln
                165                 170                 175

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro
            180                 185                 190

Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly
        195                 200                 205

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser
    210                 215                 220

Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val
225                 230                 235                 240

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His
                245                 250                 255

Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp
            260                 265                 270

Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn
        275                 280                 285
```

275 280 285

Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn
290 295 300

Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn
305 310 315 320

Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala
325 330 335

Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln
340 345 350

Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe
355 360 365

Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn
370 375 380

Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr
385 390 395 400

Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr
405 410 415

Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser
420 425 430

Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu
435 440 445

Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu
450 455 460

Phe Ser Gln Ala Gly Pro Ser Asn Met Ser Ala Gln Ala Lys Asn Trp

465 470 475 480

Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser
485 490 495

Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His
500 505 510

Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr
515 520 525

His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met
530 535 540

Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val
545 550 555 560

Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr
565 570 575

```
Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Thr Ala
            580                 585                 590

Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val
        595                 600                 605

Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile
    610                 615                 620

Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe
625                 630                 635                 640

Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val
                645                 650                 655

Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe
            660                 665                 670

Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu
        675                 680                 685

Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr
    690                 695                 700

Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu
705                 710                 715                 720

Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg
                725                 730                 735

Asn Leu
```

<210> 12
<211> 2214
<212> DNA
<213> Adeno-associated virus

<220>
<221> variation
<222> (1411) .. (1413)
<223> /replace="aat"

<220>
<221> misc_feature
<222> (1) .. (2214)
<223> /note="Variation nucleotides given in the sequence have no preference with respect to those in the annotations for variation positions"

<400> 12

```
atggctgccg atggttatct tccagattgg ctcgaggaca acctctctga gggcattcgc        60

gagtggtggg acttgaaacc tggagccccg aaacccaaag ccaaccagca aaagcaggac       120

gacggccggg gtctggtgct tcctggctac aagtacctcg gacccttcaa cggactcgac       180
```

aaggggagc ccgtcaacgc ggcggacgca gcggccctcg agcacgacaa ggcctacgac 240

cagcagctca aagcgggtga caatccgtac ctgcggtata accacgccga cgccgagttt 300

caggagcgtc tgcaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttccag 360

gccaagaagc gggttctcga acctctcggt ctggttgagg aaggcgctaa gacggctcct 420

ggaaagaaga gaccggtaga gccatcaccc cagcgttctc cagactcctc tacgggcatc 480

ggcaagaaag gccagcagcc cgcgaaaaag agactcaact ttgggcagac tggcgactca 540

gagtcagtgc ccgaccctca accaatcgga gaaccccccg caggcccctc tggtctggga 600

tctggtacaa tggctgcagg cggtggcgct ccaatggcag acaataacga aggcgccgac 660

ggagtgggta gttcctcagg aaattggcat tgcgattcca catggctggg cgacagagtc 720

atcaccacca gcacccgaac ctgggccctc cccacctaca acaaccacct ctacaagcaa 780

atctccaacg ggacttcggg aggaagcacc aacgacaaca cctacttcgg ctacagcacc 840

ccctgggggt attttgactt taacagattc cactgccact tctcaccacg tgactggcag 900

cgactcatca acaacaactg gggattccgg cccaagagac tcaacttcaa gctcttcaac 960

atccaggtca aggaggtcac gcagaatgaa ggcaccaaga ccatcgccaa taaccttacc 1020

agcacgattc aggtctttac ggactcggaa taccagctcc cgtacgtcct cggctctgcg 1080

caccagggct gcctgcctcc gttcccggcg gacgtcttca tgattcctca gtacgggtac 1140

ctgactctga acaatggcag tcaggccgtg ggccgttcct ccttctactg cctggagtac 1200

tttccttctc aaatgctgag aacgggcaac aactttgagt tcagctacac gtttgaggac 1260

gtgcctttc acagcagcta cgcgcacagc caaagcctgg accggctgat gaacccctc 1320

atcgaccagt acctgtacta cctgtctcgg actcagtcca cgggaggtac cgcaggaact 1380

cagcagttgc tattttctca ggccgggcct agtaacatgt cggctcaggc caaaaactgg 1440

ctacccgggc cctgctaccg gcagcaacgc gtctccacga cactgtcgca aaataacaac 1500

agcaactttg cctggaccgg tgccaccaag tatcatctga atggcagaga ctctctggta 1560

aatcccggtg tcgctatggc aacccacaag gacgacgaag agcgattttt tccgtccagc 1620

ggagtcttaa tgtttgggaa acagggagct ggaaaagaca acgtggacta tagcagcgtt 1680

atgctaacca gtgaggaaga aattaaaacc accaacccag tggccacaga acagtacggc 1740

gtggtggccg ataacctgca acagcaaaac accgctccta ttgtaggggc cgtcaacagt 1800

caaggagcct tacctggcat ggtctggcag aaccgggacg tgtacctgca gggtcctatc 1860

tgggccaaga ttcctcacac ggacggaaac tttcatccct cgccgctgat gggaggcttt 1920

ggactgaaac acccgcctcc tcagatcctg attaagaata cacctgttcc cgcggatcct 1980

ccaactacct tcagtcaagc taagctggcg tcgttcatca cgcagtacag caccggacag 2040

gtcagcgtgg aaattgaatg ggagctgcag aaagaaaaca gcaaacgctg gaacccagag 2100

attcaataca cttccaacta ctacaaatct acaaatgtgg actttgctgt taacacagaa 2160

ggcacttatt ctgagcctcg ccccatcggc acccgttacc tcacccgtaa tctg 2214

<210> 13

<211> 737

<212> PRT
<213> Adeno-associated virus

<220>
<221> VARIANT
<222> (148)..(148)
<223> /replace="Gln"

<220>
<221> VARIANT
<222> (169)..(169)
<223> /replace="Arg"

<220>
<221> VARIANT
<222> (314)..(314)
<223> /replace="Asn"

<220>
<221> VARIANT
<222> (466)..(466)
<223> /replace="His"

<220>
<221> VARIANT
<222> (563)..(563)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (580) .. (580)
<223> /replace="Ile"

<220>
<221> VARIANT
<222> (588) .. (588)
<223> /replace="Ser"

<220>
<221> misc_feature
<222> (1)..(737)
<223> /note="Variant residues given in the sequence have no preference with respect to those in the annotations for variant positions"

<400> 13

```
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1               5                   10                  15
```

```
Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
            20                  25                  30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
        35                  40                  45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
    50                  55                  60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65                  70                  75                  80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
                85                  90                  95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
            100                 105                 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
        115                 120                 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
    130                 135                 140

Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile
145                 150                 155                 160

Gly Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln
                165                 170                 175

Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro
            180                 185                 190

Pro Ala Ala Pro Ser Gly Val Gly Ser Gly Thr Met Ala Ala Gly Gly
        195                 200                 205

Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn
    210                 215                 220

Ala Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val
225                 230                 235                 240

Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His
                245                 250                 255

Leu Tyr Lys Gln Ile Ser Ser Gln Ser Ala Gly Ser Thr Asn Asp Asn
            260                 265                 270

Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg
        275                 280                 285

Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn
    290                 295                 300

Asn Trp Gly Phe Arg Pro Lys Lys Leu Arg Phe Lys Leu Phe Asn Ile
305                 310                 315                 320
```

Gln Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn
325 330 335

Asn Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu
340 345 350

Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro
355 360 365

Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn
370 375 380

Gly Ser Gln Ser Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe
385 390 395 400

Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr
405 410 415

Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu
420 425 430

Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala
435 440 445

Arg Thr Gln Ser Thr Thr Gly Gly Thr Ala Gly Asn Arg Glu Leu Gln
450 455 460

Phe Tyr Gln Ala Gly Pro Ser Thr Met Ala Glu Gln Ala Lys Asn Trp
465 470 475 480

Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Leu Asp
485 490 495

Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His
500 505 510

Leu Asn Gly Arg Asn Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr
515 520 525

His Lys Asp Asp Glu Asp Arg Phe Phe Pro Ser Ser Gly Val Leu Ile
530 535 540

Phe Gly Lys Thr Gly Ala Ala Asn Lys Thr Thr Leu Glu Asn Val Leu
545 550 555 560

Met Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu
565 570 575

Glu Tyr Gly Val Val Ser Ser Asn Leu Gln Ser Ala Asn Thr Ala Pro
580 585 590

Gln Thr Gln Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp
595 600 605

Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro
610 615 620

His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly
625 630 635 640

Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro
645 650 655

Ala Asn Pro Pro Glu Val Phe Thr Pro Ala Lys Phe Ala Ser Phe Ile
660 665 670

Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu
675 680 685

Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser
690 695 700

Asn Tyr Asp Lys Ser Thr Asn Val Asp Phe Ala Val Asp Ser Glu Gly
705 710 715 720

Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn
725 730 735

Leu

<210> 14
<211> 2211
<212> DNA
<213> Adeno-associated virus

<220>
<221> variation
<222> (442)..(444)
<223> /replace="cag"

<220>
<221> variation
<222> (505) .. (507)
<223> /replace="aga"

<220>
<221> variation
<222> (940)..(942)
<223> /replace="aac"

<220>
<221> variation
<222> (1396)..(1398)
<223> /replace="cac"

<220>
<221> variation
<222> (1687)..(1689)
<223> /replace="agt"

<220>
<221> variation
<222> (1738) .. (1740)
<223> /replace="ata"

<220>
<221> variation
<222> (1762)..(1764)
<223> /replace="tct"

<220>
<221> misc_feature
<222> (1) .. (2211)
<223> /note="Variation nucleotides given in the sequence have no preference with respect to those in the annotations for variation positions"

<400> 14

```
atggctgccg atggttatct tccagattgg ctcgaggaca acctctctga gggcattcgc        60

gagtggtggg acctgaaacc tggagccccg aaacccaaag ccaaccagca aaagcaggac       120

gacggccggg gtctggtgct tcctggctac aagtacctcg gacccttcaa cggactcgac       180

aaggggggagc ccgtcaacgc ggcggacgca gcggccctcg agcacgacaa ggcctacgac      240

cagcagctca aagcgggtga caatccgtac ctgcggtata accacgccga cgccgagttt       300

caggagcgtc tgcaagaaga tacgtcattt gggggcaacc tcgggcgagc agtcttccag       360

gccaagaagc gggttctcga acctctcggt ctggttgagg aaggcgctaa gacggctcct       420

ggaaagaaga gaccggtaga gccgtcacct cagcgttccc ccgactcctc cacgggcatc       480

ggcaagaaag gccagcagcc cgccaaaaag agactcaatt tcggtcagac tggcgactca       540

gagtcagtcc ccgaccctca acctctcgga gaacctccag cagcgccctc tggtgtggga       600

tctggtacaa tggctgcagg cggtggcgca ccaatggcag acaataacga aggtgccgac       660

ggagtgggta atgcctcagg aaattggcat tgcgattcca catggctggg cgacagagtc       720

attaccacca gcacccgaac ctgggccctg cccacctaca acaaccacct ctacaagcaa       780

atctccagtc aaagtgcagg tagtaccaac gacaacacct acttcggcta cagcaccccc       840

tgggggtatt ttgactttaa cagattccac tgccacttct caccacgtga ctggcagcga       900

ctcatcaaca acaactgggg attccggccc aagaagctgc ggttcaagct cttcaacatc       960

caggtcaagg aggtcacgac gaatgacggc gttacgacca tcgctaataa ccttaccagc      1020

acggttcagg tattctcgga ctcggaatac cagctgccgt acgtcctcgg ctctgcgcac      1080

cagggctgcc tgcctccgtt cccggcggac gtcttcatga ttcctcagta cggctacctg      1140

actctcaaca atggcagtca gtctgtggga cgttcctcct tctactgcct ggagtacttc      1200
```

ccctctcaga tgctgagaac gggcaacaac tttgagttca gctacacctt cgaggacgtg 1260

cctttccaca gcagctacgc acacagccag agcctggacc ggctgatgaa tcccctcatc 1320

gaccagtact tgtactacct ggccagaaca cagagtacca caggaggcac agctggcaat 1380

cgggaactgc agttttacca ggccgggcct tcaactatgg ccgaacaagc caagaattgg 1440

ttacctggac cttgctaccg gcaacaaaga gtctccaaaa cgctggatca aaacaacaac 1500

agcaactttg cttggactgg tgccaccaaa tatcacctga acggcagaaa ctcgttggtt 1560

aatcccggcg tcgccatggc aactcacaag gacgacgagg accgcttttt cccatccagc 1620

-

ggagtcctga tttttggaaa aactggagca gctaacaaaa ctacattgga aaatgtgtta 1680

atgacaaatg aagaagaaat taaaactact aatcctgtag ccacggaaga atacggggta 1740

gtcagcagca acttacaatc ggctaatact gcaccccaga cacaaactgt caacagccag 1800

ggagccttac ctggcatggt ctggcagaac cgggacgtgt acctgcaggg tcccatctgg 1860

gccaagattc ctcacacgga tggcaacttt cacccgtctc ctttgatggg cggctttgga 1920

cttaaacatc cgcctcctca gatcctgatc aagaacactc ccgttcccgc taatcctccg 1980

gaggtgttta ctcctgccaa gtttgcttcg ttcatcacac agtacagcac cggacaagtc 2040

agcgtggaaa tcgagtggga gctgcagaag gaaaacagca agcgctggaa cccggagatt 2100

cagtacacct ccaactatga taagtcgact aatgtggact ttgccgttga cagcgagggt 2160

gtttactctg agcctcgccc tattggcact cgttacctca cccgtaatct g 2211

<210> 15

<211> 735

<212> PRT

<213> Adeno-associated virus

<220>

<221> VARIANT

<222> (162)..(162)

<223> /replace="Thr"

<220>

<221> VARIANT

<222> (168)..(168)

<223> /replace="Arg"

<220>

<221> VARIANT

<222> (224)..(224)

<223> /replace="Ser"

<220>

<221> VARIANT

<222> (310) .. (310)

<223> /replace="Lys"

<220>
<221> VARIANT
<222> (410)..(410)
<223> /replace="Gln"

<220>
<221> VARIANT
<222> (446)..(446)
<223> /replace="Asn"

<220>
<221> VARIANT
<222> (461)..(461)
<223> /replace="Leu"

<220>
<221> VARIANT
<222> (471)..(471)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (708)..(708)
<223> /replace="Thr"

<220>
<221> misc_feature
<222> (1)..(735)
<223> /note="Variant residues given in the sequence have no preference with respect to those in the annotations for variant positions"

<400> 15

```
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1               5                   10                  15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
            20                  25                  30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
        35                  40                  45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
    50                  55                  60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65                  70                  75                  80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
```

85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145 150 155 160

Lys Ser Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
180 185 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ser Gly Gly Gly
195 200 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Ala Ser Asn Asp Asn His Tyr
260 265 270

Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His
275 280 285

Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp
290 295 300

Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val
305 310 315 320

Lys Glu Val Thr Thr Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu
325 330 335

Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr
340 345 350

Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp
355 360 365

Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser
370 375 380

Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser
385 390 395 400

Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu
405 410 415

Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg
420 425 430

Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr
435 440 445

Gln Thr Thr Ser Gly Thr Ala Gln Asn Arg Glu Leu Gln Phe Ser Gln
450 455 460

Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Lys Asn Trp Leu Pro Gly
465 470 475 480

Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Ala Asn Asp Asn Asn
485 490 495

Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly
500 505 510

Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Ser His Lys Asp
515 520 525

Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Leu Ile Phe Gly Lys
530 535 540

Gln Gly Ala Gly Ala Ser Asn Val Asp Leu Asp Asn Val Met Ile Thr
545 550 555 560

Asp Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr
565 570 575

Gly Thr Val Ala Thr Asn Leu Gln Ser Ser Asn Thr Ala Pro Ala Thr
580 585 590

Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln Asp
595 600 605

Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
610 615 620

Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys
625 630 635 640

His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn
645 650 655

Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser Phe Ile Thr Gln
660 665 670

Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys
675 680 685

-

Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr
690 695 700

Asn Lys Ser Ala Asn Val Asp Phe Thr Val Asp Thr Asn Gly Val Tyr
705 710 715 720

Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735

<210> 16
<211> 2205
<212> DNA
<213> Adeno-associated virus

<220>
<221> variation
<222> (484)..(486)
<223> /replace="aca"

<220>
<221> variation
<222> (502)..(504)
<223> /replace="aga"

<220>
<221> variation
<222> (670)..(672)
<223> /replace="tcc"

<220>
<221> variation
<222> (928)..(930)
<223> /replace="aaa"

<220>
<221> variation
<222> (1228) .. (1230)
<223> /replace="cag"

<220>
<221> variation
<222> (1336) .. (1338)
<223> /replace="aac"

<220>
<221> variation
<222> (1381)..(1383)

<223> /replace="ctg"

<220>
<221> variation
<222> (1411) .. (1413)
<223> /replace="tct"

<220>
<221> variation
<222> (2122) .. (2124)
<223> /replace="acc"

<220>
<221> misc_feature
<222> (1)..(2205)
<223> /note="Variation nucleotides given in the sequence have no preference with respect to those in the annotations for variation positions"

<400> 16

```
atggctgccg atggttatct tccagattgg ctcgaggaca acctctctga gggcattcgc       60
gagtggtggg acttgaaacc tggagccccg aaacccaaag ccaaccagca aaagcaggac      120
gacggccggg gtctggtgct tcctggctac aagtacctcg gacccttcaa cggactcgac      180
aaggggagc ccgtcaacgc ggcggatgca gcggccctcg agcacgacaa ggcctacgac       240
cagcagctca aagcgggtga caatccgtac ctgcggtata accacgccga cgccgagttt      300
caggagcgtc tgcaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttccag      360
gccaagaaga gggttctcga acctcttggt ctggttgagg aaggtgctaa gacggctcct      420
ggaaagaaac gtccggtaga gcagtcgcca caagagccag actcctcctc gggcattggc      480
aagtcaggcc agcagcccgc taaaaagaga ctcaattttg gtcagactgg cgactcagag      540
tcagtccccg acccacaacc tctcggagaa cctccagcag ccccctctgg tgtgggatct      600
aatacaatgg cttcaggcgg tggcgcacca atggcagaca ataacgaagg cgccgacgga      660
gtgggtaatg cctcaggaaa ttggcattgc gattccacat ggctgggcga cagagtcatc      720
accaccagca cccgaacatg ggccttgccc acctataaca accacctcta caagcaaatc      780
tccagtcaat caggggccag caacgacaac cactacttcg gctacagcac cccctggggg      840
tattttgatt tcaacagatt ccactgccat ttctcaccac gtgactggca gcgactcatc      900
aacaacaatt ggggattccg gcccaagaga ctcaacttca agctcttcaa catccaagtc      960
aaggaggtca cgacgaatga tggcaccacg accatcgcta ataaccttac cagcacggtt     1020
caagtcttca cggactcgga gtaccagttg ccgtacgtcc tcggctctgc gcaccagggc     1080
tgcctccctc cgttcccggc ggacgtgttc atgattccgc agtacggcta cctaacgctc     1140
aacaatggca gccaggcagt gggacggtca tcctttttact gcctggaata tttcccatcg     1200
cagatgctga gaacgggcaa taactttacc ttcagctaca ccttcgagga cgtgcctttc     1260
cacagcagct acgcgcacag ccagagcctg gaccggctga tgaatcctct catcgaccag     1320
```

tacctgtatt acctgagcag aactcagact acgtccggaa ctgcccaaaa cagggagttg 1380

cagtttagcc aggcgggtcc atctagcatg gctaatcagg ccaaaaactg gctacctgga 1440

ccctgttacc ggcagcagcg cgtttctaaa acagcaaatg acaacaacaa cagcaacttt 1500

gcctggactg gtgctacaaa atatcacctt aatgggcgtg attctttagt caaccctggc 1560

cctgctatgg cctcacacaa agacgacgaa gacaagttct ttcccatgag cggtgtcttg 1620

attttggaa agcagggcgc cggagcttca aacgttgatt tggacaatgt catgatcaca 1680

gacgaagagg aaatcaaaac cactaacccc gtggccaccg aacaatatgg gactgtggca 1740

accaatctcc agagcagcaa cacagccccct gcgaccggaa ctgtgaattc tcagggagcc 1800

ttacctggaa tggtgtggca agacagagac gtatacctgc agggtcctat ttgggccaaa 1860

attcctcaca cggatggaca ctttcacccg tctcctctca tgggcggctt tggacttaag 1920

cacccgcctc ctcagatcct catcaaaaac acgcctgttc ctgcgaatcc tccgacaacg 1980

ttttcgcctg caaagtttgc ttcattcatc acccagtatt ccacaggaca agtgagcgtg 2040

gagattgaat gggagctgca gaaagaaaac agcaaacgct ggaatcccga aatacagtat 2100

acatctaact ataataaatc tgccaacgtt gatttcactg tggacaccaa tggagtttat 2160

agtgagcctc gccccattgg cacccgttac ctcacccgta acctg 2205

<210> 17
<211> 735
<212> PRT
<213> Adeno-associated virus

<220>
<221> VARIANT
<222> (42) .. (42)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (168)..(168)
<223> /replace="Lys"

<220>
<221> VARIANT
<222> (310) .. (310)
<223> /replace="Arg"

<220>
<221> VARIANT
<222> (410)..(410)
<223> /replace="Gln"

<220>
<221> VARIANT

<222> (446)..(446)
<223> /replace="Arg"

<220>
<221> VARIANT
<222> (461)..(461)
<223> /replace="Leu"

<220>
<221> VARIANT
<222> (471)..(471)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (475)..(475)
<223> /replace="Arg"

<220>
<221> VARIANT
<222> (504) .. (504)
<223> /replace="Ala"

<220>
<221> VARIANT
<222> (539)..(539)
<223> /replace="Asn"

<220>
<221> misc_feature
<222> (1)..(735)
<223> /note="Variant residues given in the sequence have no preference with respect to those in the annotations for variant positions"

<400> 17

```
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1               5                   10                  15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Gln Pro
            20                  25                  30

Lys Ala Asn Gln Gln His Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
        35                  40                  45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
    50                  55                  60

Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65                  70                  75                  80
```

```
Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala
                85                  90                  95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
            100                 105                 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
        115                 120                 125

Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Arg
    130                 135                 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145                 150                 155                 160

Lys Ser Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln Thr

                165                 170                 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
            180                 185                 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ser Gly Gly Gly
        195                 200                 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser
    210                 215                 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225                 230                 235                 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
                245                 250                 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Ala Ser Asn Asp Asn His Tyr
            260                 265                 270

Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His
        275                 280                 285

Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp
    290                 295                 300

Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln Val
305                 310                 315                 320

Lys Glu Val Thr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu
                325                 330                 335

Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr
            340                 345                 350

Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp
        355                 360                 365
```

Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser
370 375 380

Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser
385 390 395 400

Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu
405 410 415

Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg
420 425 430

Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr
435 440 445

Gln Thr Thr Ser Gly Thr Thr Gln Gln Ser Arg Leu Gln Phe Ser Gln
450 455 460

Ala Gly Pro Ser Ser Met Ala Gln Gln Ala Lys Asn Trp Leu Pro Gly
465 470 475 480

Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Ala Asn Asp Asn Asn
485 490 495

Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly
500 505 510

Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Ser His Lys Asp
515 520 525

Asp Glu Glu Lys Phe Phe Pro Met His Gly Val Leu Ile Phe Gly Lys
530 535 540

Gln Gly Thr Gly Ala Ser Asn Val Asp Leu Asp Asn Val Met Ile Thr
545 550 555 560

Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr
565 570 575

Gly Thr Val Ala Thr Asn Leu Gln Ser Ser Asn Thr Ala Pro Ala Thr
580 585 590

Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln Asp
595 600 605

Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr
610 615 620

Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys
625 630 635 640

His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn
645 650 655

Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser Phe Ile Thr Gln
660 665 670

Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys
675 680 685

Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr
690 695 700

Asn Lys Ser Val Asn Val Asp Phe Thr Val Asp Thr Asn Gly Val Tyr
705 710 715 720

Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735

<210> 18
<211> 2205
<212> DNA
<213> Adeno-associated virus

<220>
<221> variation
<222> (124)..(126)
<223> /replace="agt"

<220>
<221> variation
<222> (502)..(504)
<223> /replace="aaa"

<220>
<221> variation
<222> (928)..(930)
<223> /replace="aga"

<220>
<221> variation
<222> (1228) .. (1230)
<223> /replace="cag"

<220>
<221> variation
<222> (1336) .. (1338)
<223> /replace="aga"

<220>
<221> variation
<222> (1381)..(1383)
<223> /replace="ctc"

<220>
<221> variation

<222> (1411) .. (1413)
<223> /replace="tct"

<220>
<221> variation
<222> (1423)..(1425)
<223> /replace="aga"

<220>
<221> variation
<222> (1510) .. (1512)
<223> /replace="gcg"

<220>
<221> variation
<222> (1615)..(1617)
<223> /replace="gac"

<220>
<221> misc_feature
<222> (1)..(2205)
<223> /note="Variation nucleotides given in the sequence have no preference with respect to those in the annotations for variation positions"

<400> 18

atggctgctg acggttatct tccagattgg ctcgaggaca acctttctga aggcattcgt 60

gagtggtggg atctgaaacc tggagcccct caacccaaag cgaaccaaca acaccaggac 120

gacggtcggg gtcttgtgct tccgggttac aaatacctcg gacccttaa cggactcgac 180

aaaggagagc cggtcaacga ggcggacgcg gcagccctcg aacacgacaa agcttacgac 240

cagcagctca aggccggtga caacccgtac ctcaagtaca accacgccga cgccgagttt 300

caggagcgtc ttcaagaaga tacgtctttt gggggcaacc ttggcagagc agtcttccag 360

gccaaaaaga gggtccttga gcctcttggt ctggttgagg aagcagctaa aacggctcct 420

ggaaagaaga ggcctgtaga acagtctcct caggaaccgg actcatcatc tggtattggc 480

aaatcgggcc aacagcctgc cagaaaaaga ctaaatttcg gtcagactgg agactcagag 540

tcagtcccag accctcaacc tctcggagaa ccaccagcag ccccctcagg tgtgggatct 600

aatacaatgg cttcaggcgg tggcgcacca atggcagaca ataacgaggg tgccgatgga 660

gtgggtaatt cctcaggaaa ttggcattgc gattccacat ggctgggcga cagagtcatc 720

accaccagca ccagaacctg ggccctgccc acttacaaca accatctcta caagcaaatc 780

tccagccaat caggagcttc aaacgacaac cactactttg gctacagcac cccttggggg 840

tattttgact ttaacagatt ccactgccac ttctcaccac gtgactggca gcgactcatt 900

aacaacaact ggggattccg gcccaagaaa ctcaacttca agctcttcaa catccaagtt 960

aaagaggtca cgcagaacga tggcacgacg actattgcca ataaccttac cagcacggtt 1020

caagtgttta cggactcgga gtatcagctc ccgtacgtgc tcgggtcggc gcaccaaggc 1080

tgtctcccgc cgtttccagc ggacgtcttc atgatccctc agtatggata cctcaccctg 1140

aacaacggaa gtcaagcggt gggacgctca tcctttttact gcctggagta cttcccttcg 1200

cagatgctaa ggactggaaa taacttcaca ttcagctata ccttcgagga tgtacctttt 1260

cacagcagct acgctcacag ccagagtttg gatcgcttga tgaatcctct tattgatcag 1320

tatctgtact acctgagcag aacgcaaaca acctctggaa caacccaaca atcacggctg 1380

caatttagcc aggctgggcc ttcgtctatg gctcagcagg ccaaaaattg gctacctggg 1440

ccctgctacc ggcaacagag agtttcaaag actgctaacg acaacaacaa cagtaacttt 1500

gcttggacag gggccaccaa atatcatctc aatggccgcg actcgctggt gaatccagga 1560

ccagctatgg ccagtcacaa ggacgatgaa gaaaaatttt tccctatgca cggcgttcta 1620

atatttggca aacaagggac aggggcaagt aacgtagatt tagataatgt aatgattacg 1680

gatgaagaag agattcgtac caccaatcct gtggcaacag agcagtatgg aactgtggca 1740

actaacttgc agagctcaaa tacagctccc gcgactggaa ctgtcaatag tcaggggggcc 1800

ttacctggca tggtgtggca agatcgtgac gtgtaccttc aaggacctat ctgggcaaag 1860

attcctcaca cggatggaca ctttcatcct tctcctctga tgggaggctt tggactgaaa 1920

catccgcctc ctcaaatctt gatcaaaaat actccggtac cggcaaatcc tccgacgact 1980

ttcagcccgg ccaagtttgc ttcatttatc actcagtact ccactggaca ggtcagcgtg 2040

gaaattgagt gggagctaca gaaagaaaac agcaaacgtt ggaatccaga gattcagtac 2100

acttccaact acaacaagtc tgttaatgtg gactttactg tagacactaa tggtgtttat 2160

agtgaacctc gccctattgg aacccggtat ctcacacgaa acttg 2205

<210> 19

<211> 736

<212> PRT

<213> Adeno-associated virus

<400> 19

```
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1               5                  10                  15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
            20                  25                  30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
        35                  40                  45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
    50                  55                  60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65                  70                  75                  80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
                85                  90                  95
```

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145 150 155 160

Lys Lys Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
180 185 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ala Gly Gly Gly
195 200 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Gly Ser Thr Asn Asp Asn Thr
260 265 270

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285

His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300

Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320

Val Lys Glu Val Thr Thr Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn
325 330 335

Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro
340 345 350

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
370 375 380

Ser Gln Ala Val Glu Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro

Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe
405 410 415

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg
435 440 445

Thr Gln Thr Thr Ser Gly Thr Ala Gly Asn Arg Thr Leu Gln Phe Ser
450 455 460

Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Lys Asn Trp Leu Pro
465 470 475 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Ala Asn Gln Asn
485 490 495

Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn
500 505 510

Gly Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Thr His Lys
515 520 525

Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Leu Ile Phe Gly
530 535 540

Lys Gln Gly Ala Gly Asn Ser Asn Val Asp Leu Asp Asn Val Met Ile
545 550 555 560

Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Gln
565 570 575

Tyr Gly Thr Val Ala Thr Asn Leu Gln Ser Ala Asn Thr Ala Pro Ala
580 585 590

Thr Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln
595 600 605

Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620

Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
625 630 635 640

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655

Asn Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser Phe Ile Thr
660 665 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700

Tyr Asn Lys Ser Thr Asn Val Asp Phe Ala Val Asp Thr Asn Gly Val
705 710 715 720

Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735

<210> 20

<211> 736

<212> PRT

<213> Adeno-associated virus

<400> 20

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145 150 155 160

Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
180 185 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ser Gly Gly Gly
195 200 205

```
Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
    210                 215                 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225                 230                 235                 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
                245                 250                 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Ala Ser Thr Asn Asp Asn Thr
            260                 265                 270

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
        275                 280                 285

His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
    290                 295                 300

Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305                 310                 315                 320

Val Lys Glu Val Thr Thr Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn
                325                 330                 335

Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro
            340                 345                 350

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
        355                 360                 365

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
    370                 375                 380

Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385                 390                 395                 400

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr Phe
                405                 410                 415

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
            420                 425                 430

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg
        435                 440                 445

Thr Gln Thr Thr Ser Gly Thr Ala Gly Asn Arg Glu Leu Gln Phe Ser
    450                 455                 460

Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Lys Asn Trp Leu Pro
465                 470                 475                 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Thr Asn Gln Asn
                485                 490                 495

Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn
            500                 505                 510
```

Gly Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Thr His Lys
515 520 525

Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Leu Ile Phe Gly
530 535 540

Lys Gln Gly Ala Gly Asn Ser Asn Val Asp Leu Asp Asn Val Met Ile
545 550 555 560

Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Glu
565 570 575

Tyr Gly Thr Val Ala Thr Asn Leu Gln Ser Ala Asn Thr Ala Pro Ala
580 585 590

Thr Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln
595 600 605

Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620

Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
625 630 635 640

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655

Asn Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser Phe Ile Thr
660 665 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700

Tyr Asn Lys Ser Thr Asn Val Asp Phe Ala Val Asp Thr Asn Gly Val
705 710 715 720

Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735

<210> 21

<211> 736

<212> PRT

<213> Adeno-associated virus

<400> 21

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145 150 155 160

Lys Lys Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
180 185 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ala Gly Gly Gly
195 200 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Gly Ser Thr Asn Asp Asn Thr
260 265 270

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285

His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300

Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320

```
Val Lys Glu Val Thr Thr Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn
                325                 330                 335

Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro
            340                 345                 350

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
        355                 360                 365

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
    370                 375                 380

Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385                 390                 395                 400

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe
                405                 410                 415

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
            420                 425                 430

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg
        435                 440                 445

Thr Gln Thr Thr Ser Gly Thr Ala Gly Asn Arg Glu Leu Gln Phe Ser
    450                 455                 460

Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Lys Asn Trp Leu Pro
465                 470                 475                 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Thr Asn Gln Asn
                485                 490                 495

Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn
            500                 505                 510

Gly Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Thr His Lys
        515                 520                 525

Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Leu Ile Phe Gly
    530                 535                 540

Lys Gln Gly Ala Gly Asn Ser Asn Val Asp Leu Asp Asn Val Met Ile
545                 550                 555                 560

Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Glu
                565                 570                 575

Tyr Gly Thr Val Ala Thr Asn Leu Gln Ser Ser Asn Thr Ala Pro Ala
            580                 585                 590

Thr Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln
        595                 600                 605

Glu Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
    610                 615                 620
```

```
Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
625                 630                 635                 640

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
                645                 650                 655

Asn Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser Phe Ile Thr
            660                 665                 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
        675                 680                 685

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
    690                 695                 700

Tyr Asn Lys Ser Thr Asn Val Asp Phe Ala Val Asp Thr Asn Gly Val
705                 710                 715                 720

Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
                725                 730                 735
```

<210> 22

<211> 736

<212> PRT

<213> Adeno-associated virus

<400> 22

```
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1               5                   10                  15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
            20                  25                  30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
        35                  40                  45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
    50                  55                  60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65                  70                  75                  80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
                85                  90                  95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
            100                 105                 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
        115                 120                 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
    130                 135                 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Glu Ile Glu
```

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145 150 155 160

Lys Lys Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
180 185 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ser Gly Gly Gly
195 200 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Gly Ser Thr Asn Asp Asn Thr
260 265 270

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285

His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300

Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320

Val Lys Glu Val Thr Thr Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn
325 330 335

Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro
340 345 350

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
370 375 380

Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe
405 410 415

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg
435 440 445

Thr Gln Thr Thr Ser Glu Thr Ala Glu Asn Arg Glu Leu Gln Phe Ser

Thr Gln Thr Thr Ser Gly Thr Ala Gly Asn Arg Glu Leu Gln Phe Ser
450 455 460

Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Lys Asn Trp Leu Pro
465 470 475 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Thr Asn Gln Asn
485 490 495

Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn
500 505 510

Gly Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Thr His Lys
515 520 525

Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Leu Ile Phe Gly
530 535 540

Lys Gln Gly Ala Gly Asn Ser Asn Val Asp Leu Asp Asn Val Met Ile
545 550 555 560

Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Glu
565 570 575

Tyr Gly Thr Val Ala Thr Asn Leu Gln Ser Ala Asn Thr Ala Pro Ala
580 585 590

Thr Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln
595 600 605

Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620

Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
625 630 635 640

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655

Asn Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser Phe Ile Thr
660 665 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700

Tyr Asn Lys Ser Thr Asn Val Asp Phe Ala Val Asp Thr Asn Gly Val
705 710 715 720

Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735

<210> 23

<211> 736

<212> PRT

<213> Adeno-associated virus

<400> 23

```
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1               5                  10                  15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
            20                  25                  30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
        35                  40                  45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
    50                  55                  60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65                  70                  75                  80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
                85                  90                  95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
            100                 105                 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
        115                 120                 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
    130                 135                 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145                 150                 155                 160

Lys Lys Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln Thr
                165                 170                 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
            180                 185                 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ala Gly Gly Gly
        195                 200                 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
    210                 215                 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225                 230                 235                 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
                245                 250                 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Gly Ser Thr Asn Asp Asn Thr
            260                 265                 270
```

```
Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
        275                 280                 285

His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
    290                 295                 300

Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln
305                 310                 315                 320

Val Lys Glu Val Thr Thr Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn
                325                 330                 335

Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro
            340                 345                 350

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
        355                 360                 365

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
    370                 375                 380

Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385                 390                 395                 400

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr Phe
                405                 410                 415

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
            420                 425                 430

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg
        435                 440                 445

Thr Gln Thr Thr Ser Gly Thr Ala Gly Asn Arg Thr Leu Gln Phe Ser
    450                 455                 460

Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Lys Asn Trp Leu Pro
465                 470                 475                 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Thr Asn Gln Asn
                485                 490                 495

Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn
            500                 505                 510

Gly Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Thr His Lys
        515                 520                 525

Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Leu Ile Phe Gly
    530                 535                 540

Lys Gln Gly Ala Gly Asn Ser Asn Val Asp Leu Asp Asn Val Met Ile
545                 550                 555                 560

Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Glu
                565                 570                 575
```

Tyr Gly Thr Val Ala Thr Asn Leu Gln Ser Ala Asn Thr Ala Pro Ala
580 585 590

Thr Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln

595 600 605

Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620

Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
625 630 635 640

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
645 650 655

Asn Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser Phe Ile Thr
660 665 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
675 680 685

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700

Tyr Asn Lys Ser Thr Asn Val Asp Phe Ala Val Asp Thr Asn Gly Val
705 710 715 720

Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735

<210> 24

<211> 736

<212> PRT

<213> Adeno-associated virus

<400> 24

Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
85 90 95

```
Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
            100                 105                 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
        115                 120                 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
    130                 135                 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145                 150                 155                 160

Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
                165                 170                 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
            180                 185                 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ala Gly Gly Gly
        195                 200                 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
    210                 215                 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225                 230                 235                 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
                245                 250                 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Gly Ser Thr Asn Asp Asn Thr
            260                 265                 270

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
        275                 280                 285

His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
    290                 295                 300

Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln
305                 310                 315                 320

Val Lys Glu Val Thr Thr Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn
                325                 330                 335

Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro

            340                 345                 350

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
        355                 360                 365

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
    370                 375                 380
```

```
Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385                 390                 395                 400

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe
                405                 410                 415

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
            420                 425                 430

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg
        435                 440                 445

Thr Gln Thr Thr Ser Gly Thr Ala Gly Asn Arg Thr Leu Gln Phe Ser
    450                 455                 460

Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Lys Asn Trp Leu Pro
465                 470                 475                 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Ala Asn Gln Asn
                485                 490                 495

Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn
            500                 505                 510

Gly Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Thr His Lys
        515                 520                 525

Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Leu Ile Phe Gly
    530                 535                 540

Lys Gln Gly Ala Gly Asn Ser Asn Val Asp Leu Asp Asn Val Met Ile
545                 550                 555                 560

Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Gln
                565                 570                 575

Tyr Gly Thr Val Ala Thr Asn Leu Gln Ser Ser Asn Thr Ala Pro Ala
            580                 585                 590

Thr Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln
        595                 600                 605

Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
    610                 615                 620

Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
625                 630                 635                 640

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
                645                 650                 655

Asn Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser Phe Ile Thr
            660                 665                 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
        675                 680                 685
```

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
690 695 700

Tyr Asn Lys Ser Thr Asn Val Asp Phe Ala Val Asp Thr Asn Gly Val
705 710 715 720

Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
725 730 735

<210> 25
<211> 736
<212> PRT
<213> Adeno-associated virus

<400> 25
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1 5 10 15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
20 25 30

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala

85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145 150 155 160

Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
180 185 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ser Gly Gly Gly
195 200 205

195 200 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Gly Ser Thr Asn Asp Asn Thr
260 265 270

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285

His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300

Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320

Val Lys Glu Val Thr Thr Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn
325 330 335

Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro
340 345 350

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
370 375 380

Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe
405 410 415

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg
435 440 445

Thr Gln Thr Thr Ser Gly Thr Ala Gly Asn Arg Thr Leu Gln Phe Ser
450 455 460

Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Lys Asn Trp Leu Pro
465 470 475 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Ala Asn Gln Asn
485 490 495

Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn
500 505 510

```
                 500                 505                 510

Gly Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Thr His Lys
        515                 520                 525

Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Leu Ile Phe Gly
    530                 535                 540

Lys Gln Gly Ala Gly Asn Ser Asn Val Asp Leu Asp Asn Val Met Ile
545                 550                 555                 560

Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Glu
                565                 570                 575

Tyr Gly Thr Val Ala Thr Asn Leu Gln Ser Ser Asn Thr Ala Pro Ala
            580                 585                 590

                                    -

Thr Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln
        595                 600                 605

Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
    610                 615                 620

Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
625                 630                 635                 640

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
                645                 650                 655

Asn Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser Phe Ile Thr
            660                 665                 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
        675                 680                 685

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
    690                 695                 700

Tyr Asn Lys Ser Thr Asn Val Asp Phe Ala Val Asp Thr Asn Gly Val
705                 710                 715                 720

Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
                725                 730                 735
```

<210> 26

<211> 736

<212> PRT

<213> Adeno-associated virus

<400> 26

```
Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser
1               5                   10                  15

Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro
            20                  25                  30
```

Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro
35 40 45

Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro
50 55 60

Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp
65 70 75 80

Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala
85 90 95

Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly
100 105 110

Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro
115 120 125

Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg
130 135 140

Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly
145 150 155 160

Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr
165 170 175

Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro
180 185 190

Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ser Gly Gly Gly
195 200 205

Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala
210 215 220

Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile
225 230 235 240

Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu
245 250 255

Tyr Lys Gln Ile Ser Ser Gln Ser Gly Gly Ser Thr Asn Asp Asn Thr
260 265 270

Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe
275 280 285

His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn
290 295 300

Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln
305 310 315 320

Val Lys Glu Val Thr Thr Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn
325 330 335

Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro
340 345 350

Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala
355 360 365

Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly
370 375 380

Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro
385 390 395 400

Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr Phe
405 410 415

Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp
420 425 430

Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg
435 440 445

Thr Gln Thr Thr Ser Gly Thr Ala Gly Asn Arg Glu Leu Gln Phe Ser
450 455 460

Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Lys Asn Trp Leu Pro
465 470 475 480

Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Thr Asn Gln Asn
485 490 495

Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn
500 505 510

Gly Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Thr His Lys
515 520 525

Asp Asp Glu Asp Lys Phe Phe Pro Met Ser Gly Val Leu Ile Phe Gly
530 535 540

Lys Gln Gly Ala Gly Asn Ser Asn Val Asp Leu Asp Asn Val Met Ile
545 550 555 560

Thr Asn Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Gln
565 570 575

Tyr Gly Thr Val Ala Thr Asn Leu Gln Ser Ala Asn Thr Ala Pro Ala
580 585 590

Thr Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln
595 600 605

Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His
610 615 620

```
Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu
625                 630                 635                 640

Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala
                645                 650                 655

Asn Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser Phe Ile Thr
            660                 665                 670

Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln
        675                 680                 685

Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn
    690                 695                 700

Tyr Asn Lys Ser Thr Asn Val Asp Phe Ala Val Asp Thr Asn Gly Val
705                 710                 715                 720

Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu
                725                 730                 735
```

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US20140601 63W [0110]
- US61889827B [0110]

Non-patent literature cited in the description

- **CALCEDO et al.** J. Infect. Dis., 2009, vol. 199, 381-90 [0021] [0048]
- **BOUTIN et al.** Human Gene Ther., 2010, vol. 21, 704-12 [0021]
- **THOMPSON et al.** Nuc. Acids Res., 1994, vol. 22, 4673-90 [0027]
- **LASSMANN et al.** Nuc. Acids Res., 2006, vol. 34, W596-99 [0027]

- **KATOH et al.**Nuc. Acids Res., 2005, vol. 33, 511-8 [0027]
- **EDGAR**BMC Bioinform., 2004, vol. 5, 113- [0027]
- **NOTREDAME et al.**J. Mol. Biol., 2000, vol. 302, 205-17 [0027]
- **LOYTYNOJAGOLDMAN**Science, 2008, vol. 320, 1632-5 [0028]
- **LOYTYNOJAGOLDMAN**PNAS USA, 2005, vol. 102, 10557-62 [0028]
- **DAYHOFF et al.**Atlas of Protein Sequence and Structure19780000345-52 [0029]
- **JONES et al.**Comp. Appl. Biosci., 1992, vol. 8, 275-82 [0029] [0068]
- **WHELANGOLDMAN**Mol. Biol. Evol., 2001, vol. 18, 691-9 [0029]
- **HENIKOFFHENIKOFF**PNAS USA, 1992, vol. 89, 10915-9 [0029]
- **REEVES**J. Mol. Evol., 1992, vol. 35, 17-31 [0030]
- **YANG**Mol. Biol. Evol., 1993, vol. 10, 1396-1401 [0030] [0068]
- **CAO et al.**J. Mol. Evol., 1994, vol. 39, 519-27 [0030] [0068]
- **AKAIKE**Second International Symposium on Information TheoryBudapest, Akademiai Kiado19730000267-81 [0031]
- **SCHWARZ**Ann. Statist., 1978, vol. 6, 461-4 [0031]
- **DARRIBA et al.**Bioinformatics, 2011, vol. 27, 81164-5 [0032] [0068]
- **GUINDONGASCUEL**Systematic Biology, 2003, vol. 52, 696-704 [0033] [0069]
- **GASCUEL**Mol. Biol. Evol., 1997, vol. 14, 685-95 [0033]
- **FELSENSTEIN**Systematic Biology, 1973, vol. 22, 240-9 [0033]
- **ANISIMOVAGASCUEL**Systematic Biology, 2006, vol. 55, 539-52 [0034] [0069]
- **YANG**Comp. Applic. BioSci., 1997, vol. 13, 555-6 [0035] [0070]
- **XU et al.**Am. J. Obstet. Gynecol., 2007, vol. 196, 43.e1-6 [0046]
- **PAUL et al.**J. Infect. Dis., 1994, vol. 169, 801-6 [0046]
- **SAUERBREI et al.**Eurosurv., 2011, vol. 16, 443- [0046]
- **SAKHRIA et al.**PLoS Negl. Trop. Dis., 2013, vol. 7, e2429- [0046]
- **FISHER et al.**Nature Med., 1997, vol. 3, 306-12 [0047]
- **MANNING et al.**Human Gene Ther., 1998, vol. 9, 477-85 [0047]
- **BOUTIN et al.**Prevalence of serum IgG and neutralizing factors against AAV types 1, 2, 5, 6, 8 and 9 in the healthy population: implications for gene therapy using AAV vectorsHum. Gene Ther., 2010, vol. 21, 704-12 [0048]
- **ALTSCHUL et al.**Nucleic Acids Res., 1997, vol. 25, 33893402- [0052]
- PCR Primer: A Laboratory ManualCold Spring Harbor Laboratory Press19950000 [0057]
- **HIROTUGU**IEEE Transactions on Automatic Control, 1974, vol. 19, 716-23 [0068]
- **SCHNEIDER et al.**BMC Bioinform., 2005, vol. 6, 134- [0072]
- **BALAZS et al.**Nat. Biotechnol., 2013, vol. 31, 647-52 [0105]
- **LIMBERIS et al.**Sci. Transl. Med., 2013, vol. 5, 187ra72- [0105]
- **BALAZS et al.**Nature, 2012, vol. 481, 81-4 [0105]
- **DEAL et al.**PNAS USA, 2014, vol. 111, 12528-32 [0105]
- **MAO et al.**Hum. Gene Ther., 2011, vol. 22, 1525-35 [0106]
- **XIE et al.**Gynecol. Oncol., 2014, [0106]
- **WATANABE et al.**Gene Ther., 2010, vol. 17, 1042-51 [0106]

P A T E N T K R A V

1. Adeno-associeret virus (AAV)-kapsidpolypeptid med mindst 95 % sekvensidentitet med aminosyresekvensen vist i SEQ ID NO: 23.

2. AAV-kapsidpolypeptid ifølge krav 1, hvor AAV-kapsidpolypeptidet eller en viruspartikel, der omfatter AAV-kapsidpolypeptidet:

fremviser en lavere seroprævalens end et AAV2-kapsidpolypeptid eller en viruspartikel, der omfatter et AAV2-kapsidpolypeptid, og hvor AAV-kapsidpolypeptidet eller en viruspartikel, der omfatter AAV-kapsidpolypeptidet, fremviser ca. den samme eller en lavere seroprævalens end et AAV8-kapsidpolypeptid eller en viruspartikel, der omfatter et AAV8-kapsidpolypeptid; og/eller

er neutraliseret i en mindre udstrækning af humant serum end et AAV2-kapsidpolypeptid eller en viruspartikel, der omfatter et AAV2-kapsidpolypeptid, og hvor AAV-kapsidpolypeptidet eller en viruspartikel, der omfatter AAV-kapsidpolypeptidet, er neutraliseret i en tilsvarende eller mindre udstrækning af humant serum end et AAV8-kapsidpolypeptid eller en viruspartikel, der omfatter et AAV8-kapsidpolypeptid.

3. AAV-kapsidpolypeptid ifølge krav 1, hvor AAV-kapsidpolypeptidet er oprenset.

4. AAV-kapsidpolypeptid ifølge krav 1, hvor polypeptidet har mindst 97 % sekvensidentitet med aminosyresekvensen vist i SEQ ID NO: 23.

5. AAV-kapsidpolypeptid ifølge krav 1, hvor polypeptidet har mindst 98 % sekvensidentitet med aminosyresekvensen vist i SEQ ID NO: 23.

6. AAV-kapsidpolypeptid ifølge krav 1, hvor polypeptidet har mindst 99 % sekvensidentitet med aminosyresekvensen vist i SEQ ID NO: 23.

7. AAV-kapsidpolypeptid ifølge krav 1, hvor polypeptidet har 100 % sekvensidentitet med aminosyresekvensen vist i SEQ ID NO: 23.

8. Viruspartikel, der omfatter AAV-kapsidpolypeptidet ifølge krav 1.

9. Viruspartikel ifølge krav 8, der endvidere omfatter et transgen.

DRAWINGS



FIG. 1

E	I	K	A	T	N	P	V	A	T	E	R	F	G	T	V	A	V	N	F	Q
E	I	K	A	T	N	P	V	A	T	E	R	F	G	T	V	A	V	N	L	Q
E	I	R	T	T	N	P	V	A	T	E	Q	Y	G	S	V	S	T	N	L	Q
E	I	R	T	T	N	P	V	A	T	E	Q	Y	G	T	V	A	N	N	L	Q

FIG. 2A



FIG. 2B

E	I	K	A	T	N	P	V	A	T	E	R	F	G	T	V	A	V	N	L	Q
E	I	R	T	T	N	P	V	A	T	E	Q	Y	G	T	V	A	T	N	L	Q
E	I	K	T	T	N	P	V	A	T	E	Q	Y	G	T	V	A	T	N	L	Q

FIG. 2C



FIG. 2D


AAV5 VP1
AAV4 VP1
AAV rh.34
AAV rh.32
AAV rh.33
rh.61
rh.58
rh.50
rh.57
rh.52
rh.51
rh.64
rh.49
hu.39
rh.53
Anc84
rh.2
rh.40
hu.37
hu.41
hu.40
hu.42
rh.38
pi.2
pi.1
pi.3
Anc83
Anc94
hu.17
hu.6
rh.25
rh.10
bb.1
bb.2
Anc82
AAV8
rh.43
rh.8
AAV9
hu.31
hu.32
Anc110
A
B

FIG. 3


A
B
Anc81
rh.36
rh.35
rh.37
cy.6
cy.4
rh.13
cy.5
cy.3
Anc113
rh.54
rh.55
rh.48
rh.62
Anc80-Lib
cy.2
AAV7
Anc80
AAV3
AAV3B
Anc127
ch.5
hu.23
hu.22
hu.27
hu.21
hu.24
hu.19
hu.20
hu.13
Anc126
hu.28
hu.29
hu.45
hu.47
AAV2
hu.34
hu.35
AAV6
hu.44
hu.46
hu.48
hu.43
AAV1
0.05

FIG. 3 (Cont.)

```
                10        20        30        40        50        60        70        80        90        100
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
L0065  MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADAEF
L0027  ....................................................................................................
L0033  ....................................................................................................
L0036  ....................................................................................................
L0044  ....................................................................................................
L0059  ....................................................................................................
L0060  ....................................................................................................
L0062  ....................................................................................................

                110       120       130       140       150       160       170       180       190       200
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
L0065  QERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGAKTAPGKKRPVEQSPQEPDSSSGIGKKGQQPARKRLNFGQTGDSESVPDPQPLGEPPAAPSGVGS
L0027  ....................................................................................................
L0033  ...................................................................K................................
L0036  ...................................................................K................................
L0044  ...................................................................K................................
L0059  ...................................................................K................................
L0060  ....................................................................................................
L0062  ....................................................................................................

                210       220       230       240       250       260       270       280       290       300
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
L0065  NTMAAGGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISSQSGGSTNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRL
L0027  ....................................................................................................
L0033  ....................................................................................................
L0036  ....S.................................................................................................
L0044  ....S.................................................................................................
L0059  ....S...............................................................A....................................
L0060  ....................................................................................................
L0062  ....S.................................................................................................

                310       320       330       340       350       360       370       380       390       400
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
L0065  INNNWGFRPKKLNFKLFNIQVKEVTTNDGTTTIANNLTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFP
L0027  ..........R.................................................................................
L0033  ....................................................................................................
L0036  ....................................................................................................
L0044  ....................................................................................................
L0059  ..........R.................................................................................
L0060  ..........R.................................................................................
L0062  ....................................................................................................
```

FIG. 4

```
                410       420       430       440       450       460       470       480       490       500
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
L0065   SQMLRTGNNFQFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQTTSGTAGNRTLQFSQAGPSSMANQAKNWLPGPCYRQQRVSKTTNQNNNSN
L0027   ..........E.....................................................................................A.......
L0033   ..........E.....................................................................................A.......
L0036   ..........E.....................................................................................A.......
L0044   ..................................................E..............................................
L0059   ..................................................E..............................................
L0060   ..........E.......................................E..............................................
L0062   ..........E.......................................E..............................................

                510       520       530       540       550       560       570       580       590       600
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
L0065   FAWTGATKYHLNGRDSLVNPGPAMATHKDDEDKFFPMSGVLIFGKQGAGNSNVDLDNVMITNEEEIKTTNPVATEEYGTVATNLQSANTAPATGTVNSQG
L0027   ..........................................................................Q.....................
L0033   ..........................................................S.....Q.....S.....................
L0036   ..........................................................S.....S.....S.....................
L0044   ..........................................................................Q.....................
L0059   ..............................................................................................
L0060   ..........................................................S.....S.....S.....................
L0062   ..........................................................S.....S.....S.....................

                610       620       630       640       650       660       670       680       690       700
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
L0065   ALPGMVWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPTTFSPAKFASFITQYSTGQVSVEIEWELQKENSKRWNPEIQ
L0027   ..............................................................................................
L0033   ........N.....................................................................................
L0036   ........N.....................................................................................
L0044   ..............................................................................................
L0059   ........N.....................................................................................
L0060   ........E.....................................................................................
L0062   ..............................................................................................

                710       720       730
                ....|....|....|....|....|....|....|..
L0065   YTSNYNKSTNVDFAVDTNGVYSEPRPIGTRYLTRNL*
L0027   ....................................*
L0033   ....................................*
L0036   ....................................*
L0044   ....................................*
L0059   ....................................*
L0060   ....................................*
L0062   ....................................*
```

FIG. 4 (Cont.)

DK/EP 3459965 T3

```
                10        20        30        40        50        60        70        80        90       100
                |....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
LO065   MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADAEF
LO027   ....................................................................................................
LO033   ....................................................................................................
LO036   ....................................................................................................
LO060   ....................................................................................................
LO062   ....................................................................................................
LO044   ....................................................................................................
LO059   ....................................................................................................
AAV8    ......................A.............................................................Q.............
AAV9    ......................A.....Q.....H..NA............G.....................................K.........
AAV6    ....................................................................................................
AAV1    ....................................................................................................
AAV2    .............T.....Q..K....P.P..PAERHK..S.....................E.............R..DS.....K.........
AAV3    ......................A....V.Q.....H..NR............G.....E.....................K.........
AAV3B   ......................A....V.Q.....H..NR............G.....E.....................K.........
AAV7    ....................................N...........................................................

                110       120       130       140       150       160       170       180       190       200
                |....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
LO065   QERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVEEGAKTAPGKKRPVEQSPQ-EPDSSSGIGKKGQQPARKRLNFGQTGDSESVPDPQPLGEPPAAPSGVG
LO027   ...................................................-................................................
LO033   ...................................................-................K...............................
LO036   ...................................................-................K...............................
LO060   ...................................................-................................................
LO062   ...................................................-................................................
LO044   ...................................................-................K...............................
LO059   ...................................................-................K...............................
AAV8    ..............................................P...RS....T.........................................
AAV9    ....K..................L.........A..............-.....A...S.A...K.........T........I...........
AAV6    ...........................F.....................-.........T....K.....................T.AA..
AAV1    ....................................................-.....T....K.....................T.AA..
AAV2    ....K.....................PV..........H..V-.......T..A.............AD.........Q.......L.
AAV3    ......................I.........A........GA.D....-.......V..S.K.....................TSL.
AAV3B   ......................I.........A............D....-.......V..S.K.....................TSL.
AAV7    ..................................A......P...RS....T.....................................S..
```

FIG. 5A

```
                210       220       230       240       250       260       270       280       290       300
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
L0065   SNTMAAGGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQIS-SQSGGSTNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQ
L0027   ..........................................................................-..........................
L0033   ..........................................................................-..........................
L0036   .....S....................................................................-..........................
L0060   ..........................................................................-..........................
L0062   .....S....................................................................-..........................
I0044   .....S....................................................................-..........................
L0059   .....S....................................................................-....A.....................
AAV8    P.....................SS.....................................................NGT...A.....................
AAV9    .L...S....V...........SS........Q.....................................N.T....S...A.....................
AAV6    PT...S.....................................................................-.A.T.AS...H.....................
AAV1    PT...S.....................................................................-.A.T.AS...H.....................
AAV2    T....T.S.................S..........M.....................................-...-.AS...H.....................
AAV3    .....S...................S........Q.....................................-...-.AS...H.....................
AAV3B   .....S...................S........Q.....................................-...-.AS...H.....................
AAV7    .G.V.......................................................................-.ETA.....................


                310       320       330       340       350       360       370       380       390       400
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
L0065   RLINNNWGFRPKKLNFKLFNIQVKEVTTNDGTTTIANNLTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEY
L0027   ............R.............................................................................................
L0033   ..........................................................................................................
L0036   ..........................................................................................................
L0060   ............R.............................................................................................
L0062   ..........................................................................................................
I0044   ..........................................................................................................
L0059   ............R.............................................................................................
AAV8    ............R.S...........Q.E..K.........I.....................................................................
AAV9    ............R.............D.N.VK..............D..........E.....................D.............
AAV6    ............R...............V.............S.....................................................
AAV1    ............R...............V.............S.....................................................
AAV2    ............R.............Q.....................................................V.....................
AAV3    ..............S.......RG..Q.....................................................V.....................
AAV3B   ..............S...........Q.....................................................V.....................
AAV7    ............R...............V.........I...S.....................................................S..........
```

FIG. 5A (Cont.)

```
                  410       420       430       440       450       460       470       480       490       500
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
L0065   FPSQMLRTGNNFQFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQ-TTSGTAGNRTLQFSQAGPSSMANQAKNWLPGPCYRQQRVSKTTNQNN
L0027   ............E.............................................-.............................................A....
L0033   ............E.............................................-.............................................A....
L0036   ............E.............................................-.............................................A....
L0060   ............E.............................................-.........E...................................
L0062   ............E.............................................-.........E...................................
L0044   ..........................................................-.........E...................................
L0059   ..........................................................-.........E...................................
AAV8    ..............T.............................................-..G...NTQ..G...G..NT.....................T..G...
AAV9    ................E..N.....................................K.--INGSGQNQQ..K..V....N..V.GR.YI...S.......T.VT...
AAV6    ............T.....................................N...-NQ..S.Q.KD.L..RGS.AG.SV.P.................KTD..
AAV1    ............T.....E...............................N...-NQ..S.Q.KD.L..RGS.AG.SV.P.................KTD..
AAV2    ............T.....................................N-.P...TTQSR.......A.DIRD.SR.................SAD..
AAV3    ..........................................N...G.....TNQSR.L......Q..SL..R.............L...A.D..
AAV3B   ..........................................N...G.....TNQSR.L......Q..SL..R.............L...A.D..
AAV7    ............E...S.....................................A...SNPG......E...Y.G...T..E.........F........LD...

                  510       520       530       540       550       560       570       580       590       600
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
L0065   NSNFAWTGATKYHLNGRDSLVNPGPAMATHKDDEDKFFPMSGVLIFGKQGAGNSNVDLDNVMITNEEEIKTTNPVATEEYGTVATNLQSANTAPATGTVN
L0027   ..................................................................................Q.....................
L0033   ..........................................................S.....................Q..........S..........
L0036   ..........................................................S.....................................S..........
L0060   ..........................................................S.....................................S..........
L0062   ..................................................................................Q.....................
L0044   ..........................................................................................................
L0059   ..........................................................................................................
AAV8    .......AG.........N..A...I.........ER...SN.I......N.ARD.A.YSD..L.S.................I..D...QQ....QI....
AAV9    ..E...P..SSWA....N..M.......S..EG..R...L..S.......T.RD...A.K.....................S..Q....H...QAQAQ..W.Q
AAV6    ....T....S..N....E.II...T...S....K.........M....ES..A..TA.......D.....A.......RF....V....SS.D....D.H
AAV1    ....T....S..N....E.II...T...S..............M....ES..A..TA.......D.....A.......RF....V.F..SS.D....D.H
AAV2    ..EYS.....................S.....E....Q..........SEKT...IEK....D....R........Q..S.S....RG.RQA..AD..
AAV3    ....P..A.S.................S.....E.....H.N.....E.TTA..AE.......D....R........Q.....N....S....T.....
AAV3B   ....P..A.S.................S.....E.....H.N.....E.TTA..AE.......D....R........Q.....N....S....T.R...
AAV7    ................N......V..........R...S........T..T.KTT-.E..LM......RP..........I.SS...A...AQ.QV..
```

FIG. 5B

```
                610       620       630       640       650       660       670       680       690       700
          ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
L0065     SQGALPGMVWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPTTFSPAKFASFITQYSTGQVSVEIEWELQKENSKRWNP
L0027     ..........................................................................................................
L0033     ..........N...............................................................................................
L0036     ..........N...............................................................................................
L0060     ..........E...............................................................................................
L0062     ..........................................................................................................
L0044     ..........................................................................................................
L0059     ..........N...............................................................................................
AAV8      ..........N.................N.....................D.....NQS.LN.............................
AAV9      N..I.......................N.........M.............D...A.NKD.LN.............................
AAV6      VM........................................................AE..AT.............................
AAV1      AM..........................................N.............AE..AT.............................
AAV2      T..V.......................................................S...A.............................
AAV3      H.....................................................M....................................
AAV3B     D.....................................................M....................................
AAV7      N.........N.................N.....................EV.T.............................

                710       720       730
          ....|....|....|....|....|....|....
L0065     EIQYTSNYNKSTNVDFAVDTNGVYSEPRPIGTRYLTRNL
L0027     ..........R...............................
L0033     .........................................
L0036     .........................................
L0060     ..........R...............................
L0062     .........................................
L0044     .........................................
L0059     .........................................
AAV8      .........Y...S.....N.E....................
AAV9      .........Y..N..E...N.E....................
AAV6      .V.......A..A....T..N..L.T...........P.
AAV1      .V.......A..A....T..N..L.T...........P.
AAV2      ..........V....T..........................
AAV3      ..........V....T..........................
```

FIG. 5B (Cont.)


Anc80
L0065
Anc80
L0027
Ladder
VP1
VP2
VP3
Anc80
L0044
Ladder
AAV2/8
VP1
VP2
VP3

FIG. 6


Transduction (RLU)
10000000
1000000
100000
10000
1000
100
AAV2
AAV8
Anc27
Anc44
Anc65
no cap

FIG. 7

VP1 seq.Δ	AAV5	AAV2	AAV8	rh10	Anc80L65	Anc80Lib
AAV5	ID	43.0%	42.6%	43.0%	40.5%	39.9-40.5%
AAV2	320	ID	17.1%	15.9%	12.2%	12.0-12.8%
AAV8	317	127	ID	6.5%	9.1%	8.7-10.1%
rh10	320	118	48	ID	8.6%	7.8-8.9%
L0065	301	91	68	64		0-1.5%
Anc80Lib	297-302	89-95	65-75	58-66	0-11	ID

FIG. 9



FIG. 10A



FIG. 10B



FIG. 10C



FIG. 10D



FIG. 11

	L0065	Anc81	Anc126	Anc127	Anc82	Anc83	Anc84	Anc110	AAV8	Anc113	AAV7	AAV3	AAV1	AAV2	AAV9
L0065	ID	97.8%	97.2%	95.5%	95.5%	94.0%	92.1%	94.0%	90.7%	93.4%	90.7%	90.5%	89.5%	87.9%	86.1%
Anc81		ID	95.9%	93.6%	97.4%	95.6%	93.9%	95.1%	92.1%	94.7%	91.4%	88.6%	88.3%	86.7%	86.5%
Anc126			ID	97.4%	93.4%	92.0%	90.7%	92.5%	89.1%	91.8%	88.8%	91.9%	91.5%	89.2%	85.8%
Anc127				ID	91.7%	90.7%	89.7%	90.7%	88.3%	89.8%	87.3%	94.4%	89.4%	90.7%	86.0%
Anc82					ID	98.2%	96.2%	97.4%	94.7%	92.8%	89.7%	86.8%	86.4%	85.2%	87.8%
Anc83						ID	97.8%	95.6%	96.0%	91.7%	89.3%	86.1%	85.3%	84.8%	87.1%
Anc84							ID	93.7%	94.5%	91.3%	89.1%	85.5%	85.0%	84.1%	86.3%
Anc110								ID	92.5%	90.5%	88.2%	86.3%	86.5%	85.6%	89.0%
AAV8									ID	89.7%	87.8%	85.3%	84.0%	82.9%	85.2%
Anc113										ID	96.4%	85.9%	86.7%	83.8%	83.3%
AAV7											ID	84.2%	85.0%	82.3%	81.8%
AAV3												ID	86.4%	87.3%	83.7%
AAV1													ID	83.2%	82.4%
AAV2														ID	81.9%
AAV9															ID

FIG. 13A

	L0065	Anc81	Anc126	Anc127	Anc82	Anc83	Anc84	Anc110	AAV8	AAV3	Anc113	AAV7	AAV2	AAV1	AAV9
L0065	ID	97.3%	96.6%	94.9%	94.3%	92.1%	90.2%	92.1%	88.5%	90.6%	92.1%	88.7%	88.7%	86.8%	84.1%
Anc81		ID	94.7%	92.7%	96.6%	94.3%	92.7%	93.6%	90.4%	88.4%	93.4%	89.7%	87.4%	85.2%	84.4%
Anc126			ID	97.5%	91.5%	89.7%	88.7%	89.9%	86.7%	92.6%	89.9%	86.5%	90.8%	89.5%	83.3%
Anc127				ID	90.2%	88.7%	88.0%	88.5%	86.3%	94.9%	88.2%	85.2%	92.1%	87.6%	83.1%
Anc82					ID	97.7%	95.7%	97.0%	93.8%	86.1%	90.6%	87.1%	85.6%	82.8%	86.3%
Anc83						ID	97.7%	94.7%	95.5%	85.0%	89.3%	86.3%	84.8%	81.4%	85.6%
Anc84							ID	92.8%	93.4%	84.8%	88.4%	85.8%	84.4%	81.6%	84.6%
Anc110								ID	91.4%	85.0%	88.0%	85.6%	85.7%	82.4%	87.8%
AAV8									ID	84.5%	86.7%	84.5%	82.4%	80.1%	83.5%
AAV3										ID	85.4%	82.8%	88.9%	85.7%	80.9%
Anc113											ID	95.8%	84.1%	83.5%	80.5%
AAV7												ID	82.4%	81.8%	78.9%
AAV2													ID	83.3%	81.4%
AAV1														ID	79.6%
AAV9															ID

FIG. 13B


Production of Ancestral Viruses
GC/Cell
1E+05
1E+04
1E+03
1E+02
1E+01
Neg
AAV2
AAV8
Anc127
Anc126
Anc113
Anc110
Anc84
Anc83
Anc82
Anc81
Anc80-...

FIG. 14

Viral Production Relative to AAV8 (%)	
Anc80-L0065	21.75%
Anc81	54.14%
Anc82	100.99%
Anc83	76.86%
Anc84	91.20%
Anc110	118.97%
Anc113	183.10%
Anc126	2.71%
Anc127	25.34%
AAV2	32.56%
Neg	0.27%

FIG. 15


Anc126*
Anc127
Neg
Anc84
Anc110
Anc113
Anc81
Anc82
Anc83
AAV8
AAV2
L0065

FIG. 16


Prep 1
Prep 2
Prep 3
Neg
AAV8
AAV2
Anc127
Anc126*
Anc113
Anc110
Anc84
Anc83
Anc82
Anc81
Anc80-L0065
1E+07
1E+06
1E+05
1E+04
1E+03
1E+02
Relative Luminescence Units

FIG. 17

Viral Infectivity Relative to AAV8 (%)	
Anc80-L0065	850.83%
Anc81	102.26%
Anc82	28.31%
Anc83	47.36%
Anc84	68.78%
Anc110	24.56%
Anc113	117.12%
Anc127	113.78%
AAV2	5225.61%
Neg	0.35%

FIG. 18

	AAV8	AAV2	Anc80-L0065	Anc81	Anc82	Anc83	Anc84	Anc110	Anc113	Anc126	Anc127
Infectivity	=	+++	+++	=	-	-	-	--	=	ND	=
Production	=	-	--	-	=	=	=	=	++	--	-

Key

+++ : > 225%
++ : 175% - 224.5%
+ : 125 - 174.9%
= : 75% - 124.9%
- : 25-74.9%
-- : 0-24.9%
ND : Not Determined

FIG. 19